<!DOCTYPE html>

<html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="google" content="notranslate"><meta http-equiv="X-UA-Compatible" content="IE=edge;"><style>@font-face{font-family:'Roboto';font-style:normal;font-weight:300;src:local('Roboto Light'),local('Roboto-Light'),url(//fonts.gstatic.com/s/roboto/v15/0eC6fl06luXEYWpBSJvXCBJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0460-052F,U+20B4,U+2DE0-2DFF,U+A640-A69F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;src:local('Roboto Light'),local('Roboto-Light'),url(//fonts.gstatic.com/s/roboto/v15/Fl4y0QdOxyyTHEGMXX8kcRJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0400-045F,U+0490-0491,U+04B0-04B1,U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;src:local('Roboto Light'),local('Roboto-Light'),url(//fonts.gstatic.com/s/roboto/v15/-L14Jk06m6pUHB-5mXQQnRJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;src:local('Roboto Light'),local('Roboto-Light'),url(//fonts.gstatic.com/s/roboto/v15/I3S1wsgSg9YCurV6PUkTORJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0370-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;src:local('Roboto Light'),local('Roboto-Light'),url(//fonts.gstatic.com/s/roboto/v15/NYDWBdD4gIq26G5XYbHsFBJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0102-0103,U+1EA0-1EF9,U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;src:local('Roboto Light'),local('Roboto-Light'),url(//fonts.gstatic.com/s/roboto/v15/Pru33qjShpZSmG3z6VYwnRJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0100-024F,U+1E00-1EFF,U+20A0-20AB,U+20AD-20CF,U+2C60-2C7F,U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:300;src:local('Roboto Light'),local('Roboto-Light'),url(//fonts.gstatic.com/s/roboto/v15/Hgo13k-tfSpn0qi1SFdUfVtXRa8TVwTICgirnJhmVJw.woff2)format('woff2');unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2212,U+2215,U+E0FF,U+EFFD,U+F000;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;src:local('Roboto Regular'),local('Roboto-Regular'),url(//fonts.gstatic.com/s/roboto/v15/ek4gzZ-GeXAPcSbHtCeQI_esZW2xOQ-xsNqO47m55DA.woff2)format('woff2');unicode-range:U+0460-052F,U+20B4,U+2DE0-2DFF,U+A640-A69F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;src:local('Roboto Regular'),local('Roboto-Regular'),url(//fonts.gstatic.com/s/roboto/v15/mErvLBYg_cXG3rLvUsKT_fesZW2xOQ-xsNqO47m55DA.woff2)format('woff2');unicode-range:U+0400-045F,U+0490-0491,U+04B0-04B1,U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;src:local('Roboto Regular'),local('Roboto-Regular'),url(//fonts.gstatic.com/s/roboto/v15/-2n2p-_Y08sg57CNWQfKNvesZW2xOQ-xsNqO47m55DA.woff2)format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;src:local('Roboto Regular'),local('Roboto-Regular'),url(//fonts.gstatic.com/s/roboto/v15/u0TOpm082MNkS5K0Q4rhqvesZW2xOQ-xsNqO47m55DA.woff2)format('woff2');unicode-range:U+0370-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;src:local('Roboto Regular'),local('Roboto-Regular'),url(//fonts.gstatic.com/s/roboto/v15/NdF9MtnOpLzo-noMoG0miPesZW2xOQ-xsNqO47m55DA.woff2)format('woff2');unicode-range:U+0102-0103,U+1EA0-1EF9,U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;src:local('Roboto Regular'),local('Roboto-Regular'),url(//fonts.gstatic.com/s/roboto/v15/Fcx7Wwv8OzT71A3E1XOAjvesZW2xOQ-xsNqO47m55DA.woff2)format('woff2');unicode-range:U+0100-024F,U+1E00-1EFF,U+20A0-20AB,U+20AD-20CF,U+2C60-2C7F,U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:400;src:local('Roboto Regular'),local('Roboto-Regular'),url(//fonts.gstatic.com/s/roboto/v15/CWB0XYA8bzo0kSThX0UTuA.woff2)format('woff2');unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2212,U+2215,U+E0FF,U+EFFD,U+F000;}@font-face{font-family:'Roboto';font-style:italic;font-weight:400;src:local('Roboto Italic'),local('Roboto-Italic'),url(//fonts.gstatic.com/s/roboto/v15/WxrXJa0C3KdtC7lMafG4dRTbgVql8nDJpwnrE27mub0.woff2)format('woff2');unicode-range:U+0460-052F,U+20B4,U+2DE0-2DFF,U+A640-A69F;}@font-face{font-family:'Roboto';font-style:italic;font-weight:400;src:local('Roboto Italic'),local('Roboto-Italic'),url(//fonts.gstatic.com/s/roboto/v15/OpXUqTo0UgQQhGj_SFdLWBTbgVql8nDJpwnrE27mub0.woff2)format('woff2');unicode-range:U+0400-045F,U+0490-0491,U+04B0-04B1,U+2116;}@font-face{font-family:'Roboto';font-style:italic;font-weight:400;src:local('Roboto Italic'),local('Roboto-Italic'),url(//fonts.gstatic.com/s/roboto/v15/1hZf02POANh32k2VkgEoUBTbgVql8nDJpwnrE27mub0.woff2)format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:italic;font-weight:400;src:local('Roboto Italic'),local('Roboto-Italic'),url(//fonts.gstatic.com/s/roboto/v15/cDKhRaXnQTOVbaoxwdOr9xTbgVql8nDJpwnrE27mub0.woff2)format('woff2');unicode-range:U+0370-03FF;}@font-face{font-family:'Roboto';font-style:italic;font-weight:400;src:local('Roboto Italic'),local('Roboto-Italic'),url(//fonts.gstatic.com/s/roboto/v15/K23cxWVTrIFD6DJsEVi07RTbgVql8nDJpwnrE27mub0.woff2)format('woff2');unicode-range:U+0102-0103,U+1EA0-1EF9,U+20AB;}@font-face{font-family:'Roboto';font-style:italic;font-weight:400;src:local('Roboto Italic'),local('Roboto-Italic'),url(//fonts.gstatic.com/s/roboto/v15/vSzulfKSK0LLjjfeaxcREhTbgVql8nDJpwnrE27mub0.woff2)format('woff2');unicode-range:U+0100-024F,U+1E00-1EFF,U+20A0-20AB,U+20AD-20CF,U+2C60-2C7F,U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:italic;font-weight:400;src:local('Roboto Italic'),local('Roboto-Italic'),url(//fonts.gstatic.com/s/roboto/v15/vPcynSL0qHq_6dX7lKVByfesZW2xOQ-xsNqO47m55DA.woff2)format('woff2');unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2212,U+2215,U+E0FF,U+EFFD,U+F000;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(//fonts.gstatic.com/s/roboto/v15/77FXFjRbGzN4aCrSFhlh3hJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0460-052F,U+20B4,U+2DE0-2DFF,U+A640-A69F;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(//fonts.gstatic.com/s/roboto/v15/isZ-wbCXNKAbnjo6_TwHThJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0400-045F,U+0490-0491,U+04B0-04B1,U+2116;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(//fonts.gstatic.com/s/roboto/v15/UX6i4JxQDm3fVTc1CPuwqhJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+1F00-1FFF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(//fonts.gstatic.com/s/roboto/v15/jSN2CGVDbcVyCnfJfjSdfBJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0370-03FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(//fonts.gstatic.com/s/roboto/v15/PwZc-YbIL414wB9rB1IAPRJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0102-0103,U+1EA0-1EF9,U+20AB;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(//fonts.gstatic.com/s/roboto/v15/97uahxiqZRoncBaCEI3aWxJtnKITppOI_IvcXXDNrsc.woff2)format('woff2');unicode-range:U+0100-024F,U+1E00-1EFF,U+20A0-20AB,U+20AD-20CF,U+2C60-2C7F,U+A720-A7FF;}@font-face{font-family:'Roboto';font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(//fonts.gstatic.com/s/roboto/v15/d-6IYplOFocCacKzxwXSOFtXRa8TVwTICgirnJhmVJw.woff2)format('woff2');unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2212,U+2215,U+E0FF,U+EFFD,U+F000;}</style><title>MC Inquiry report28 08 16_edited_clean.pdf - Google Drive</title><meta property="og:title" content="MC Inquiry report28 08 16_edited_clean.pdf"><meta property="og:type" content="article"><meta property="og:site_name" content="Google Docs"><meta property="og:url" content="https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view?usp=sharing&amp;usp=embed_facebook"><meta property="og:image" content="https://lh4.googleusercontent.com/d5AyzJjLPMqcP5O04bbLdUbW6P0ZA8iCHV5dzDfkMc0DD0XdhZTdfQ=w1200-h630-p"><meta property="og:image:width" content="1200"><meta property="og:image:height" content="630"><script src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/cb=gapi.loaded_1" async="" type="2fb05f019e6e60363ddfa077-text/javascript"></script><script src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/cb=gapi.loaded_0" async="" type="2fb05f019e6e60363ddfa077-text/javascript"></script><script src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/client.js.download" async="" gapi_processed="true" type="2fb05f019e6e60363ddfa077-text/javascript"></script><script type="2fb05f019e6e60363ddfa077-text/javascript">(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(h){}};this.tick("start",null,a)}var a,d;window.performance&&(d=(a=window.performance.timing)&&a.responseStart);var f=0<d?new e(d):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_","_wtsrt",
d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><script type="2fb05f019e6e60363ddfa077-text/javascript">window.gapi_onload=function(){};var scriptEl$$inline_0=document.createElement("script");scriptEl$$inline_0.src="https://apis.google.com/js/client.js";scriptEl$$inline_0.async=!0;var firstScriptEl$$inline_1=document.getElementsByTagName("script")[0];firstScriptEl$$inline_1.parentNode.insertBefore(scriptEl$$inline_0,firstScriptEl$$inline_1);
</script><link rel="shortcut icon" href="https://ssl.gstatic.com/docs/doclist/images/icon_14_pdf_favicon.ico"><link rel="stylesheet" href="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/4096001506-projector_css_ltr.css">
<script type="2fb05f019e6e60363ddfa077-text/javascript">_docs_flag_initialData={"docs-aiiws":"docs_cold_sdf","docs-ails":"docs_cold","docs-fwds":"docs_sdf","info_params":{"token":"HUbTW1cBAAA.PNaXEkJCh9oFOpH8UlemHA.1Gz7QRHe1ULg9vliPx2-iA"},"docosEmbedApiJs":"//docs.google.com/comments/u/0/d/AAHRpnXsXvKfvu-Sc0Bus9b49qEEeMXcuyXfK3MaWuH5gavj_EtEQQxYyXZWoN_V1v8GBdkZ_MX9ah4TJAUiH_wXfDiX2H9ld4A/api/js?hl\u003den_GB\u0026token\u003dAGNctVZ0yTuRQqHVQIby51VNpLiQ8jZlFg:1474714235229","docosUnreadCommentsEnabled":false,"uls":"{\"langs\":[\"en_GB\"],\"itcs\":[],\"override\":\"\",\"selected\":\"\",\"activated\":false}","icso":false,"docs-obsImUrl":"https://ssl.gstatic.com/docs/common/cleardot.gif","docs_oogt":"NONE","docs-egc":true,"docs-chat_wabel":false,"docs-ce":true,"docs-ut":1,"docs-chat_pvt":"AMP3uWafOS8wZadprT6-3SBHd8MEds6V9qSeQ0VK8Pb0s4Bljmb8ek_TmIFy-sZH2PF2aji4JyrIoEME7VSI3ebD4ZxF79IyBrDQ4EsLq2dub9VXVitYa0A","docs-chat_base_url":"talkgadget.google.com/talkgadget/","docs-chat_domain_rotation":true,"docs-cwd":"","docs-epuv2":false,"promo_url":"","promo_title":"","promo_title_prefix":"","promo_content_html":"","promo_link_text":"","promo_element_id":"","promo_orientation":1,"promo_arrow_alignment":0,"promo_show_on_click":false,"promo_hide_arrow":false,"promo_show_on_load":false,"show_promo":false,"promo_mark_dismissed_on_show":false,"promo_use_global_preference":false,"promo_close_button_text":"","promo_icon_url":"","promo_action_id":"","docs-encp":false,"buildLabel":"texmex_2016.37-Thu_RC0","docs-show_debug_info":false,"ondlburl":"//docs.google.com","drive_url":"//drive.google.com?authuser\u003d0","app_url":"https://drive.google.com/file/?authuser\u003d0","docs-mid":2048,"docs-eicd":false,"docs-icdmt":[],"docs-sup":"/file","docs-uptc":["lsrp","noreplica","dl","usp","urp","utm_source","utm_medium","utm_campaign","utm_term","utm_content","sle"],"docs-cwsd":"","docs-al":[0,0,0,1,0],"docs-ndt":"Untitled Texmex","docs-rpe":true,"docs-ebcr":false,"docs-etdimo":false,"docs-mdck":"","docs-mas":"","docs-etiff":false,"docs-spfe":true,"docs-mriim":1800000,"docs-eccbs":false,"docs-net-ernjp":false,"docos-sosj":false,"docs-rlmp":false,"docs-mmpt":15000,"docs-erd":false,"docs-erfar":false,"docs-ssi":false,"docs-ensb":false,"docs-ddts":false,"ecid":true,"docs-emo":false,"docs-eos":false,"docs-pedd":true,"docs-eir":false,"docs-edll":false,"docs-eivu":false,"docs-escd":false,"docs-dc-ca":false,"server_time_ms":1474714235233,"gaia_session_id":"0","app-bc":"#d1d1d1","enable_iframed_embed_api":true,"docs-fut":"//drive.google.com?authuser\u003d0#folders/{folderId}","esid":true,"esubid":false,"docs-etbs":true,"docs-isb":true,"docs-enct":false,"docs-dc":false,"docs-pid":"108679276981805690748","docs-mib":5242880,"docs-mip":6250000,"docs-tdd":false,"enable_kennedy":true,"docs-gth":"","opendv":false,"onePickImportDocumentUrl":"","opmbs":5242880,"opmpd":2500,"opbu":"https://docs.google.com/picker","opru":"https://drive.google.com/relay.html","opdu":true,"opccp":false,"ophi":"texmex","opst":"000770F20345E2F2DD6F872F23399BAE510831AEA77D68D9D2","opuci":"","opest":false,"jobset":"prod","docs-se":false,"docs-ebcrsct":false,"docs-iror":true,"enable_pinned_revisions":false,"enable_edit_blob_revisions":false,"upload_url":"https://docs.google.com/upload/resumableupload?authuser\u003d0","enable_toolbar":true,"enable_link_opener":true,"enable_microscope":true,"enable_manage_timed_text":true,"video_embed_type":"PREFER_FLASH","enable_maps_embed":false,"maps_api_uri":"https://maps.googleapis.com/maps/api/js?key\u003dAIzaSyBCjpnguVjzi6vS67NdBtyYuvCYz3yBxCY\u0026sensor\u003dfalse","maps_display_uri":"https://maps.google.com/maps","docs-epcc":false,"docs_abuse_link":"https://docs.google.com/abuse?id\u003d0B6pbCLVGabYiTXFWaURCWmZZZjQ","enable_csi":true,"csi_service_name":"texmex","enable_chrome_webstore_link":true}; _docs_flag_cek= null ;</script><script type="2fb05f019e6e60363ddfa077-text/javascript">;this.gbar_={CONFIG:[[[0,"www.gstatic.com","og.qtm.en_US.0CZJJEJZa_A.O","co.nz","en-GB","25",0,[4,2,".40.40.40.40.","","0","1474425399","0"],null,"e1rmV8z-DaaCjwSeq7No",null,0,"og.qtm.-1azhalbnuqwtq.L.W.O","AA2YrTtGC5EbF0_R5rT2vwM6i588LJBFJA","AA2YrTuIwHgWd2H9mfuNI2enyxSxd47EJA","",2,0,200,"NZL"],null,null,null,[1,1,0,null,"0","lebrun_shane@hotmail.com","","APfa0bqbid68r20vETgWA2mgFX-PRrsxxtQfv3vI4RjqFICkMvO0Cg5sdzDP-L7LFR0Q4UlSO2ss-lReRaEn_XSv2Vf1zlIDsw=="],[0,1,"",1,0,0,0],["%1$s (default)","Brand Account",1,"%1$s (delegated)",0,null,96,"/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view?usp=sharing\u0026authuser=$authuser",null,null,null,1,"https://accounts.google.com/b/0/ListAccounts?mo=1\u0026mn=1\u0026hl=en-GB",0,"dashboard/overview",null,"Business account that you own","Business account that you manage","Business account icon","Profile","",1,1],null,["1","gci_91f30755d6a6b787dcc2a4062e6e9824.js","googleapis.client:plusone:gapi.iframes","0","en-GB"],null,null,null,[1,null,null,"[[]]",["https","plus.google.com",0,"/u/0","rt=j\u0026sourceid=25",["/u/0/_/og/storage/get",""],["/u/0/_/og/storage/set",""],["/u/0/_/og/storage/remove",""]],"APfa0bqbid68r20vETgWA2mgFX-PRrsxxtQfv3vI4RjqFICkMvO0Cg5sdzDP-L7LFR0Q4UlSO2ss-lReRaEn_XSv2Vf1zlIDsw=="],["m;/_/scs/abc-static/_/js/k=gapi.gapi.en.I_ZVJb_pzks.O/m=__features__/rt=j/d=1/rs=AHpOoo8NNXa6ND5OamMO-moF9Aq-DewphA","https://apis.google.com","","1","1","",null,1,"es_plusone_gc_20160915.0_p0","en-GB"],[0.009999999776482582,"co.nz","25",[null,"","w",null,1,5184000,1,0,"",0],null,[["","","0",0,0,-1]],null,0,null,null,["5061451","google\\.(com|ru|ca|by|kz|com\\.mx|com\\.tr)$",1]],[0,0.001000000047497451,1,40400,25,"NZL","en-GB","1474425399.0"],[[null,null,null,"//www.gstatic.com/og/_/js/k=og.qtm.en_US.0CZJJEJZa_A.O/rt=j/m=qgl,q_d,qdid/exm=qaaw,qabr,qadd,qaid,qalo,qano,qebr,qein,qhaw,qhbr,qhch,qhga,qhid,qhin,qhlo,qhmn,qhno,qhpc,qhpr,qhsf,qhtb,qhtt/d=1/ed=1/rs=AA2YrTtGC5EbF0_R5rT2vwM6i588LJBFJA"],[null,null,null,"//www.gstatic.com/og/_/ss/k=og.qtm.-1azhalbnuqwtq.L.W.O/m=q_d,qdid/excm=qaaw,qabr,qadd,qaid,qalo,qano,qebr,qein,qhaw,qhbr,qhch,qhga,qhid,qhin,qhlo,qhmn,qhno,qhpc,qhpr,qhsf,qhtb,qhtt/d=1/ed=1/rs=AA2YrTuIwHgWd2H9mfuNI2enyxSxd47EJA"]]]],};this.gbar_=this.gbar_||{};(function(_){var window=this;
try{
var aa,ba,ca,da,sa,ta;for(_.k,aa="function"==typeof Object.defineProperties?Object.defineProperty:function(a,c,d){if(d.get||d.set)throw new TypeError("ES3 does not support getters and setters.");a!=Array.prototype&&a!=Object.prototype&&(a[c]=d.value)},ba="undefined"!=typeof window&&window===this?this:"undefined"!=typeof window.global&&null!=window.global?window.global:this,ca=["String","prototype","startsWith"],da=0;da<ca.length-1;da++){var fa=ca[da];fa in ba||(ba[fa]={});ba=ba[fa]}
var ga=ca[ca.length-1],ha=ba[ga],ia=ha?ha:function(a,c){var d;if(null==this)throw new TypeError("The 'this' value for String.prototype.startsWith must not be null or undefined");if(a instanceof RegExp)throw new TypeError("First argument to String.prototype.startsWith must not be a regular expression");d=this+"";a+="";for(var e=d.length,f=a.length,g=Math.max(0,Math.min(c|0,d.length)),h=0;h<f&&g<e;)if(d[g++]!=a[h++])return!1;return h>=f};ia!=ha&&null!=ia&&aa(ba,ga,{configurable:!0,writable:!0,value:ia});
_.ja=_.ja||{};_.m=this;_.ka=function(a){return void 0!==a};_.la=function(){};_.ma=function(a){a.Aa=function(){return a.Le?a.Le:a.Le=new a}};
_.na=function(a){var c=typeof a;if("object"==c)if(a){if(a instanceof Array)return"array";if(a instanceof Object)return c;var d=Object.prototype.toString.call(a);if("[object Window]"==d)return"object";if("[object Array]"==d||"number"==typeof a.length&&"undefined"!=typeof a.splice&&"undefined"!=typeof a.propertyIsEnumerable&&!a.propertyIsEnumerable("splice"))return"array";if("[object Function]"==d||"undefined"!=typeof a.call&&"undefined"!=typeof a.propertyIsEnumerable&&!a.propertyIsEnumerable("call"))return"function"}else return"null";
else if("function"==c&&"undefined"==typeof a.call)return"object";return c};_.oa=function(a){return"array"==_.na(a)};_.n=function(a){return"string"==typeof a};_.pa=function(a){return"number"==typeof a};_.ra="closure_uid_"+(1E9*Math.random()>>>0);sa=function(a,c,d){return a.call.apply(a.bind,arguments)};
ta=function(a,c,d){if(!a)throw Error();if(2<arguments.length){var e=Array.prototype.slice.call(arguments,2);return function(){var d=Array.prototype.slice.call(arguments);Array.prototype.unshift.apply(d,e);return a.apply(c,d)}}return function(){return a.apply(c,arguments)}};_.q=function(a,c,d){_.q=Function.prototype.bind&&-1!=Function.prototype.bind.toString().indexOf("native code")?sa:ta;return _.q.apply(null,arguments)};_.ua=Date.now||function(){return+new Date};
_.t=function(a,c){var d=a.split("."),e=_.m;d[0]in e||!e.execScript||e.execScript("var "+d[0]);for(var f;d.length&&(f=d.shift());)!d.length&&_.ka(c)?e[f]=c:e[f]?e=e[f]:e=e[f]={}};_.u=function(a,c){function d(){}d.prototype=c.prototype;a.H=c.prototype;a.prototype=new d;a.prototype.constructor=a;a.Uh=function(a,d,g){for(var e=Array(arguments.length-2),f=2;f<arguments.length;f++)e[f-2]=arguments[f];return c.prototype[d].apply(a,e)}};
_.va=function(a){if(Error.captureStackTrace)Error.captureStackTrace(this,_.va);else{var c=Error().stack;c&&(this.stack=c)}a&&(this.message=String(a))};_.u(_.va,Error);_.va.prototype.name="CustomError";var xa;_.wa=String.prototype.trim?function(a){return a.trim()}:function(a){return a.replace(/^[\s\xa0]+|[\s\xa0]+$/g,"")};
_.ya=function(a,c){for(var d=0,e=(0,_.wa)(String(a)).split("."),f=(0,_.wa)(String(c)).split("."),g=Math.max(e.length,f.length),h=0;0==d&&h<g;h++){var l=e[h]||"",p=f[h]||"";do{l=/(\d*)(\D*)(.*)/.exec(l)||["","","",""];p=/(\d*)(\D*)(.*)/.exec(p)||["","","",""];if(0==l[0].length&&0==p[0].length)break;d=xa(0==l[1].length?0:(0,window.parseInt)(l[1],10),0==p[1].length?0:(0,window.parseInt)(p[1],10))||xa(0==l[2].length,0==p[2].length)||xa(l[2],p[2]);l=l[3];p=p[3]}while(0==d)}return d}; xa=function(a,c){return a<c?-1:a>c?1:0};
_.za=Array.prototype.indexOf?function(a,c,d){return Array.prototype.indexOf.call(a,c,d)}:function(a,c,d){d=null==d?0:0>d?Math.max(0,a.length+d):d;if(_.n(a))return _.n(c)&&1==c.length?a.indexOf(c,d):-1;for(;d<a.length;d++)if(d in a&&a[d]===c)return d;return-1};_.Aa=Array.prototype.forEach?function(a,c,d){Array.prototype.forEach.call(a,c,d)}:function(a,c,d){for(var e=a.length,f=_.n(a)?a.split(""):a,g=0;g<e;g++)g in f&&c.call(d,f[g],g,a)};
_.Ba=Array.prototype.filter?function(a,c,d){return Array.prototype.filter.call(a,c,d)}:function(a,c,d){for(var e=a.length,f=[],g=0,h=_.n(a)?a.split(""):a,l=0;l<e;l++)if(l in h){var p=h[l];c.call(d,p,l,a)&&(f[g++]=p)}return f};_.Ca=Array.prototype.map?function(a,c,d){return Array.prototype.map.call(a,c,d)}:function(a,c,d){for(var e=a.length,f=Array(e),g=_.n(a)?a.split(""):a,h=0;h<e;h++)h in g&&(f[h]=c.call(d,g[h],h,a));return f}; _.Da=Array.prototype.some?function(a,c,d){return Array.prototype.some.call(a,c,d)}:function(a,c,d){for(var e=a.length,f=_.n(a)?a.split(""):a,g=0;g<e;g++)if(g in f&&c.call(d,f[g],g,a))return!0;return!1};
a:{var Fa=_.m.navigator;if(Fa){var Ga=Fa.userAgent;if(Ga){_.Ea=Ga;break a}}_.Ea=""}_.v=function(a){return-1!=_.Ea.indexOf(a)};var Ha;Ha="constructor hasOwnProperty isPrototypeOf propertyIsEnumerable toLocaleString toString valueOf".split(" ");_.Ia=function(a,c){for(var d,e,f=1;f<arguments.length;f++){e=arguments[f];for(d in e)a[d]=e[d];for(var g=0;g<Ha.length;g++)d=Ha[g],Object.prototype.hasOwnProperty.call(e,d)&&(a[d]=e[d])}};
var Ka=function(){return(_.v("Chrome")||_.v("CriOS"))&&!_.v("Edge")};_.La=function(){return _.v("iPhone")&&!_.v("iPod")&&!_.v("iPad")};_.Ma=function(a){_.Ma[" "](a);return a};_.Ma[" "]=_.la;var Oa=function(a,c){var d=Na;return Object.prototype.hasOwnProperty.call(d,a)?d[a]:d[a]=c(a)};var Va,Wa,Na,fb;_.Pa=_.v("Opera");_.x=_.v("Trident")||_.v("MSIE");_.Qa=_.v("Edge");_.Ra=_.Qa||_.x;_.Sa=_.v("Gecko")&&!(-1!=_.Ea.toLowerCase().indexOf("webkit")&&!_.v("Edge"))&&!(_.v("Trident")||_.v("MSIE"))&&!_.v("Edge");_.z=-1!=_.Ea.toLowerCase().indexOf("webkit")&&!_.v("Edge");_.Ta=_.v("Macintosh");_.Ua=_.v("Linux")||_.v("CrOS");Va=function(){var a=_.m.document;return a?a.documentMode:void 0};
a:{var Xa="",Ya=function(){var a=_.Ea;if(_.Sa)return/rv\:([^\);]+)(\)|;)/.exec(a);if(_.Qa)return/Edge\/([\d\.]+)/.exec(a);if(_.x)return/\b(?:MSIE|rv)[: ]([^\);]+)(\)|;)/.exec(a);if(_.z)return/WebKit\/(\S+)/.exec(a);if(_.Pa)return/(?:Version)[ \/]?(\S+)/.exec(a)}();Ya&&(Xa=Ya?Ya[1]:"");if(_.x){var Za=Va();if(null!=Za&&Za>(0,window.parseFloat)(Xa)){Wa=String(Za);break a}}Wa=Xa}_.bb=Wa;Na={};_.cb=function(a){return Oa(a,function(){return 0<=_.ya(_.bb,a)})};_.eb=function(a){return Number(db)>=a}; var gb=_.m.document;fb=gb&&_.x?Va()||("CSS1Compat"==gb.compatMode?(0,window.parseInt)(_.bb,10):5):void 0;var db=fb;
_.hb=_.v("Firefox");_.ib=_.La()||_.v("iPod");_.jb=_.v("iPad");_.kb=_.v("Android")&&!(Ka()||_.v("Firefox")||_.v("Opera")||_.v("Silk"));_.lb=Ka();_.mb=_.v("Safari")&&!(Ka()||_.v("Coast")||_.v("Opera")||_.v("Edge")||_.v("Silk")||_.v("Android"))&&!(_.La()||_.v("iPad")||_.v("iPod"));
var nb=null;var ob;_.pb=function(a,c){return(new ob(c)).f(a)};ob=function(a){this.b=a};ob.prototype.f=function(a){var c=[];qb(this,a,c);return c.join("")};
var qb=function(a,c,d){if(null==c)d.push("null");else{if("object"==typeof c){if(_.oa(c)){var e=c;c=e.length;d.push("[");for(var f="",g=0;g<c;g++)d.push(f),f=e[g],qb(a,a.b?a.b.call(e,String(g),f):f,d),f=",";d.push("]");return}if(c instanceof String||c instanceof Number||c instanceof Boolean)c=c.valueOf();else{d.push("{");g="";for(e in c)Object.prototype.hasOwnProperty.call(c,e)&&(f=c[e],"function"!=typeof f&&(d.push(g),rb(e,d),d.push(":"),qb(a,a.b?a.b.call(c,e,f):f,d),g=","));d.push("}");return}}switch(typeof c){case "string":rb(c,
d);break;case "number":d.push((0,window.isFinite)(c)&&!(0,window.isNaN)(c)?String(c):"null");break;case "boolean":d.push(String(c));break;case "function":d.push("null");break;default:throw Error("d`"+typeof c);}}},sb={'"':'\\"',"\\":"\\\\","/":"\\/","\b":"\\b","\f":"\\f","\n":"\\n","\r":"\\r","\t":"\\t","\x0B":"\\u000b"},tb=/\uffff/.test("\uffff")?/[\\\"\x00-\x1f\x7f-\uffff]/g:/[\\\"\x00-\x1f\x7f-\xff]/g,rb=function(a,c){c.push('"',a.replace(tb,function(a){var c=sb[a];c||(c="\\u"+(a.charCodeAt(0)| 65536).toString(16).substr(1),sb[a]=c);return c}),'"')};
var wb;_.A=function(){};_.ub="function"==typeof window.Uint8Array;_.B=function(a,c,d,e,f){a.b=null;c||(c=d?[d]:[]);a.N=d?String(d):void 0;a.A=0===d?-1:0;a.j=c;a:{if(a.j.length&&(c=a.j.length-1,(d=a.j[c])&&"object"==typeof d&&!_.oa(d)&&!(_.ub&&d instanceof window.Uint8Array))){a.B=c-a.A;a.o=d;break a}-1<e?(a.B=e,a.o=null):a.B=Number.MAX_VALUE}a.F={};if(f)for(e=0;e<f.length;e++)c=f[e],c<a.B?(c+=a.A,a.j[c]=a.j[c]||_.vb):a.o[c]=a.o[c]||_.vb};_.vb=[];
_.C=function(a,c){if(c<a.B){var d=c+a.A,e=a.j[d];return e===_.vb?a.j[d]=[]:e}e=a.o[c];return e===_.vb?a.o[c]=[]:e};_.D=function(a,c,d){a=_.C(a,c);return null==a?d:a};_.E=function(a,c,d){a.b||(a.b={});if(!a.b[d]){var e=_.C(a,d);e&&(a.b[d]=new c(e))}return a.b[d]};wb=function(a){if(a.b)for(var c in a.b){var d=a.b[c];if(_.oa(d))for(var e=0;e<d.length;e++)d[e]&&d[e].nb();else d&&d.nb()}};_.A.prototype.nb=function(){wb(this);return this.j};var xb=_.m.JSON&&_.m.JSON.stringify||"object"===typeof JSON&&JSON.stringify;
_.A.prototype.f=_.ub?function(){var a=window.Uint8Array.prototype.toJSON;window.Uint8Array.prototype.toJSON=function(){if(!nb){nb={};for(var a=0;65>a;a++)nb[a]="ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=".charAt(a)}for(var a=nb,c=[],f=0;f<this.length;f+=3){var g=this[f],h=f+1<this.length,l=h?this[f+1]:0,p=f+2<this.length,r=p?this[f+2]:0,w=g>>2,g=(g&3)<<4|l>>4,l=(l&15)<<2|r>>6,r=r&63;p||(r=64,h||(l=64));c.push(a[w],a[g],a[l],a[r])}return c.join("")};try{var c=xb.call(null,this.nb(),
yb)}finally{window.Uint8Array.prototype.toJSON=a}return c}:xb?function(){return xb.call(null,this.nb(),yb)}:function(){return _.pb(this.nb(),yb)};var yb=function(a,c){if(_.pa(c)){if((0,window.isNaN)(c))return"NaN";if(window.Infinity===c)return"Infinity";if(-window.Infinity===c)return"-Infinity"}return c};_.A.prototype.toString=function(){wb(this);return this.j.toString()};
_.F=function(){this.Da=this.Da;this.yb=this.yb};_.F.prototype.Da=!1;_.F.prototype.ma=function(){this.Da||(this.Da=!0,this.L())};_.F.prototype.L=function(){if(this.yb)for(;this.yb.length;)this.yb.shift()()};var zb=function(a){_.B(this,a,0,-1,null)};_.u(zb,_.A);_.Ab=function(a){_.B(this,a,0,-1,null)};_.u(_.Ab,_.A);_.Bb=function(a){_.B(this,a,0,-1,null)};_.u(_.Bb,_.A);var Cb=function(a){_.F.call(this);this.j=a;this.b=[];this.f={}};_.u(Cb,_.F);var Db=function(a){_.F.call(this);this.w=a;this.j=this.b=null;this.B=0;this.o={};this.f=!1;a=window.navigator.userAgent;0<=a.indexOf("MSIE")&&0<=a.indexOf("Trident")&&(a=/\b(?:MSIE|rv)[: ]([^\);]+)(\)|;)/.exec(a))&&a[1]&&9>(0,window.parseFloat)(a[1])&&(this.f=!0)};_.u(Db,_.F);
_.Eb=function(a,c,d){if(!a.f)if(d instanceof Array)for(var e in d)_.Eb(a,c,d[e]);else{e=(0,_.q)(a.A,a,c);var f=a.B+d;a.B++;c.setAttribute("data-eqid",f);a.o[f]=e;c&&c.addEventListener?c.addEventListener(d,e,!1):c&&c.attachEvent?c.attachEvent("on"+d,e):a.w.log(Error("e`"+c))}};Db.prototype.A=function(a,c){this.b=c;this.j=a;c.preventDefault?c.preventDefault():c.returnValue=!1};
_.Gb=function(a){_.B(this,a,0,-1,null)};_.u(_.Gb,_.A);_.Hb=function(a){_.B(this,a,0,-1,null)};_.u(_.Hb,_.A);_.G=function(a,c){return null!=a?!!a:!!c};_.H=function(a,c){void 0==c&&(c="");return null!=a?a:c};_.I=function(a,c){void 0==c&&(c=0);return null!=a?a:c};var Ib,Lb,Kb;_.Jb=function(a){var c="//www.google.com/gen_204?",c=c+a.f(2040-c.length);Ib(c)};Ib=function(a){var c=new window.Image,d=Kb;c.onerror=c.onload=c.onabort=function(){d in Lb&&delete Lb[d]};Lb[Kb++]=c;c.src=a};Lb=[];Kb=0;var Mb=function(a){this.b=a};Mb.prototype.log=function(a,c){try{if(this.A(a)){var d=this.j(a,c);this.f(d)}}catch(e){}};Mb.prototype.f=function(a){this.b?a.b():_.Jb(a)};_.Nb=function(){this.data={}};_.Nb.prototype.b=function(){window.console&&window.console.log&&window.console.log("Log data: ",this.data)};_.Nb.prototype.f=function(a){var c=[],d;for(d in this.data)c.push((0,window.encodeURIComponent)(d)+"="+(0,window.encodeURIComponent)(String(this.data[d])));return("atyp=i&zx="+(new Date).getTime()+"&"+c.join("&")).substr(0,a)};
var Ob=function(a,c){this.data={};var d=_.E(a,zb,8)||new zb;this.data.ei=_.H(_.C(a,10));this.data.ogf=_.H(_.C(d,3));var e;e=window.google&&window.google.sn?/.*hp$/.test(window.google.sn)?!1:!0:_.G(_.C(a,7));this.data.ogrp=e?"1":"";this.data.ogv=_.H(_.C(d,6))+"."+_.H(_.C(d,7));this.data.ogd=_.H(_.C(a,21));this.data.ogc=_.H(_.C(a,20));this.data.ogl=_.H(_.C(a,5));c&&(this.data.oggv=c)};_.u(Ob,_.Nb);
_.Pb=function(a,c,d,e,f){Ob.call(this,a,c);_.Ia(this.data,{jexpid:_.H(_.C(a,9)),srcpg:"prop="+_.H(_.C(a,6)),jsr:Math.round(1/e),emsg:d.name+":"+d.message});if(f){f._sn&&(f._sn="og."+f._sn);for(var g in f)this.data[(0,window.encodeURIComponent)(g)]=f[g]}};_.u(_.Pb,Ob);
var Qb=function(a){_.B(this,a,0,-1,null)};_.u(Qb,_.A);_.Rb=function(a){_.B(this,a,0,-1,null)};_.u(_.Rb,_.A);var Xb;_.Sb=function(){this.b={};this.f={}};_.ma(_.Sb);_.Ub=function(a,c){var d=_.Sb.Aa();if(a in d.b){if(d.b[a]!=c)throw new Tb;}else{d.b[a]=c;var e=d.f[a];if(e)for(var f=0,g=e.length;f<g;f++)e[f].b(d.b,a);delete d.f[a]}};_.Wb=function(a,c){if(c in a.b)return a.b[c];throw new Vb;};Xb=function(){_.va.call(this)};_.u(Xb,_.va);var Tb=function(){_.va.call(this)};_.u(Tb,Xb);var Vb=function(){_.va.call(this)};_.u(Vb,Xb);
var Yb=function(a,c,d,e){this.b=e;this.Da=c;this.G=d;this.B=_.I(+_.D(a,2,.001),.001);this.N=_.G(_.C(a,1))&&Math.random()<this.B;this.C=_.I(_.D(a,3,1),1);this.w=0;this.o=null;this.F=_.G(_.D(a,4,!0),!0)};_.u(Yb,Mb);Yb.prototype.log=function(a,c){Yb.H.log.call(this,a,c);if(this.b&&this.F)throw a;};Yb.prototype.A=function(){return this.b||this.N&&this.w<this.C};Yb.prototype.j=function(a,c){try{return(this.o||_.Wb(_.Sb.Aa(),"lm")).b(a,c)}catch(d){return new _.Pb(this.Da,this.G,a,this.B,c)}}; Yb.prototype.f=function(a){Yb.H.f.call(this,a);this.w++};
var Zb=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,50,51,52,53,55,56,57,58,59,500],ac=function(a,c,d,e,f,g){Ob.call(this,a,c);_.Ia(this.data,{oge:e,ogex:_.H(_.C(a,9)),ogp:_.H(_.C(a,6)),ogsr:Math.round(1/($b(e)?_.I(+_.D(d,3,1)):_.I(+_.D(d,2,1E-4)))),ogus:f});if(g){"ogw"in g&&(this.data.ogw=g.ogw,delete g.ogw);"ved"in g&&(this.data.ved=g.ved,delete g.ved);a=[];for(var h in g)0!=a.length&&a.push(","),a.push((h+"").replace(".","%2E").replace(",","%2C")),a.push("."),a.push((g[h]+ "").replace(".","%2E").replace(",","%2C"));g=a.join("");""!=g&&(this.data.ogad=g)}};_.u(ac,Ob);var bc=null,$b=function(a){if(!bc){bc={};for(var c=0;c<Zb.length;c++)bc[Zb[c]]=!0}return!!bc[a]};
var cc=function(a,c,d,e,f){this.b=f;this.N=a;this.F=c;this.Da=e;this.C=_.I(+_.D(a,2,1E-4),1E-4);this.w=_.I(+_.D(a,3,1),1);c=Math.random();this.B=_.G(_.C(a,1))&&c<this.C;this.o=_.G(_.C(a,1))&&c<this.w;a=0;_.G(_.C(d,1))&&(a|=1);_.G(_.C(d,2))&&(a|=2);_.G(_.C(d,3))&&(a|=4);this.G=a};_.u(cc,Mb);cc.prototype.A=function(a){return this.b||($b(a)?this.o:this.B)};cc.prototype.j=function(a,c){return new ac(this.F,this.Da,this.N,a,this.G,c)};
var dc=function(a){this.f=a;this.b=[]};dc.prototype.then=function(a,c,d){this.b.push(new ec(a,c,d));_.fc(this)};_.fc=function(a){if(0<a.b.length){var c=void 0!==a.f;if(c){c=c?a.j:a.o;try{(0,_.Aa)(a.b,c,a)}catch(d){window.console.error(d)}a.b=[]}}};dc.prototype.j=function(a){a.f&&a.f.call(a.b,this.f)};dc.prototype.o=function(a){a.j&&a.j.call(a.b,void 0)};var ec=function(a,c,d){this.f=a;this.j=c;this.b=d};
_.gc=function(){this.f=new dc;this.b=new dc;this.w=new dc;this.j=new dc;this.o=new dc;this.B=new dc};_.ma(_.gc);_.k=_.gc.prototype;_.k.Nf=function(){return this.f};_.k.Tf=function(){return this.b};_.k.Yf=function(){return this.w};_.k.Sf=function(){return this.j};_.k.Wf=function(){return this.o};_.k.Zf=function(){return this.B};
var hc=function(a){_.B(this,a,0,-1,null)};_.u(hc,_.A);_.jc=function(){return _.E(_.ic,_.Ab,1)};_.kc=function(){return _.E(_.ic,_.Bb,5)};var lc;window.gbar_&&window.gbar_.CONFIG?lc=window.gbar_.CONFIG[0]||{}:lc=[];_.ic=new hc(lc);_.t("gbar_._DumpException",function(a){if(this._D)throw a;_.J?_.J.log(a):window.console.error(a)});var mc,nc,oc,pc,qc;mc=_.E(_.ic,_.Rb,3)||new _.Rb;nc=_.jc()||new _.Ab;_.J=new Yb(mc,nc,"quantum:gapiBuildLabel",!1);oc=_.jc()||new _.Ab;pc=_.kc()||new _.Bb;qc=_.E(_.ic,Qb,4)||new Qb;_.rc=new cc(qc,oc,pc,"quantum:gapiBuildLabel",!1);_.sc=new Db(_.J);_.rc.log(8,{m:"BackCompat"==window.document.compatMode?"q":"s"});_.t("gbar.A",dc);dc.prototype.aa=dc.prototype.then;_.t("gbar.B",_.gc);_.gc.prototype.ba=_.gc.prototype.Tf;_.gc.prototype.bb=_.gc.prototype.Yf;_.gc.prototype.bd=_.gc.prototype.Wf;_.gc.prototype.be=_.gc.prototype.Zf;_.gc.prototype.bf=_.gc.prototype.Nf;_.gc.prototype.bg=_.gc.prototype.Sf;_.t("gbar.a",_.gc.Aa());var tc=new Cb(window);_.Ub("api",tc);var uc=_.kc()||new _.Bb,vc=_.H(_.C(uc,8));window.__PVT=vc;_.Ub("eq",_.sc);

}catch(e){_._DumpException(e)}
try{
var wc;wc=function(a){return _.z?"webkit"+a:_.Pa?"o"+a.toLowerCase():a.toLowerCase()};_.xc=_.x?"focusin":"DOMFocusIn";_.yc=wc("AnimationEnd");_.zc=wc("TransitionEnd");
}catch(e){_._DumpException(e)}
try{
var Ac=function(a){_.B(this,a,0,-1,null)};_.u(Ac,_.A);var Bc=function(){_.F.call(this);this.f=[];this.b=[]};_.u(Bc,_.F);Bc.prototype.j=function(a,c){this.f.push({Nc:a,options:c})};Bc.prototype.init=function(a,c,d){window.gapi={};var e=window.___jsl={};e.h=_.H(_.C(a,1));e.ms=_.H(_.C(a,2));e.m=_.H(_.C(a,3));e.l=[];_.C(c,1)&&(a=_.C(c,3))&&this.b.push(a);_.C(d,1)&&(d=_.C(d,2))&&this.b.push(d);_.t("gapi.load",(0,_.q)(this.j,this));return this};
var Cc=_.E(_.ic,_.Gb,14)||new _.Gb,Dc=_.H(_.C(Cc,7));window.__PVT=Dc;var Ec=_.E(_.ic,_.Hb,9)||new _.Hb,Fc=new Ac,Gc=new Bc;Gc.init(Cc,Ec,Fc);_.Ub("gs",Gc);
}catch(e){_._DumpException(e)}
})(this.gbar_);
// Google Inc.
</script><style>@import url('//fonts.googleapis.com/css?lang=en-GB&family=Product+Sans|Roboto:400:700');.gb_6c{font:13px/27px Roboto,RobotoDraft,Arial,sans-serif;z-index:986}@-webkit-keyframes gb__a{0%{opacity:0}50%{opacity:1}}@keyframes gb__a{0%{opacity:0}50%{opacity:1}}a.gb_Ca{border:none;color:#4285f4;cursor:default;font-weight:bold;outline:none;text-align:center;text-decoration:none;text-transform:uppercase;white-space:nowrap;-webkit-user-select:none}a.gb_Ca:hover{background-color:rgba(153,153,153,.2);text-decoration:none}a.gb_Ca:active{background-color:rgba(153,153,153,.4);text-decoration:none}a.gb_Da{background-color:#4285f4;color:#fff}a.gb_Da:hover{background-color:#4285f4}a.gb_Da:active{background-color:#0043b2}.gb_Ea{-webkit-box-shadow:0 1px 1px rgba(0,0,0,.16);box-shadow:0 1px 1px rgba(0,0,0,.16)}.gb_Ca,.gb_Da,.gb_Fa,.gb_Ha{display:inline-block;line-height:28px;padding:0 12px;-webkit-border-radius:2px;border-radius:2px}.gb_Fa{background:#f8f8f8;border:1px solid #c6c6c6}.gb_Ha{background:#f8f8f8}.gb_Fa,#gb a.gb_Fa.gb_Fa,.gb_Ha{color:#666;cursor:default;text-decoration:none}#gb a.gb_Ha.gb_Ha{cursor:default;text-decoration:none}.gb_Ha{border:1px solid #4285f4;font-weight:bold;outline:none;background:#4285f4;background:-webkit-linear-gradient(top,#4387fd,#4683ea);background:linear-gradient(top,#4387fd,#4683ea);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr=#4387fd,endColorstr=#4683ea,GradientType=0)}#gb a.gb_Ha.gb_Ha{color:#fff}.gb_Ha:hover{-webkit-box-shadow:0 1px 0 rgba(0,0,0,.15);box-shadow:0 1px 0 rgba(0,0,0,.15)}.gb_Ha:active{-webkit-box-shadow:inset 0 2px 0 rgba(0,0,0,.15);box-shadow:inset 0 2px 0 rgba(0,0,0,.15);background:#3c78dc;background:-webkit-linear-gradient(top,#3c7ae4,#3f76d3);background:linear-gradient(top,#3c7ae4,#3f76d3);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr=#3c7ae4,endColorstr=#3f76d3,GradientType=0)}.gb_6a{display:none!important}.gb_Hc{display:inline-block;vertical-align:middle}.gb_sc{position:relative}.gb_b{display:inline-block;outline:none;vertical-align:middle;-webkit-border-radius:2px;border-radius:2px;-webkit-box-sizing:border-box;box-sizing:border-box;height:40px;width:40px;color:#000;cursor:default;text-decoration:none}#gb#gb a.gb_b{color:#000;cursor:default;text-decoration:none}.gb_ib{border-color:transparent;border-bottom-color:#fff;border-style:dashed dashed solid;border-width:0 8.5px 8.5px;display:none;position:absolute;left:11.5px;top:43px;z-index:1;height:0;width:0;-webkit-animation:gb__a .2s;animation:gb__a .2s}.gb_jb{border-color:transparent;border-style:dashed dashed solid;border-width:0 8.5px 8.5px;display:none;position:absolute;left:11.5px;z-index:1;height:0;width:0;-webkit-animation:gb__a .2s;animation:gb__a .2s;border-bottom-color:#ccc;border-bottom-color:rgba(0,0,0,.2);top:42px}x:-o-prefocus,div.gb_jb{border-bottom-color:#ccc}.gb_ga{background:#fff;border:1px solid #ccc;border-color:rgba(0,0,0,.2);color:#000;-webkit-box-shadow:0 2px 10px rgba(0,0,0,.2);box-shadow:0 2px 10px rgba(0,0,0,.2);display:none;outline:none;overflow:hidden;position:absolute;right:8px;top:56px;-webkit-animation:gb__a .2s;animation:gb__a .2s;-webkit-border-radius:2px;border-radius:2px;-webkit-user-select:text}.gb_Hc.gb_g .gb_ib,.gb_Hc.gb_g .gb_jb,.gb_Hc.gb_g .gb_ga,.gb_g.gb_ga{display:block}.gb_Hc.gb_g.gb_ke .gb_ib,.gb_Hc.gb_g.gb_ke .gb_jb{display:none}.gb_le{position:absolute;right:8px;top:56px;z-index:-1}.gb_9a .gb_ib,.gb_9a .gb_jb,.gb_9a .gb_ga{margin-top:-10px}.gb_Hc:first-child,#gbsfw:first-child+.gb_Hc{padding-left:4px}.gb_hc{position:relative;float:right}.gb_b{padding:8px}.gb_zd button:focus svg,.gb_ec .gb_vb:focus img,.gb_b:focus{background-color:rgba(0,0,0,0.20);outline:none;-webkit-border-radius:50%;border-radius:50%}.gb_Hc{padding:4px}.gb_ga{z-index:991;line-height:normal}.gb_ga.gb_Ad{left:8px;right:auto}@media (max-width:350px){.gb_ga.gb_Ad{left:0}}.gb_Qb{display:inline-block;position:relative;top:2px;-webkit-user-select:none}.gb_ad .gb_Za{min-width:74px}.gb_rd .gb_Qb{display:none}.gb_ad .gb_Rb{line-height:normal;position:relative;padding-left:16px}.gb_Tb .gb_ic:before{content:url('//www.gstatic.com/images/branding/googlelogo/svg/googlelogo_clr_74x24px.svg');display:inline-block;height:24px;width:74px}.gb_Tb .gb_ic{height:24px;width:74px}.gb_Tb{direction:ltr}.gb_Tb .gb_ic,.gb_Tb{display:inline-block;outline:none;vertical-align:middle}.gb_Xa{display:inline-block;vertical-align:middle}.gb_Wb{border:none;display:block;visibility:hidden}.gb_hd .gb_Tb .gb_ic:before{content:url('//www.gstatic.com/images/branding/googlelogo/svg/googlelogo_light_clr_74x24px.svg')}.gb_gd .gb_Tb .gb_ic:before{content:url('//www.gstatic.com/images/branding/googlelogo/svg/googlelogo_dark_clr_74x24px.svg')}.gb_Xa{background-repeat:no-repeat}.gb_md{display:inline-block;font-family:'Product Sans',Arial,sans-serif;font-size:22px;line-height:24px;padding-left:8px;position:relative;top:-1.5px;vertical-align:middle}.gb_id.gb_md{opacity:.54}.gb_ld:focus .gb_md{text-decoration:underline}.gb_ea .gb_b,.gb_fa .gb_ea .gb_b{background-position:-64px -29px}.gb_X .gb_ea .gb_b{background-position:-29px -29px;opacity:1}.gb_ea .gb_b,.gb_ea .gb_b:hover,.gb_ea .gb_b:focus{opacity:1}.gb_7c{display:none}.gb_xc{color:inherit;font-size:22px;font-weight:500;line-height:48px;padding-left:16px;position:relative;vertical-align:middle;top:2px}.gb_ec.gb_1b .gb_yc{position:relative;top:-1px}.gb_ec{min-width:320px;position:relative}.gb_ec svg{fill:currentColor}.gb_8c{position:fixed;top:0;width:100%}.gb_9c{height:64px}.gb_ec:not(.gb_3b) .gb_Ac,.gb_ec:not(.gb_3b) .gb_2c{display:none!important}.gb_ad{display:table;-webkit-box-sizing:border-box;box-sizing:border-box;position:relative;width:100%}.gb_ec:not(.gb_1b) .gb_ad{padding:8px}.gb_ec.gb_1b .gb_ad{padding:4px}.gb_fc{display:table-cell;vertical-align:middle;white-space:nowrap;-webkit-user-select:none}.gb_cd{width:100%}.gb_ec .gb_dd{-webkit-box-sizing:border-box;box-sizing:border-box;padding-left:24px;width:100%}.gb_cd>*,.gb_gc>*{display:table-cell;vertical-align:middle}.gb_cd>:only-child{display:inline-block}.gb_gc{height:48px;line-height:normal;padding:0 4px}.gb_ed{font-size:14px;max-width:200px;overflow:hidden;padding:0 12px;text-overflow:ellipsis;white-space:nowrap;-webkit-user-select:text}.gb_ec{color:black}.gb_fd{background-color:#fff;-webkit-transition:background-color .4s;transition:background-color .4s}.gb_gd{color:black;background-color:#e0e0e0}.gb_hd{color:white;background-color:#616161}.gb_ec a,.gb_0b a{color:inherit}.gb_ec svg,.gb_0b svg{color:black;opacity:.54}.gb_hd svg{color:white;opacity:1}.gb_id{color:inherit;opacity:1;text-rendering:optimizeLegibility;-webkit-font-smoothing:antialiased}.gb_hd .gb_id,.gb_gd .gb_id{opacity:1}.gb_jd>*{display:block;min-height:48px}.gb_ec.gb_1b .gb_jd>*{padding-top:4px;padding-bottom:4px;padding-left:16px}.gb_ec:not(.gb_1b) .gb_jd>*{padding-top:8px;padding-bottom:8px;padding-left:24px}.gb_jd .gb_Qb{display:table-cell;height:48px;vertical-align:middle}.gb_jd .gb_gc{background-color:#f5f5f5;display:block}.gb_ec.gb_1b .gb_jd .gb_gc{padding:4px}.gb_ec:not(.gb_1b) .gb_jd .gb_gc{padding:8px}.gb_jd .gb_8a{width:40px}.gb_jd .gb_bb{position:absolute;right:0;top:50%}.gb_kd{position:relative}.gb_0b .gb_ld{text-decoration:none}.gb_0b .gb_md{display:inline;white-space:normal;word-break:break-all;word-break:break-word}body.gb_nd [data-ogpc]{-webkit-transition:margin-left .25s cubic-bezier(0.4,0.0,0.2,1),visibility 0s linear .25s;transition:margin-left .25s cubic-bezier(0.4,0.0,0.2,1),visibility 0s linear .25s}body.gb_nd.gb_od [data-ogpc]{-webkit-transition:margin-left .25s cubic-bezier(0.4,0.0,0.2,1),visibility 0s linear 0s;transition:margin-left .25s cubic-bezier(0.4,0.0,0.2,1),visibility 0s linear 0s}body [data-ogpc]{margin-left:0}body.gb_od [data-ogpc]{margin-left:280px}.gb_Va{background-color:#f5f5f5;display:inline-block;overflow:hidden;padding:0;vertical-align:middle;-webkit-border-radius:4px;border-radius:4px;-webkit-box-shadow:0 2px 1px -1px rgba(0,0,0,0.2),0 1px 1px 0 rgba(0,0,0,0.14),0 1px 3px 0 rgba(0,0,0,0.12);box-shadow:0 2px 1px -1px rgba(0,0,0,0.2),0 1px 1px 0 rgba(0,0,0,0.14),0 1px 3px 0 rgba(0,0,0,0.12)}.gb_Wa{background-color:#fff;padding:8px;display:inline-block;line-height:32px;text-align:center;vertical-align:middle}.gb_Va .gb_Xa.gb_Za{min-width:0}.gb_7a{-webkit-background-size:32px 32px;background-size:32px 32px;-webkit-border-radius:50%;border-radius:50%;display:block;margin:0;overflow:hidden;position:relative;height:32px;width:32px;z-index:0}@media (min-resolution:1.25dppx),(-o-min-device-pixel-ratio:5/4),(-webkit-min-device-pixel-ratio:1.25),(min-device-pixel-ratio:1.25){.gb_7a::before{display:inline-block;-webkit-transform:scale(.5);transform:scale(.5);-webkit-transform-origin:left 0;transform-origin:left 0}.gb_rb::before{display:inline-block;-webkit-transform:scale(.5);transform:scale(.5);-webkit-transform-origin:left 0;transform-origin:left 0}}.gb_7a:hover,.gb_7a:focus{-webkit-box-shadow:0 1px 0 rgba(0,0,0,.15);box-shadow:0 1px 0 rgba(0,0,0,.15)}.gb_7a:active{-webkit-box-shadow:inset 0 2px 0 rgba(0,0,0,.15);box-shadow:inset 0 2px 0 rgba(0,0,0,.15)}.gb_7a:active::after{background:rgba(0,0,0,.1);-webkit-border-radius:50%;border-radius:50%;content:'';display:block;height:100%}.gb_8a{cursor:pointer;line-height:40px;min-width:30px;opacity:.75;overflow:hidden;vertical-align:middle;text-overflow:ellipsis}.gb_b.gb_8a{width:auto}.gb_8a:hover,.gb_8a:focus{opacity:.85}.gb_9a .gb_8a,.gb_9a .gb_ab{line-height:26px}#gb#gb.gb_9a a.gb_8a,.gb_9a .gb_ab{font-size:11px;height:auto}.gb_bb{border-top:4px solid #000;border-left:4px dashed transparent;border-right:4px dashed transparent;display:inline-block;margin-left:6px;opacity:.75;vertical-align:middle}.gb_cb:hover .gb_bb{opacity:.85}.gb_X .gb_8a,.gb_X .gb_bb{opacity:1}#gb#gb.gb_X.gb_X a.gb_8a,#gb#gb .gb_X.gb_X a.gb_8a{color:#fff}.gb_X.gb_X .gb_bb{border-top-color:#fff;opacity:1}.gb_fa .gb_7a:hover,.gb_X .gb_7a:hover,.gb_fa .gb_7a:focus,.gb_X .gb_7a:focus{-webkit-box-shadow:0 1px 0 rgba(0,0,0,.15),0 1px 2px rgba(0,0,0,.2);box-shadow:0 1px 0 rgba(0,0,0,.15),0 1px 2px rgba(0,0,0,.2)}.gb_db .gb_eb,.gb_fb .gb_eb{position:absolute;right:1px}.gb_eb.gb_R,.gb_gb.gb_R,.gb_cb.gb_R{-webkit-flex:0 1 auto;flex:0 1 auto;-webkit-flex:0 1 main-size;flex:0 1 main-size}.gb_hb.gb_W .gb_8a{width:30px!important}.gb_eb .gb_b{padding:4px}.gb_qd{display:none}.gb_Xb{-webkit-border-radius:50%;border-radius:50%;display:inline-block;margin:0 4px;padding:12px;overflow:hidden;vertical-align:middle;height:24px;width:24px;-webkit-user-select:none}.gb_Xb:focus{background-color:rgba(0,0,0,0.16);outline:none}.gb_Zb{display:none}.gb_0b{background-color:#fff;bottom:0;color:#000;height:-webkit-calc(100vh - 100%);height:calc(100vh - 100%);overflow-y:auto;overflow-x:hidden;position:absolute;top:100%;z-index:990;will-change:visibility;visibility:hidden;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;-webkit-transition:transform .25s cubic-bezier(0.4,0.0,0.2,1),visibility 0s linear .25s;transition:transform .25s cubic-bezier(0.4,0.0,0.2,1),visibility 0s linear .25s}.gb_0b.gb_1b{width:264px;-webkit-transform:translateX(-264px);transform:translateX(-264px)}.gb_0b:not(.gb_1b){width:280px;-webkit-transform:translateX(-280px);transform:translateX(-280px)}.gb_0b.gb_g{-webkit-transform:translateX(0);transform:translateX(0);visibility:visible;-webkit-box-shadow:0 0 4px rgba(0,0,0,.28);box-shadow:0 0 4px rgba(0,0,0,.28);-webkit-transition:transform .25s cubic-bezier(0.4,0.0,0.2,1),visibility 0s linear 0s;transition:transform .25s cubic-bezier(0.4,0.0,0.2,1),visibility 0s linear 0s}.gb_2b.gb_3b{background-color:transparent;-webkit-box-shadow:0 0;box-shadow:0 0}.gb_2b.gb_3b>:not(.gb_4b){display:none}.gb_4b{display:-webkit-flex;display:flex;-webkit-flex:1 1 auto;flex:1 1 auto;-webkit-flex-direction:column;flex-direction:column}.gb_4b>.gb_5b{-webkit-flex:1 0 auto;flex:1 0 auto}.gb_4b>.gb_6b{-webkit-flex:0 0 auto;flex:0 0 auto}.gb_7b{list-style:none;margin-top:0;margin-bottom:0;padding:8px 0}.gb_0b:not(.gb_2b) .gb_7b:first-child{padding:0 0 8px 0}.gb_7b:not(:last-child){border-bottom:1px solid #ddd}.gb_8b{display:block;min-height:40px;padding-bottom:4px;padding-top:4px;cursor:pointer;font-family:Roboto,RobotoDraft,Helvetica,Arial,sans-serif;color:#767676}.gb_0b.gb_1b .gb_8b{padding-left:16px}.gb_0b:not(.gb_1b) .gb_8b{padding-left:24px}.gb_8b:hover{background-color:rgba(0,0,0,.03)}.gb_8b.gb_9b{background:rgba(0,0,0,.05);font-weight:bold;color:#212121}.gb_8b .gb_ac{text-decoration:none;display:inline-block;width:100%}.gb_8b .gb_ac:focus{outline:none}.gb_8b .gb_bc{padding-left:32px;display:inline-block;line-height:40px;vertical-align:top;width:176px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}.gb_4b.gb_6 .gb_ac:focus .gb_bc{text-decoration:underline}.gb_8b .gb_cc{height:24px;width:24px;float:left;margin-top:8px;vertical-align:middle}.gb_pc .gb_sc{font-size:14px;font-weight:bold;top:0;right:0}.gb_pc .gb_b{display:inline-block;vertical-align:middle;-webkit-box-sizing:border-box;box-sizing:border-box;height:40px;width:40px}.gb_pc .gb_ib{border-bottom-color:#e5e5e5}.gb_tc{background-color:rgba(0,0,0,.55);color:white;font-size:12px;font-weight:bold;line-height:24px;margin:5px;padding:0 2px;text-align:center;-webkit-box-sizing:border-box;box-sizing:border-box;-webkit-border-radius:50%;border-radius:50%;height:24px;width:24px}.gb_tc.gb_uc{background-position:-79px 0}.gb_tc.gb_vc{background-position:-79px -64px}.gb_b:hover .gb_tc,.gb_b:focus .gb_tc{background-color:rgba(0,0,0,.85)}#gbsfw.gb_wc{background:#e5e5e5;border-color:#ccc}.gb_fa .gb_tc{background-color:rgba(0,0,0,.7)}.gb_X .gb_tc.gb_tc,.gb_X .gb_mc .gb_tc.gb_tc,.gb_X .gb_mc .gb_b:hover .gb_tc,.gb_X .gb_mc .gb_b:focus .gb_tc{background-color:#fff;color:#404040}.gb_X .gb_tc.gb_uc{background-position:-54px -64px}.gb_X .gb_tc.gb_vc{background-position:0 -64px}.gb_mc .gb_tc.gb_tc{background-color:#db4437;color:white}.gb_mc .gb_b:hover .gb_tc,.gb_mc .gb_b:focus .gb_tc{background-color:#a52714}.gb_sd{line-height:20px;margin:2px;text-align:center;vertical-align:middle;-webkit-box-sizing:border-box;box-sizing:border-box;-webkit-border-radius:50%;border-radius:50%;height:20px;width:20px}.gb_pc a{line-height:24px;-webkit-border-radius:50%;border-radius:50%}.gb_td.gb_uc .gb_sd{display:none}.gb_td svg{display:none;height:24px;width:24px}.gb_td.gb_uc svg{display:block}.gb_td.gb_vc svg{display:none}.gb_mc .gb_sd{color:white;background-color:#db4437;opacity:1}.gb_gd .gb_mc .gb_sd{color:white;background-color:#db4437}.gb_hd .gb_mc .gb_sd{color:#212121;background-color:white}.gb_ud{display:none}.gb_he{cursor:pointer;padding:13px}.gb_ie{background-color:rgba(0,0,0,0.1);-webkit-box-shadow:inset 1px 1px 3px rgba(0,0,0,.24);box-shadow:inset 1px 1px 3px rgba(0,0,0,.24);width:34px;height:17px;-webkit-border-radius:8px;border-radius:8px;position:relative;-webkit-transition:background-color ease 150ms;transition:background-color ease 150ms}.gb_he[aria-pressed=true] .gb_ie{background-color:rgba(255,255,255,0.1)}.gb_je{position:absolute;width:25px;height:25px;-webkit-border-radius:50%;border-radius:50%;-webkit-box-shadow:0 0 2px rgba(0,0,0,.12),0 2px 4px rgba(0,0,0,.24);box-shadow:0 0 2px rgba(0,0,0,.12),0 2px 4px rgba(0,0,0,.24);top:-4px;-webkit-transform:translateX(-12px);transform:translateX(-12px);background-color:white;-webkit-transition:transform ease 150ms;transition:transform ease 150ms}.gb_he[aria-pressed=true] .gb_je{-webkit-transform:translateX(20px);transform:translateX(20px)}.gb_je img{position:absolute;margin:5px;width:15px;height:15px}.gb_vd{line-height:0;padding-left:16px;-webkit-user-select:none}.gb_cd>.gb_vd:only-child{float:right}.gb_vd .gb_vb{display:inline-block}.gb_vd .gb_vb img{opacity:.54;width:24px;height:24px;padding:12px}.gb_hd .gb_vd .gb_vb img{opacity:1}.gb_vd .gb_wd{display:table-cell;height:48px;overflow:hidden;vertical-align:middle}.gb_zc{display:none}.gb_zc.gb_g{display:block}.gb_Ac{background-color:#fff;-webkit-box-shadow:0 1px 0 rgba(0,0,0,0.08);box-shadow:0 1px 0 rgba(0,0,0,0.08);color:#000;height:40px;padding:16px 24px;position:relative;white-space:nowrap;z-index:986}.gb_Ac .gb_vb{border:0;font-weight:500;font-size:14px;line-height:36px;min-width:32px;padding:0 16px;position:relative;vertical-align:middle}.gb_Ac .gb_vb:before{content:'';height:6px;left:0;position:absolute;top:-6px;width:100%}.gb_Ac .gb_vb:after{bottom:-6px;content:'';height:6px;left:0;position:absolute;width:100%}.gb_Ac .gb_vb+.gb_vb{margin-left:8px}.gb_Bc{height:48px;padding:4px;margin:-8px 0 0 -8px}.gb_Cc{display:inline-block;vertical-align:top;font-family:Roboto,RobotoDraft,Helvetica,Arial,sans-serif;padding-left:8px;overflow:hidden;width:640px}.gb_Dc{background-color:inherit;display:inline-block;position:absolute;top:18px;right:24px}.gb_Ec{line-height:20px;font-size:16px;font-weight:700;color:rgba(0,0,0,.87);width:640px}.gb_Fc{line-height:20px;font-size:13px;font-weight:400;color:rgba(0,0,0,.54);width:640px}.gb_Hc.gb_Ic{padding:0}.gb_Ic .gb_ga{padding:26px 26px 22px 13px;background:#ffffff}.gb_Jc.gb_Ic .gb_ga{background:#4d90fe}a.gb_Kc{color:#666666!important;font-size:22px;height:9px;opacity:.8;position:absolute;right:14px;top:4px;text-decoration:none!important;width:9px}.gb_Jc a.gb_Kc{color:#c1d1f4!important}a.gb_Kc:hover,a.gb_Kc:active{opacity:1}.gb_Lc{padding:0;width:258px;white-space:normal;display:table}.gb_Mc .gb_ga{top:56px;border:0;padding:16px;-webkit-box-shadow:4px 4px 12px rgba(0,0,0,0.4);box-shadow:4px 4px 12px rgba(0,0,0,0.4)}.gb_Mc .gb_Lc{width:328px}.gb_Mc .gb_Ha,.gb_Mc .gb_Nc,.gb_Mc .gb_Oc,.gb_Mc .gb_Ca,.gb_Pc{line-height:normal;font-family:Roboto,RobotoDraft,Helvetica,Arial,sans-serif}.gb_Mc .gb_Ha,.gb_Mc .gb_Nc,.gb_Mc .gb_Ca{font-weight:500}.gb_Mc .gb_Ha,.gb_Mc .gb_Ca{border:0;padding:10px 8px}.gb_Ic .gb_Ha:active{outline:none;-webkit-box-shadow:0 4px 5px rgba(0,0,0,.16);box-shadow:0 4px 5px rgba(0,0,0,.16)}.gb_Mc .gb_Nc{color:#222;margin-bottom:8px}.gb_Mc .gb_Oc{color:#808080;font-size:14px}.gb_Qc{text-align:right;font-size:14px;padding-bottom:10px;white-space:nowrap}.gb_Qc .gb_Rc{margin-left:8px}.gb_Qc .gb_Sc.gb_Rc img{background-color:inherit;-webkit-border-radius:initial;border-radius:initial;height:1.5em;margin:-0.25em 10px -0.25em 2px;vertical-align:text-top;width:1.5em}.gb_Mc .gb_Lc .gb_Tc .gb_Sc{border:2px solid transparent}.gb_Mc .gb_Lc .gb_Tc .gb_Sc:focus{border-color:#bbccff}.gb_Pc{background-color:#404040;color:#fff;padding:16px;position:absolute;top:56px;width:328px;right:8px;-webkit-border-radius:2px;border-radius:2px;-webkit-box-shadow:4px 4px 12px rgba(0,0,0,0.4);box-shadow:4px 4px 12px rgba(0,0,0,0.4)}.gb_Pc a,.gb_Pc a:visited{color:#5e97f6;text-decoration:none}.gb_Uc{position:absolute;right:20px;text-transform:uppercase}.gb_Jc .gb_Lc{width:200px}.gb_Nc{color:#333333;font-size:16px;line-height:20px;margin:0;margin-bottom:16px}.gb_Jc .gb_Nc{color:#ffffff}.gb_Oc{color:#666666;line-height:17px;margin:0;margin-bottom:5px}.gb_Jc .gb_Oc{color:#ffffff}.gb_Vc{text-decoration:none;color:#5e97f6}.gb_Vc:visited{color:#5e97f6}.gb_Vc:hover,.gb_Vc:active{text-decoration:underline}.gb_Wc{position:absolute;background:transparent;top:-999px;z-index:-1;visibility:hidden;margin-top:1px;margin-left:1px}#gb .gb_Ic{margin:0}.gb_Ic .gb_vb{background:#4d90fe;border-color:#3079ed;margin-top:15px}.gb_Mc .gb_Ha{background:#4285f4}#gb .gb_Ic a.gb_vb.gb_vb{color:#ffffff}.gb_Ic .gb_vb:hover{background:#357ae8;border-color:#2f5bb7}.gb_Xc .gb_sc .gb_ib{border-bottom-color:#ffffff;display:block}.gb_Zc .gb_sc .gb_ib{border-bottom-color:#4d90fe;display:block}.gb_Xc .gb_sc .gb_jb,.gb_Zc .gb_sc .gb_jb{display:block}.gb_0c,.gb_Tc{display:table-cell}.gb_0c{vertical-align:middle}.gb_Mc .gb_0c{vertical-align:top}.gb_Tc{padding-left:13px;width:100%}.gb_Mc .gb_Tc{padding-left:20px}.gb_1c{color:#ff0000}.gb_2c{color:#ffffff;font-size:13px;font-weight:bold;height:25px;line-height:19px;padding-top:5px;padding-left:12px;position:relative;background-color:#4d90fe}.gb_2c .gb_3c{color:#ffffff;cursor:default;font-size:22px;font-weight:normal;position:absolute;right:12px;top:5px}.gb_2c .gb_Rc,.gb_2c .gb_4c{color:#ffffff;display:inline-block;font-size:11px;margin-left:16px;padding:0 8px;white-space:nowrap}.gb_5c{background:none;background-image:-webkit-gradient(linear,left top,left bottom,from(rgba(0,0,0,0.16)),to(rgba(0,0,0,0.2)));background-image:-webkit-linear-gradient(top,rgba(0,0,0,0.16),rgba(0,0,0,0.2));background-image:linear-gradient(top,rgba(0,0,0,0.16),rgba(0,0,0,0.2));background-image:-webkit-linear-gradient(top,rgba(0,0,0,0.16),rgba(0,0,0,0.2));border-radius:2px;border:1px solid #dcdcdc;border:1px solid rgba(0,0,0,0.1);cursor:default!important;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr=#160000ff,endColorstr=#220000ff);text-decoration:none!important;-webkit-border-radius:2px}.gb_5c:hover{background:none;background-image:-webkit-gradient(linear,left top,left bottom,from(rgba(0,0,0,0.14)),to(rgba(0,0,0,0.2)));background-image:-webkit-linear-gradient(top,rgba(0,0,0,0.14),rgba(0,0,0,0.2));background-image:linear-gradient(top,rgba(0,0,0,0.14),rgba(0,0,0,0.2));background-image:-webkit-linear-gradient(top,rgba(0,0,0,0.14),rgba(0,0,0,0.2));border:1px solid rgba(0,0,0,0.2);box-shadow:0 1px 1px rgba(0,0,0,0.1);-webkit-box-shadow:0 1px 1px rgba(0,0,0,0.1);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr=#14000000,endColorstr=#22000000)}.gb_5c:active{box-shadow:inset 0 1px 2px rgba(0,0,0,0.3);-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,0.3)}.gb_ec .gb_Ca{color:#4285f4}.gb_ec .gb_Da{color:#fff}.gb_ec .gb_vb:focus{outline:none}.gb_Wd,.gb_Xd,.gb_Zd{display:none}.gb_dd{width:100%;height:48px}.gb_zd{background:rgba(0,0,0,0.04);border:1px solid rgba(0,0,0,0);-webkit-border-radius:4px;border-radius:4px;max-width:720px;position:relative;-webkit-transition:background 100ms ease-in,width 100ms ease-out;transition:background 100ms ease-in,width 100ms ease-out}.gb_zd.gb_0d{-webkit-border-radius:4px 4px 0 0;border-radius:4px 4px 0 0}.gb_hd .gb_zd{background:rgba(255,255,255,0.16)}.gb_zd button{background:none;border:none;opacity:.54;outline:none;padding:0 4px;line-height:0}.gb_zd button svg,.gb_zd button img{padding:7px;margin:4px}.gb_1d{float:left}.gb_2d{display:none;float:left}.gb_3d{position:absolute;right:0;cursor:default;visibility:hidden;opacity:0;-webkit-transition:opacity 250ms ease-out;transition:opacity 250ms ease-out}.gb_4d .gb_3d{right:35px}.gb_3d.gb_5d{visibility:visible;opacity:.54}.gb_6d{position:absolute;right:0}.gb_7d{height:46px;padding:0 11px;margin-right:48px}.gb_4d .gb_7d{margin-right:83px}.gb_Rd{border:none;font:normal 16px Roboto,sans-serif;height:24px;outline:none;padding:11px 16px 11px 0;width:100%;background:transparent}.gb_hd .gb_Rd{color:rgba(255,255,255,0.541)}.gb_8d{height:46px;line-height:46px;padding-bottom:0;padding-top:0}.gb_zd:not(.gb_Qd) input::-webkit-input-placeholder{color:rgba(0,0,0,0.54)}.gb_hd .gb_zd:not(.gb_Qd) input::-webkit-input-placeholder{color:rgba(255,255,255,0.70)}.gb_zd.gb_9d[aria-expanded="false"]{background:transparent;float:right;width:48px}.gb_zd.gb_9d[aria-expanded="false"] .gb_7d,.gb_zd.gb_9d[aria-expanded="false"] .gb_3d,.gb_zd.gb_9d[aria-expanded="false"] .gb_6d{display:none}.gb_zd.gb_9d[aria-expanded="true"]{margin-left:0;position:absolute;width:auto}.gb_zd.gb_9d[aria-expanded="true"] .gb_1d{display:none}.gb_zd.gb_9d[aria-expanded="true"] .gb_2d{display:block}.gb_ae{position:relative}.gb_be{margin:0 56px;padding:0;text-align:center;white-space:nowrap;-webkit-user-select:none;overflow:auto}.gb_be::-webkit-scrollbar{display:none}.gb_1b .gb_be{margin:0}.gb_ce,.gb_de{margin:12px 0;position:absolute;top:0;height:24px;width:24px}.gb_ce{left:0;margin-left:32px}.gb_de{margin-right:32px;right:0}.gb_1b .gb_ce,.gb_1b .gb_de{margin-left:0;margin-right:0}.gb_ce,.gb_de{visibility:hidden}.gb_ae.gb_ee:hover .gb_ce,.gb_ae.gb_fe:hover .gb_de{visibility:visible}.gb_ae.gb_ee .gb_be{-webkit-mask-image:-webkit-linear-gradient(left,rgba(0,0,0,0),rgba(0,0,0,1) 100px)}.gb_ae.gb_fe .gb_be{-webkit-mask-image:-webkit-linear-gradient(right,rgba(0,0,0,0),rgba(0,0,0,1) 100px)}.gb_ae.gb_ee.gb_fe .gb_be{-webkit-mask-image:-webkit-linear-gradient(left,rgba(0,0,0,0),rgba(0,0,0,1) 100px,rgba(0,0,0,1) 50%,rgba(0,0,0,0) 50%),-webkit-linear-gradient(right,rgba(0,0,0,0),rgba(0,0,0,1) 100px,rgba(0,0,0,1) 50%,rgba(0,0,0,0) 50%)}.gb_1b .gb_ae.gb_ee .gb_be{-webkit-mask-image:-webkit-linear-gradient(left,rgba(0,0,0,0),rgba(0,0,0,1) 50px)}.gb_1b .gb_ae.gb_fe .gb_be{-webkit-mask-image:-webkit-linear-gradient(right,rgba(0,0,0,0),rgba(0,0,0,1) 50px)}.gb_1b .gb_ae.gb_ee.gb_fe .gb_be{-webkit-mask-image:-webkit-linear-gradient(left,rgba(0,0,0,0),rgba(0,0,0,1) 50px,rgba(0,0,0,1) 50%,rgba(0,0,0,0) 50%),-webkit-linear-gradient(right,rgba(0,0,0,0),rgba(0,0,0,1) 50px,rgba(0,0,0,1) 50%,rgba(0,0,0,0) 50%)}.gb_ge{cursor:pointer;display:inline-table;outline:none}.gb_ge>span{border:0 solid transparent;border-width:2px 0;display:table-cell;height:44px;padding:0 24px;opacity:.7;text-transform:uppercase;vertical-align:middle}.gb_ge.gb_9b:focus{background-color:rgba(0,0,0,.16)}.gb_ge.gb_9b>span{border-bottom-color:black;opacity:1}.gb_hd .gb_ge.gb_9b>span{border-bottom-color:white}.gb_gd .gb_ge.gb_9b>span{border-bottom-color:black}sentinel{}.gbii::before{content:url(//lh3.googleusercontent.com/-CnasPhGHo70/AAAAAAAAAAI/AAAAAAAAAAA/APaXHhTWfHvY4Yn-JvZ-UjOpQffdjCibpg/s32-c-mo/photo.jpg)}.gbip::before{content:url(//lh3.googleusercontent.com/-CnasPhGHo70/AAAAAAAAAAI/AAAAAAAAAAA/APaXHhTWfHvY4Yn-JvZ-UjOpQffdjCibpg/s96-c-mo/photo.jpg)}@media (min-resolution:1.25dppx),(-o-min-device-pixel-ratio:5/4),(-webkit-min-device-pixel-ratio:1.25),(min-device-pixel-ratio:1.25){.gbii::before{content:url(//lh3.googleusercontent.com/-CnasPhGHo70/AAAAAAAAAAI/AAAAAAAAAAA/APaXHhTWfHvY4Yn-JvZ-UjOpQffdjCibpg/s64-c-mo/photo.jpg)}.gbip::before{content:url(//lh3.googleusercontent.com/-CnasPhGHo70/AAAAAAAAAAI/AAAAAAAAAAA/APaXHhTWfHvY4Yn-JvZ-UjOpQffdjCibpg/s192-c-mo/photo.jpg)}}
</style><script async="" type="2fb05f019e6e60363ddfa077-text/javascript" charset="UTF-8" src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/rs=AA2YrTtGC5EbF0_R5rT2vwM6i588LJBFJA"></script><link type="text/css" rel="stylesheet" href="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/rs=AA2YrTuIwHgWd2H9mfuNI2enyxSxd47EJA"></head><script src="/cdn-cgi/scripts/7d0fa10a/cloudflare-static/rocket-loader.min.js" data-cf-settings="2fb05f019e6e60363ddfa077-|49"></script><body dir="ltr" role="application" onload="_onProjectorLoad();" onunload="if (!window.__cfRLUnblockHandlers) return false; _disposeProjector();" itemscope="" itemtype="http://schema.org/CreativeWork/DocumentObject" class="drive-viewer-fixed-frame" data-cf-modified-2fb05f019e6e60363ddfa077-=""><div style="display:none" aria-hidden="true"><div id="one-google-bar" class="drive-viewer-one-google-bar drive-viewer-profile-icon"><div class="gb_6c"><div class="gb_gc gb_hb gb_fc" ng-non-bindable="" style="padding:0;height:auto;display:block"><div class="gb_hc" style="display:block"><div class="gb_eb gb_Hc gb_uf gb_R gb_ke"><div class="gb_sc gb_gb gb_uf gb_R"><a class="gb_b gb_cb gb_R" aria-label="Google Account: Shane Le Brun  
(lebrun_shane@hotmail.com)" href="https://accounts.google.com/SignOutOptions?hl=en-GB&amp;continue=https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view%3Fusp%3Dsharing&amp;service=writely" role="button" tabindex="0" aria-expanded="false"><span class="gb_7a gbii"></span></a><div class="gb_jb"></div><div class="gb_ib"></div></div><div class="gb_kb gb_ga" aria-label="Account Information" aria-hidden="true"><div class="gb_nb"><a class="gb_ob gb_He gb_qb" aria-label="Change profile picture." href="https://plus.google.com/u/0/me?authuser=0" target="_blank"><div class="gb_rb gbip" title="Profile"></div><span class="gb_sb">Change</span></a><div class="gb_pb"><div class="gb_tb">Shane Le Brun</div><div class="gb_ub"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="2b474e49595e457458434a454e6b43445f464a424705484446">[email&#160;protected]</a></div><div class="gb_mb"><a href="https://plus.google.com/u/0/me?authuser=0" target="_blank">Google+ Profile</a><a href="https://www.google.co.nz/intl/en-GB/policies/privacy/" target="_blank">Privacy</a></div><a class="gb_Fa gb_De gbp1 gb_vb" href="https://myaccount.google.com/?utm_source=OGB&amp;authuser=0" target="_blank">My account</a></div></div><div class="multiLogin"><div class="gb_Ab" aria-hidden="false"><a class="gb_Bb gb_Eb" href="https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view?usp=sharing&amp;authuser=0" rel="noreferrer" target="_blank"><img class="gb_Hb gb_qb" src="data:image/gif;base64,R0lGODlhAQABAIAAAP///////yH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" alt="Profile" data-src="//lh3.googleusercontent.com/-CnasPhGHo70/AAAAAAAAAAI/AAAAAAAAAAA/APaXHhTWfHvY4Yn-JvZ-UjOpQffdjCibpg/s48-c-mo/photo.jpg"><div class="gb_Db"><div class="gb_Ib">Shane Le Brun</div><div class="gb_Jb"><span class="__cf_email__" data-cfemail="1579707767607b4a667d747b70557d7a6178747c793b767a78">[email&#160;protected]</span> (default)</div></div></a><a class="gb_Bb" href="https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view?usp=sharing&amp;authuser=1" rel="noreferrer" target="_blank"><img class="gb_Hb gb_qb" src="data:image/gif;base64,R0lGODlhAQABAIAAAP///////yH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" alt="Profile" data-src="//lh3.googleusercontent.com/-xQHtdemYtDg/AAAAAAAAAAI/AAAAAAAAAAA/APaXHhQ0SvUAQEpSYSNkTJa4i8_f_DW6og/s48-c-mo/photo.jpg"><div class="gb_Db"><div class="gb_Ib"><span class="__cf_email__" data-cfemail="ec838a8a858f89ac818f8d9b8d9e8982899f9f8296c2839e8b">[email&#160;protected]</span></div><div class="gb_Jb"><span class="__cf_email__" data-cfemail="721d14141b1117321f1113051300171c1701011c085c1d0015">[email&#160;protected]</span></div></div></a></div><a class="gb_Kb gb_6a" href="https://myaccount.google.com/brandaccounts?authuser=0&amp;continue=https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view%3Fusp%3Dsharing&amp;service=/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view%3Fusp%3Dsharing%26authuser%3D%24authuser" aria-hidden="true"><span class="gb_Lb gb_Vb"></span><div class="gb_Mb">All of your Brand Accounts </div></a></div><div class="gb_wb"><div><a class="gb_Fa gb_Ce gb_vb" href="https://accounts.google.com/AddSession?service=wise&amp;continue=https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view?usp%3Dsharing" target="_blank">Add account</a></div><div><a class="gb_Fa gb_Ee gb_Me gb_vb" id="gb_71" href="https://accounts.google.com/Logout?service=wise&amp;continue=https://docs.google.com" target="_top">Sign out</a></div></div></div></div></div></div></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="2fb05f019e6e60363ddfa077-text/javascript">this.gbar_=this.gbar_||{};(function(_){var window=this;
try{
var Hc=window.document.querySelector(".gb_ea .gb_b");Hc&&_.Eb(_.sc,Hc,"click");
}catch(e){_._DumpException(e)}
try{
_.Ic=function(a,c){var d=Array.prototype.slice.call(arguments,1);return function(){var c=d.slice();c.push.apply(c,arguments);return a.apply(this,c)}};_.Jc=function(a){var c=a.length;if(0<c){for(var d=Array(c),e=0;e<c;e++)d[e]=a[e];return d}return[]};_.Kc=function(a){var c=typeof a;return"object"==c&&null!=a||"function"==c};

}catch(e){_._DumpException(e)}
try{
_.Lc=function(a){var c=[],d=0,e;for(e in a)c[d++]=a[e];return c};_.Mc=function(a){var c=_.na(a);return"array"==c||"object"==c&&"number"==typeof a.length};_.Nc=!_.x||_.eb(9);_.Oc=!_.Sa&&!_.x||_.x&&_.eb(9)||_.Sa&&_.cb("1.9.1");_.Pc=_.x&&!_.cb("9");_.Qc=_.x||_.Pa||_.z;
_.Sc=function(){this.b="";this.f=_.Rc};_.Sc.prototype.Lb=!0;_.Sc.prototype.Ab=function(){return this.b};_.Sc.prototype.toString=function(){return"Const{"+this.b+"}"};_.Rc={};_.Tc=function(a){var c=new _.Sc;c.b=a;return c};_.Vc=function(){this.b="";this.f=_.Uc};_.Vc.prototype.Lb=!0;_.Uc={};_.Vc.prototype.Ab=function(){return this.b};_.Wc=function(a){var c=new _.Vc;c.b=a;return c};_.Xc=_.Wc("");_.Zc=function(){this.b="";this.f=_.Yc};_.Zc.prototype.Lb=!0;_.Zc.prototype.Ab=function(){return this.b};_.Zc.prototype.Md=!0;_.Zc.prototype.Yb=function(){return 1};_.Yc={};_.$c=function(a){var c=new _.Zc;c.b=a;return c};_.$c("about:blank");var ad;_.bd=function(){this.b="";this.f=ad};_.bd.prototype.Lb=!0;_.bd.prototype.Ab=function(){return this.b};_.bd.prototype.Md=!0;_.bd.prototype.Yb=function(){return 1};_.cd=function(a){if(a instanceof _.bd&&a.constructor===_.bd&&a.f===ad)return a.b;_.na(a);return"type_error:TrustedResourceUrl"};ad={};_.dd=function(a){var c=new _.bd;c.b=a;return c};
_.fd=function(){this.b="";this.j=_.ed;this.f=null};_.fd.prototype.Md=!0;_.fd.prototype.Yb=function(){return this.f};_.fd.prototype.Lb=!0;_.fd.prototype.Ab=function(){return this.b};_.ed={};_.gd=function(a,c){var d=new _.fd;d.b=a;d.f=c;return d};_.gd("<!DOCTYPE html>",0);_.hd=_.gd("",0);_.id=_.gd("<br>",0);
_.jd=function(a,c){return _.n(c)?a.getElementById(c):c};_.kd=function(a,c){return(c||window.document).getElementsByTagName(String(a))};_.ld=function(a,c){return a.createElement(String(c))};
}catch(e){_._DumpException(e)}
try{
var md=function(a){var c=arguments.length;if(1==c&&_.oa(arguments[0]))return md.apply(null,arguments[0]);for(var d={},e=0;e<c;e++)d[arguments[e]]=!0;return d},nd;md("A AREA BUTTON HEAD INPUT LINK MENU META OPTGROUP OPTION PROGRESS STYLE SELECT SOURCE TEXTAREA TITLE TRACK".split(" "));_.od=function(a,c){c?a.setAttribute("role",c):a.removeAttribute("role")};
_.K=function(a,c,d){_.oa(d)&&(d=d.join(" "));var e="aria-"+c;""===d||void 0==d?(nd||(nd={atomic:!1,autocomplete:"none",dropeffect:"none",haspopup:!1,live:"off",multiline:!1,multiselectable:!1,orientation:"vertical",readonly:!1,relevant:"additions text",required:!1,sort:"none",busy:!1,disabled:!1,hidden:!1,invalid:"false"}),d=nd,c in d?a.setAttribute(e,d[c]):a.removeAttribute(e)):a.setAttribute(e,d)};

}catch(e){_._DumpException(e)}
try{
_.pd=function(a){return"function"==_.na(a)};_.qd=function(a){return _.Wb(_.Sb.Aa(),a)};_.rd=function(a){a=a.split(".");for(var c=_.m,d;d=a.shift();)if(null!=c[d])c=c[d];else return null;return c};
}catch(e){_._DumpException(e)}
try{
var sd;sd=function(a){return/^\s*$/.test(a)?!1:/^[\],:{}\s\u2028\u2029]*$/.test(a.replace(/\\["\\\/bfnrtu]/g,"@").replace(/(?:"[^"\\\n\r\u2028\u2029\x00-\x08\x0a-\x1f]*"|true|false|null|-?\d+(?:\.\d*)?(?:[eE][+\-]?\d+)?)[\s\u2028\u2029]*(?=:|,|]|}|$)/g,"]").replace(/(?:^|:|,)(?:[\s\u2028\u2029]*\[)+/g,""))};_.td=function(a){a=String(a);if(sd(a))try{return eval("("+a+")")}catch(c){}throw Error("c`"+a);};_.ud=function(a){return function(){return a}}(!0);

}catch(e){_._DumpException(e)}
try{
var yd;_.L=function(a,c,d){c<a.B?a.j[c+a.A]=d:a.o[c]=d};_.vd=function(a){return a};_.wd=function(a,c,d){a.b||(a.b={});d=d||[];for(var e=[],f=0;f<d.length;f++)e[f]=d[f].nb();a.b[c]=d;_.L(a,c,e)};_.xd=function(a,c,d){a.b||(a.b={});var e=d?d.nb():d;a.b[c]=d;_.L(a,c,e)};yd=function(a,c,d){this.o=d;this.j=a;this.w=c;this.f=0;this.b=null};yd.prototype.get=function(){var a;0<this.f?(this.f--,a=this.b,this.b=a.next,a.next=null):a=this.j();return a}; var zd=function(a,c){a.w(c);a.f<a.o&&(a.f++,c.next=a.b,a.b=c)};
var Ad=function(a){_.m.setTimeout(function(){throw a;},0)},Bd,Cd=function(){var a=_.m.MessageChannel;"undefined"===typeof a&&"undefined"!==typeof window&&window.postMessage&&window.addEventListener&&!_.v("Presto")&&(a=function(){var a=window.document.createElement("IFRAME");a.style.display="none";a.src="";window.document.documentElement.appendChild(a);var c=a.contentWindow,a=c.document;a.open();a.write("");a.close();var d="callImmediate"+Math.random(),e="file:"==c.location.protocol?"*":c.location.protocol+
"//"+c.location.host,a=(0,_.q)(function(a){if(("*"==e||a.origin==e)&&a.data==d)this.port1.onmessage()},this);c.addEventListener("message",a,!1);this.port1={};this.port2={postMessage:function(){c.postMessage(d,e)}}});if("undefined"!==typeof a&&!_.v("Trident")&&!_.v("MSIE")){var c=new a,d={},e=d;c.port1.onmessage=function(){if(_.ka(d.next)){d=d.next;var a=d.ke;d.ke=null;a()}};return function(a){e.next={ke:a};e=e.next;c.port2.postMessage(0)}}return"undefined"!==typeof window.document&&"onreadystatechange"in
window.document.createElement("SCRIPT")?function(a){var c=window.document.createElement("SCRIPT");c.onreadystatechange=function(){c.onreadystatechange=null;c.parentNode.removeChild(c);c=null;a();a=null};window.document.documentElement.appendChild(c)}:function(a){_.m.setTimeout(a,0)}};
var Dd=function(){this.f=this.b=null},Fd=new yd(function(){return new Ed},function(a){a.reset()},100);Dd.prototype.remove=function(){var a=null;this.b&&(a=this.b,this.b=this.b.next,this.b||(this.f=null),a.next=null);return a};var Ed=function(){this.next=this.scope=this.b=null};Ed.prototype.set=function(a,c){this.b=a;this.scope=c;this.next=null};Ed.prototype.reset=function(){this.next=this.scope=this.b=null};
var Kd=function(a,c){Gd||Hd();Id||(Gd(),Id=!0);var d=Jd,e=Fd.get();e.set(a,c);d.f?d.f.next=e:d.b=e;d.f=e},Gd,Hd=function(){var a=_.m.Promise;if(-1!=String(a).indexOf("[native code]")){var c=a.resolve(void 0);Gd=function(){c.then(Ld)}}else Gd=function(){var a=Ld;!_.pd(_.m.setImmediate)||_.m.Window&&_.m.Window.prototype&&!_.v("Edge")&&_.m.Window.prototype.setImmediate==_.m.setImmediate?(Bd||(Bd=Cd()),Bd(a)):_.m.setImmediate(a)}},Id=!1,Jd=new Dd,Ld=function(){for(var a;a=Jd.remove();){try{a.b.call(a.scope)}catch(c){Ad(c)}zd(Fd, a)}Id=!1};
_.Md=function(a){a.prototype.then=a.prototype.then;a.prototype.$goog_Thenable=!0};_.Nd=function(a){if(!a)return!1;try{return!!a.$goog_Thenable}catch(c){return!1}};var Qd;_.Pd=function(a,c){this.b=0;this.A=void 0;this.o=this.f=this.j=null;this.w=this.B=!1;if(a!=_.la)try{var d=this;a.call(c,function(a){Od(d,2,a)},function(a){Od(d,3,a)})}catch(e){Od(this,3,e)}};Qd=function(){this.next=this.context=this.f=this.j=this.b=null;this.o=!1};Qd.prototype.reset=function(){this.context=this.f=this.j=this.b=null;this.o=!1};var Rd=new yd(function(){return new Qd},function(a){a.reset()},100),Sd=function(a,c,d){var e=Rd.get();e.j=a;e.f=c;e.context=d;return e};
_.Pd.prototype.then=function(a,c,d){return Td(this,_.pd(a)?a:null,_.pd(c)?c:null,d)};_.Md(_.Pd);_.Pd.prototype.cancel=function(a){0==this.b&&Kd(function(){var c=new Ud(a);Vd(this,c)},this)};
var Vd=function(a,c){if(0==a.b)if(a.j){var d=a.j;if(d.f){for(var e=0,f=null,g=null,h=d.f;h&&(h.o||(e++,h.b==a&&(f=h),!(f&&1<e)));h=h.next)f||(g=h);f&&(0==d.b&&1==e?Vd(d,c):(g?(e=g,e.next==d.o&&(d.o=e),e.next=e.next.next):Wd(d),Xd(d,f,3,c)))}a.j=null}else Od(a,3,c)},Zd=function(a,c){a.f||2!=a.b&&3!=a.b||Yd(a);a.o?a.o.next=c:a.f=c;a.o=c},Td=function(a,c,d,e){var f=Sd(null,null,null);f.b=new _.Pd(function(a,h){f.j=c?function(d){try{var f=c.call(e,d);a(f)}catch(r){h(r)}}:a;f.f=d?function(c){try{var f=
d.call(e,c);!_.ka(f)&&c instanceof Ud?h(c):a(f)}catch(r){h(r)}}:h});f.b.j=a;Zd(a,f);return f.b};_.Pd.prototype.F=function(a){this.b=0;Od(this,2,a)};_.Pd.prototype.N=function(a){this.b=0;Od(this,3,a)};
var Od=function(a,c,d){if(0==a.b){a===d&&(c=3,d=new TypeError("Promise cannot resolve to itself"));a.b=1;var e;a:{var f=d,g=a.F,h=a.N;if(f instanceof _.Pd)Zd(f,Sd(g||_.la,h||null,a)),e=!0;else if(_.Nd(f))f.then(g,h,a),e=!0;else{if(_.Kc(f))try{var l=f.then;if(_.pd(l)){$d(f,l,g,h,a);e=!0;break a}}catch(p){h.call(a,p);e=!0;break a}e=!1}}e||(a.A=d,a.b=c,a.j=null,Yd(a),3!=c||d instanceof Ud||ae(a,d))}},$d=function(a,c,d,e,f){var g=!1,h=function(a){g||(g=!0,d.call(f,a))},l=function(a){g||(g=!0,e.call(f,
a))};try{c.call(a,h,l)}catch(p){l(p)}},Yd=function(a){a.B||(a.B=!0,Kd(a.C,a))},Wd=function(a){var c=null;a.f&&(c=a.f,a.f=c.next,c.next=null);a.f||(a.o=null);return c};_.Pd.prototype.C=function(){for(var a;a=Wd(this);)Xd(this,a,this.b,this.A);this.B=!1};
var Xd=function(a,c,d,e){if(3==d&&c.f&&!c.o)for(;a&&a.w;a=a.j)a.w=!1;if(c.b)c.b.j=null,be(c,d,e);else try{c.o?c.j.call(c.context):be(c,d,e)}catch(f){ce.call(null,f)}zd(Rd,c)},be=function(a,c,d){2==c?a.j.call(a.context,d):a.f&&a.f.call(a.context,d)},ae=function(a,c){a.w=!0;Kd(function(){a.w&&ce.call(null,c)})},ce=Ad,Ud=function(a){_.va.call(this,a)};_.u(Ud,_.va);Ud.prototype.name="cancel";

}catch(e){_._DumpException(e)}
try{
_.de=function(a,c){var d=(0,_.za)(a,c),e;(e=0<=d)&&Array.prototype.splice.call(a,d,1);return e};_.ee=!_.x||_.eb(9);_.fe=!_.x||_.eb(9);_.ge=_.x&&!_.cb("9");!_.z||_.cb("528");_.Sa&&_.cb("1.9b")||_.x&&_.cb("8")||_.Pa&&_.cb("9.5")||_.z&&_.cb("528");_.Sa&&!_.cb("8")||_.x&&_.cb("9");
_.he=function(a,c){this.type=a;this.b=this.target=c;this.o=!1;this.Xe=!0};_.he.prototype.stopPropagation=function(){this.o=!0};_.he.prototype.preventDefault=function(){this.Xe=!1};var ke;_.ie="closure_listenable_"+(1E6*Math.random()|0);_.je=function(a){return!(!a||!a[_.ie])};ke=0;var le;le=function(a,c,d,e,f){this.listener=a;this.b=null;this.src=c;this.type=d;this.Lc=!!e;this.Xc=f;this.key=++ke;this.dc=this.Kc=!1};_.me=function(a){a.dc=!0;a.listener=null;a.b=null;a.src=null;a.Xc=null};_.ne=function(a){this.src=a;this.b={};this.f=0};_.pe=function(a,c,d,e,f,g){var h=c.toString();c=a.b[h];c||(c=a.b[h]=[],a.f++);var l=_.oe(c,d,f,g);-1<l?(a=c[l],e||(a.Kc=!1)):(a=new le(d,a.src,h,!!f,g),a.Kc=e,c.push(a));return a};_.ne.prototype.remove=function(a,c,d,e){a=a.toString();if(!(a in this.b))return!1;var f=this.b[a];c=_.oe(f,c,d,e);return-1<c?(_.me(f[c]),Array.prototype.splice.call(f,c,1),0==f.length&&(delete this.b[a],this.f--),!0):!1};
_.qe=function(a,c){var d=c.type;if(!(d in a.b))return!1;var e=_.de(a.b[d],c);e&&(_.me(c),0==a.b[d].length&&(delete a.b[d],a.f--));return e};_.oe=function(a,c,d,e){for(var f=0;f<a.length;++f){var g=a[f];if(!g.dc&&g.listener==c&&g.Lc==!!d&&g.Xc==e)return f}return-1};
var se,xe;_.re="closure_lm_"+(1E6*Math.random()|0);se={};_.te=0;_.we=function(a){if(_.pa(a)||!a||a.dc)return!1;var c=a.src;if(_.je(c))return c.nd(a);var d=a.type,e=a.b;c.removeEventListener?c.removeEventListener(d,e,a.Lc):c.detachEvent&&c.detachEvent(_.ue(d),e);_.te--;(d=_.ve(c))?(_.qe(d,a),0==d.f&&(d.src=null,c[_.re]=null)):_.me(a);return!0};_.ue=function(a){return a in se?se[a]:se[a]="on"+a};_.ve=function(a){a=a[_.re];return a instanceof _.ne?a:null}; xe="__closure_events_fn_"+(1E9*Math.random()>>>0);_.ye=function(a){if(_.pd(a))return a;a[xe]||(a[xe]=function(c){return a.handleEvent(c)});return a[xe]};

}catch(e){_._DumpException(e)}
try{
_.ze=function(a,c,d,e,f){a=a.b[c.toString()];c=-1;a&&(c=_.oe(a,d,e,f));return-1<c?a[c]:null};_.Ae=function(a,c,d){return 2>=arguments.length?Array.prototype.slice.call(a,c):Array.prototype.slice.call(a,c,d)};_.Be=function(a,c,d,e,f){if(_.oa(c))for(var g=0;g<c.length;g++)_.Be(a,c[g],d,e,f);else d=_.ye(d),_.je(a)?a.Ed(c,d,e,f):a&&(a=_.ve(a))&&(c=_.ze(a,c,d,!!e,f))&&_.we(c)};_.M=function(){_.F.call(this);this.N=new _.ne(this);this.qb=this;this.Ca=null};_.u(_.M,_.F);_.M.prototype[_.ie]=!0;_.k=_.M.prototype;
_.k.vc=function(){return this.Ca};_.k.Rb=function(a){this.Ca=a};_.k.removeEventListener=function(a,c,d,e){_.Be(this,a,c,d,e)};
_.k.K=function(a){var c,d=this.vc();if(d)for(c=[];d;d=d.vc())c.push(d);var d=this.qb,e=a.type||a;if(_.n(a))a=new _.he(a,d);else if(a instanceof _.he)a.target=a.target||d;else{var f=a;a=new _.he(e,d);_.Ia(a,f)}var f=!0,g;if(c)for(var h=c.length-1;!a.o&&0<=h;h--)g=a.b=c[h],f=g.Vb(e,!0,a)&&f;a.o||(g=a.b=d,f=g.Vb(e,!0,a)&&f,a.o||(f=g.Vb(e,!1,a)&&f));if(c)for(h=0;!a.o&&h<c.length;h++)g=a.b=c[h],f=g.Vb(e,!1,a)&&f;return f};_.k.L=function(){_.M.H.L.call(this);this.hd();this.Ca=null};
_.k.Sa=function(a,c,d,e){return _.pe(this.N,String(a),c,!1,d,e)};_.k.Vc=function(a,c,d,e){return _.pe(this.N,String(a),c,!0,d,e)};_.k.Ed=function(a,c,d,e){return this.N.remove(String(a),c,d,e)};_.k.nd=function(a){return _.qe(this.N,a)};_.k.hd=function(a){var c;if(this.N){c=this.N;a=a&&a.toString();var d=0,e;for(e in c.b)if(!a||e==a){for(var f=c.b[e],g=0;g<f.length;g++)++d,_.me(f[g]);delete c.b[e];c.f--}c=d}else c=0;return c};
_.k.Vb=function(a,c,d){a=this.N.b[String(a)];if(!a)return!0;a=a.concat();for(var e=!0,f=0;f<a.length;++f){var g=a[f];if(g&&!g.dc&&g.Lc==c){var h=g.listener,l=g.Xc||g.src;g.Kc&&this.nd(g);e=!1!==h.call(l,d)&&e}}return e&&0!=d.Xe};_.k.Dd=function(a,c,d,e){return _.ze(this.N,String(a),c,d,e)};

}catch(e){_._DumpException(e)}
try{
var Ce,Ee,Ge,He,Ie,Je,Ke,Le,Me,Ne,Pe,Re,Xe,df,jf,nf,rf,yf;Ce=function(a,c){var d=a.listener,e=a.Xc||a.src;a.Kc&&_.we(a);return d.call(e,c)};_.De=function(a,c){try{return _.Ma(a[c]),!0}catch(d){}return!1};Ee=function(a,c,d,e){var f=!0;if(a=_.ve(a))if(c=a.b[c.toString()])for(c=c.concat(),a=0;a<c.length;a++){var g=c[a];g&&g.Lc==d&&!g.dc&&(g=Ce(g,e),f=f&&!1!==g)}return f};
_.Fe=function(a,c){_.he.call(this,a?a.type:"");this.relatedTarget=this.b=this.target=null;this.w=this.keyCode=this.button=this.clientY=this.clientX=0;this.B=this.shiftKey=this.f=this.j=!1;this.Za=this.state=null;a&&this.init(a,c)};_.u(_.Fe,_.he);
_.Fe.prototype.init=function(a,c){var d=this.type=a.type,e=a.changedTouches?a.changedTouches[0]:null;this.target=a.target||a.srcElement;this.b=c;var f=a.relatedTarget;f?_.Sa&&(_.De(f,"nodeName")||(f=null)):"mouseover"==d?f=a.fromElement:"mouseout"==d&&(f=a.toElement);this.relatedTarget=f;null===e?(this.clientX=void 0!==a.clientX?a.clientX:a.pageX,this.clientY=void 0!==a.clientY?a.clientY:a.pageY):(this.clientX=void 0!==e.clientX?e.clientX:e.pageX,this.clientY=void 0!==e.clientY?e.clientY:e.pageY);
this.button=a.button;this.keyCode=a.keyCode||0;this.w=a.charCode||("keypress"==d?a.keyCode:0);this.j=a.ctrlKey;this.f=a.altKey;this.shiftKey=a.shiftKey;this.B=a.metaKey;this.state=a.state;this.Za=a;a.defaultPrevented&&this.preventDefault()};_.Fe.prototype.stopPropagation=function(){_.Fe.H.stopPropagation.call(this);this.Za.stopPropagation?this.Za.stopPropagation():this.Za.cancelBubble=!0};
_.Fe.prototype.preventDefault=function(){_.Fe.H.preventDefault.call(this);var a=this.Za;if(a.preventDefault)a.preventDefault();else if(a.returnValue=!1,_.ge)try{if(a.ctrlKey||112<=a.keyCode&&123>=a.keyCode)a.keyCode=-1}catch(c){}};
Ge=function(a,c){if(a.dc)return!0;if(!_.fe){var d=c||_.rd("window.event"),e=new _.Fe(d,this),f=!0;if(!(0>d.keyCode||void 0!=d.returnValue)){a:{var g=!1;if(0==d.keyCode)try{d.keyCode=-1;break a}catch(p){g=!0}if(g||void 0==d.returnValue)d.returnValue=!0}d=[];for(g=e.b;g;g=g.parentNode)d.push(g);for(var g=a.type,h=d.length-1;!e.o&&0<=h;h--){e.b=d[h];var l=Ee(d[h],g,!0,e),f=f&&l}for(h=0;!e.o&&h<d.length;h++)e.b=d[h],l=Ee(d[h],g,!1,e),f=f&&l}return f}return Ce(a,new _.Fe(c,this))};He=/&/g;Ie=/</g;Je=/>/g;
Ke=/"/g;Le=/'/g;Me=/\x00/g;Ne=/[\x00&<>"']/;_.Oe=function(a){if(!Ne.test(a))return a;-1!=a.indexOf("&")&&(a=a.replace(He,"&amp;"));-1!=a.indexOf("<")&&(a=a.replace(Ie,"&lt;"));-1!=a.indexOf(">")&&(a=a.replace(Je,"&gt;"));-1!=a.indexOf('"')&&(a=a.replace(Ke,"&quot;"));-1!=a.indexOf("'")&&(a=a.replace(Le,"&#39;"));-1!=a.indexOf("\x00")&&(a=a.replace(Me,"&#0;"));return a};
Pe=function(a){if(a&&"number"==typeof a.length){if(_.Kc(a))return"function"==typeof a.item||"string"==typeof a.item;if(_.pd(a))return"function"==typeof a.item}return!1};_.Qe=function(a){return"CSS1Compat"==a.compatMode};Re={cellpadding:"cellPadding",cellspacing:"cellSpacing",colspan:"colSpan",frameborder:"frameBorder",height:"height",maxlength:"maxLength",nonce:"nonce",role:"role",rowspan:"rowSpan",type:"type",usemap:"useMap",valign:"vAlign",width:"width"};_.Se=function(a,c){this.f=a;this.b=c};
_.Te=function(a){return new _.Se(a.f,a.b)};_.Se.prototype.j=function(){return this.f*this.b};_.Se.prototype.Mb=function(){return!this.j()};_.Se.prototype.floor=function(){this.f=Math.floor(this.f);this.b=Math.floor(this.b);return this};_.Se.prototype.round=function(){this.f=Math.round(this.f);this.b=Math.round(this.b);return this};_.Ue=function(a){if(a instanceof _.fd&&a.constructor===_.fd&&a.j===_.ed)return a.b;_.na(a);return"type_error:SafeHtml"};
_.Ve=function(a,c,d){for(var e in a)c.call(d,a[e],e,a)};_.We=function(a,c){return 0<=(0,_.za)(a,c)};Xe=function(a,c,d){function e(d){d&&c.appendChild(_.n(d)?a.createTextNode(d):d)}for(var f=2;f<d.length;f++){var g=d[f];!_.Mc(g)||_.Kc(g)&&0<g.nodeType?e(g):(0,_.Aa)(Pe(g)?_.Jc(g):g,e)}};_.Ye=function(a){return a.parentWindow||a.defaultView};_.Ze=function(a){return a.scrollingElement?a.scrollingElement:!_.z&&_.Qe(a)?a.documentElement:a.body||a.documentElement};
_.$e=function(a,c){_.Ve(c,function(c,e){"style"==e?a.style.cssText=c:"class"==e?a.className=c:"for"==e?a.htmlFor=c:Re.hasOwnProperty(e)?a.setAttribute(Re[e],c):0==e.lastIndexOf("aria-",0)||0==e.lastIndexOf("data-",0)?a.setAttribute(e,c):a[e]=c})};
_.af=function(a,c){var d,e,f,g;d=window.document;d=c||d;if(d.querySelectorAll&&d.querySelector&&a)return d.querySelectorAll(""+(a?"."+a:""));if(a&&d.getElementsByClassName){var h=d.getElementsByClassName(a);return h}h=d.getElementsByTagName("*");if(a){g={};for(e=f=0;d=h[e];e++){var l=d.className;"function"==typeof l.split&&_.We(l.split(/\s+/),a)&&(g[f++]=d)}g.length=f;return g}return h};_.bf=function(a,c){this.b=_.ka(a)?a:0;this.P=_.ka(c)?c:0};
_.bf.prototype.floor=function(){this.b=Math.floor(this.b);this.P=Math.floor(this.P);return this};_.bf.prototype.round=function(){this.b=Math.round(this.b);this.P=Math.round(this.P);return this};_.cf=function(a,c){a.innerHTML=_.Ue(c)};df=function(){var a=_.fe?function(c){return Ge.call(a.src,a.listener,c)}:function(c){c=Ge.call(a.src,a.listener,c);if(!c)return c};return a};_.ef=function(a){try{return a&&a.activeElement}catch(c){}return null};
_.ff=function(a,c){if(!a||!c)return!1;if(a.contains&&1==c.nodeType)return a==c||a.contains(c);if("undefined"!=typeof a.compareDocumentPosition)return a==c||!!(a.compareDocumentPosition(c)&16);for(;c&&a!=c;)c=c.parentNode;return c==a};_.gf=function(a){return a&&a.parentNode?a.parentNode.removeChild(a):null};_.hf=function(a){for(var c;c=a.firstChild;)a.removeChild(c)};
jf=function(a,c){var d=String(c[0]),e=c[1];if(!_.Nc&&e&&(e.name||e.type)){d=["<",d];e.name&&d.push(' name="',_.Oe(e.name),'"');if(e.type){d.push(' type="',_.Oe(e.type),'"');var f={};_.Ia(f,e);delete f.type;e=f}d.push(">");d=d.join("")}d=a.createElement(d);e&&(_.n(e)?d.className=e:_.oa(e)?d.className=e.join(" "):_.$e(d,e));2<c.length&&Xe(a,d,c);return d};_.kf=function(a){return a?_.Ye(a):window};
_.lf=function(a){var c=_.Ze(a);a=_.Ye(a);return _.x&&_.cb("10")&&a.pageYOffset!=c.scrollTop?new _.bf(c.scrollLeft,c.scrollTop):new _.bf(a.pageXOffset||c.scrollLeft,a.pageYOffset||c.scrollTop)};_.mf=function(a){a=(a||window).document;a=_.Qe(a)?a.documentElement:a.body;return new _.Se(a.clientWidth,a.clientHeight)};
_.N=function(a,c){var d=c||window.document,e=null;d.getElementsByClassName?e=d.getElementsByClassName(a)[0]:d.querySelectorAll&&d.querySelector?e=d.querySelector("."+a):e=_.af(a,c)[0];return e||null};
nf=function(a,c,d,e,f,g){if(!c)throw Error("o");var h=!!f,l=_.ve(a);l||(a[_.re]=l=new _.ne(a));d=_.pe(l,c,d,e,f,g);if(d.b)return d;e=df();d.b=e;e.src=a;e.listener=d;if(a.addEventListener)a.addEventListener(c.toString(),e,h);else if(a.attachEvent)a.attachEvent(_.ue(c.toString()),e);else throw Error("p");_.te++;return d};_.of=function(a){this.b=a||_.m.document||window.document};_.k=_.of.prototype;_.k.D=function(a){return _.jd(this.b,a)};_.k.Oa=function(a,c,d){return jf(this.b,arguments)};
_.k.createElement=function(a){return _.ld(this.b,a)};_.k.Uc=function(a,c){a.appendChild(c)};_.k.ze=_.hf;_.k.Ae=_.gf;_.k.contains=_.ff;_.pf=function(a){return 9==a.nodeType?a:a.ownerDocument||a.document};_.qf=function(a){return _.Kc(a)&&1==a.nodeType};_.sf=function(a){return String(a).replace(/([-()\[\]{}+?*.$\^|,:#<!\\])/g,"\\$1").replace(/\x08/g,"\\x08")};_.tf=function(a){return/^[\s\xa0]*$/.test(a)};
_.uf=function(a,c,d,e,f){if(_.oa(c)){for(var g=0;g<c.length;g++)_.uf(a,c[g],d,e,f);return null}d=_.ye(d);return _.je(a)?a.Vc(c,d,e,f):nf(a,c,d,!0,e,f)};_.O=function(a,c,d,e,f){if(_.oa(c)){for(var g=0;g<c.length;g++)_.O(a,c[g],d,e,f);return null}d=_.ye(d);return _.je(a)?a.Sa(c,d,e,f):nf(a,c,d,!1,e,f)};_.P=function(a,c,d){return jf(window.document,arguments)};_.vf=function(a){return a?new _.of(_.pf(a)):rf||(rf=new _.of)};_.wf=function(a,c){return a==c?!0:a&&c?a.f==c.f&&a.b==c.b:!1};
_.xf=function(a,c){var d=a.length-c.length;return 0<=d&&a.indexOf(c,d)==d};yf=function(a){if(a.classList)return a.classList;a=a.className;return _.n(a)&&a.match(/\S+/g)||[]};_.Q=function(a,c){return a.classList?a.classList.contains(c):_.We(yf(a),c)};_.R=function(a,c){a.classList?a.classList.add(c):_.Q(a,c)||(a.className+=0<a.className.length?" "+c:c)};
_.zf=function(a,c){if(a.classList)(0,_.Aa)(c,function(c){_.R(a,c)});else{var d={};(0,_.Aa)(yf(a),function(a){d[a]=!0});(0,_.Aa)(c,function(a){d[a]=!0});a.className="";for(var e in d)a.className+=0<a.className.length?" "+e:e}};_.S=function(a,c){a.classList?a.classList.remove(c):_.Q(a,c)&&(a.className=(0,_.Ba)(yf(a),function(a){return a!=c}).join(" "))};_.Af=function(a,c){a.classList?(0,_.Aa)(c,function(c){_.S(a,c)}):a.className=(0,_.Ba)(yf(a),function(a){return!_.We(c,a)}).join(" ")};
var Ef;_.Bf=function(a){_.F.call(this);this.Y=a;this.R={}};_.u(_.Bf,_.F);var Cf=[];_.Bf.prototype.b=function(a,c,d,e){return Df(this,a,c,d,e)};_.Bf.prototype.B=function(a,c,d,e,f){return Df(this,a,c,d,e,f)};var Df=function(a,c,d,e,f,g){_.oa(d)||(d&&(Cf[0]=d.toString()),d=Cf);for(var h=0;h<d.length;h++){var l=_.O(c,d[h],e||a.handleEvent,f||!1,g||a.Y||a);if(!l)break;a.R[l.key]=l}return a};_.Bf.prototype.O=function(a,c,d,e){return Ef(this,a,c,d,e)};
Ef=function(a,c,d,e,f,g){if(_.oa(d))for(var h=0;h<d.length;h++)Ef(a,c,d[h],e,f,g);else{c=_.uf(c,d,e||a.handleEvent,f,g||a.Y||a);if(!c)return a;a.R[c.key]=c}return a};_.Ff=function(a){_.Ve(a.R,function(a,d){this.R.hasOwnProperty(d)&&_.we(a)},a);a.R={}};_.Bf.prototype.L=function(){_.Bf.H.L.call(this);_.Ff(this)};_.Bf.prototype.handleEvent=function(){throw Error("q");};
var Jf;_.If=function(a,c,d,e,f,g){if(!(_.x||_.Qa||_.z&&_.cb("525")))return!0;if(_.Ta&&f)return _.Gf(a);if(f&&!e)return!1;_.pa(c)&&(c=_.Hf(c));f=17==c||18==c||_.Ta&&91==c;if((!d||_.Ta)&&f||_.Ta&&16==c&&(e||g))return!1;if((_.z||_.Qa)&&e&&d)switch(a){case 220:case 219:case 221:case 192:case 186:case 189:case 187:case 188:case 190:case 191:case 192:case 222:return!1}if(_.x&&e&&c==a)return!1;switch(a){case 13:return!0;case 27:return!(_.z||_.Qa)}return _.Gf(a)};
_.Gf=function(a){if(48<=a&&57>=a||96<=a&&106>=a||65<=a&&90>=a||(_.z||_.Qa)&&0==a)return!0;switch(a){case 32:case 43:case 63:case 64:case 107:case 109:case 110:case 111:case 186:case 59:case 189:case 187:case 61:case 188:case 190:case 191:case 192:case 222:case 219:case 220:case 221:return!0;default:return!1}};_.Hf=function(a){if(_.Sa)a=Jf(a);else if(_.Ta&&_.z)switch(a){case 93:a=91}return a}; Jf=function(a){switch(a){case 61:return 187;case 59:return 186;case 173:return 189;case 224:return 91;case 0:return 224;default:return a}};
_.Kf=function(a,c){var d=_.pf(a);return d.defaultView&&d.defaultView.getComputedStyle&&(d=d.defaultView.getComputedStyle(a,null))?d[c]||d.getPropertyValue(c)||"":""};_.Lf=function(a,c){return _.Kf(a,c)||(a.currentStyle?a.currentStyle[c]:null)||a.style&&a.style[c]};_.Nf=function(a,c,d){var e;c instanceof _.bf?(e=c.b,c=c.P):(e=c,c=d);a.style.left=_.Mf(e,!1);a.style.top=_.Mf(c,!1)};
_.Of=function(a){var c;try{c=a.getBoundingClientRect()}catch(d){return{left:0,top:0,right:0,bottom:0}}_.x&&a.ownerDocument.body&&(a=a.ownerDocument,c.left-=a.documentElement.clientLeft+a.body.clientLeft,c.top-=a.documentElement.clientTop+a.body.clientTop);return c};_.Pf=function(a,c,d){if(c instanceof _.Se)d=c.b,c=c.f;else if(void 0==d)throw Error("r");a.style.width=_.Mf(c,!0);a.style.height=_.Mf(d,!0)};_.Mf=function(a,c){"number"==typeof a&&(a=(c?Math.round(a):a)+"px");return a};
_.Rf=function(a){var c=_.Qf;if("none"!=_.Lf(a,"display"))return c(a);var d=a.style,e=d.display,f=d.visibility,g=d.position;d.visibility="hidden";d.position="absolute";d.display="inline";a=c(a);d.display=e;d.position=g;d.visibility=f;return a};_.Qf=function(a){var c=a.offsetWidth,d=a.offsetHeight,e=_.z&&!c&&!d;return _.ka(c)&&!e||!a.getBoundingClientRect?new _.Se(c,d):(a=_.Of(a),new _.Se(a.right-a.left,a.bottom-a.top))};_.Sf=function(a,c){a.style.display=c?"":"none"}; _.Tf=_.Sa?"MozUserSelect":_.z||_.Qa?"WebkitUserSelect":null;

}catch(e){_._DumpException(e)}
try{
var Xf,Zf,bg;_.Uf=function(a){a&&"function"==typeof a.ma&&a.ma()};_.Vf=function(a,c,d,e,f,g){if(_.oa(d))for(var h=0;h<d.length;h++)_.Vf(a,c,d[h],e,f,g);else e=e||a.handleEvent,g=g||a.Y||a,e=_.ye(e),f=!!f,d=_.je(c)?c.Dd(d,e,f,g):c?(c=_.ve(c))?_.ze(c,d,e,f,g):null:null,d&&(_.we(d),delete a.R[d.key])};_.Wf=function(a,c){var d=_.Ic(_.Uf,c);a.Da?_.ka(void 0)?d.call(void 0):d():(a.yb||(a.yb=[]),a.yb.push(_.ka(void 0)?(0,_.q)(d,void 0):d))};Xf=0;_.Yf=function(a){return a[_.ra]||(a[_.ra]=++Xf)};
Zf=function(a,c,d,e){Array.prototype.splice.apply(a,_.Ae(arguments,1))};_.$f=function(a,c){if("textContent"in a)a.textContent=c;else if(3==a.nodeType)a.data=c;else if(a.firstChild&&3==a.firstChild.nodeType){for(;a.lastChild!=a.firstChild;)a.removeChild(a.lastChild);a.firstChild.data=c}else _.hf(a),a.appendChild(_.pf(a).createTextNode(String(c)))};_.ag=function(a){return a.contentDocument||a.contentWindow.document};bg=function(a,c){return null!==a&&c in a?a[c]:void 0};
_.cg=function(a,c){_.M.call(this);this.j=a||1;this.f=c||_.m;this.o=(0,_.q)(this.B,this);this.w=(0,_.ua)()};_.u(_.cg,_.M);_.cg.prototype.enabled=!1;_.cg.prototype.b=null;_.cg.prototype.B=function(){if(this.enabled){var a=(0,_.ua)()-this.w;0<a&&a<.8*this.j?this.b=this.f.setTimeout(this.o,this.j-a):(this.b&&(this.f.clearTimeout(this.b),this.b=null),this.K("tick"),this.enabled&&(this.b=this.f.setTimeout(this.o,this.j),this.w=(0,_.ua)()))}};
_.cg.prototype.start=function(){this.enabled=!0;this.b||(this.b=this.f.setTimeout(this.o,this.j),this.w=(0,_.ua)())};_.dg=function(a){a.enabled=!1;a.b&&(a.f.clearTimeout(a.b),a.b=null)};_.cg.prototype.L=function(){_.cg.H.L.call(this);_.dg(this);delete this.f};_.eg=function(a,c,d){if(_.pd(a))d&&(a=(0,_.q)(a,d));else if(a&&"function"==typeof a.handleEvent)a=(0,_.q)(a.handleEvent,a);else throw Error("s");return 2147483647<Number(c)?-1:_.m.setTimeout(a,c||0)};
_.fg=function(a,c,d){_.F.call(this);this.j=a;this.w=c||0;this.o=d;this.b=(0,_.q)(this.B,this)};_.u(_.fg,_.F);_.fg.prototype.f=0;_.fg.prototype.L=function(){_.fg.H.L.call(this);_.gg(this);delete this.j;delete this.o};_.fg.prototype.start=function(a){_.gg(this);this.f=_.eg(this.b,_.ka(a)?a:this.w)};_.gg=function(a){0!=a.f&&_.m.clearTimeout(a.f);a.f=0};_.fg.prototype.B=function(){this.f=0;this.j&&this.j.call(this.o)};
_.hg=function(){};_.ma(_.hg);_.hg.prototype.b=0;_.ig=function(a){return":"+(a.b++).toString(36)};var lg,mg;_.T=function(a){_.M.call(this);this.j=a||_.vf();this.ka=jg;this.Z=null;this.wa=!1;this.b=null;this.J=void 0;this.F=this.B=this.f=this.w=null;this.Qa=!1};_.u(_.T,_.M);_.T.prototype.Ya=_.hg.Aa();var jg=null;_.T.prototype.getId=function(){return this.Z||(this.Z=_.ig(this.Ya))};_.T.prototype.D=function(){return this.b};_.kg=function(a){a.J||(a.J=new _.Bf(a));return a.J};
lg=function(a,c){if(a==c)throw Error("t");var d;if(d=c&&a.f&&a.Z){d=a.f;var e=a.Z;d=d.F&&e?bg(d.F,e)||null:null}if(d&&a.f!=c)throw Error("t");a.f=c;_.T.H.Rb.call(a,c)};_.T.prototype.Rb=function(a){if(this.f&&this.f!=a)throw Error("u");_.T.H.Rb.call(this,a)};_.T.prototype.Ib=function(){this.b=this.j.createElement("DIV")};_.T.prototype.Pb=function(a){mg(this,a)};mg=function(a,c,d){if(a.wa)throw Error("v");a.b||a.Ib();c?c.insertBefore(a.b,d||null):a.j.b.body.appendChild(a.b);a.f&&!a.f.wa||a.ta()};
_.ng=function(a,c){if(a.wa)throw Error("v");if(c){a.Qa=!0;var d=_.pf(c);a.j&&a.j.b==d||(a.j=_.vf(c));a.Tb(c);a.ta()}else throw Error("w");};_.k=_.T.prototype;_.k.Tb=function(a){this.b=a};_.k.ta=function(){this.wa=!0;_.og(this,function(a){!a.wa&&a.D()&&a.ta()})};_.k.Ja=function(){_.og(this,function(a){a.wa&&a.Ja()});this.J&&_.Ff(this.J);this.wa=!1};
_.k.L=function(){this.wa&&this.Ja();this.J&&(this.J.ma(),delete this.J);_.og(this,function(a){a.ma()});!this.Qa&&this.b&&_.gf(this.b);this.f=this.w=this.b=this.F=this.B=null;_.T.H.L.call(this)};
_.k.Fb=function(a,c,d){if(a.wa&&(d||!this.wa))throw Error("v");if(0>c||c>_.pg(this))throw Error("x");this.F&&this.B||(this.F={},this.B=[]);if(a.f==this){var e=a.getId();this.F[e]=a;_.de(this.B,a)}else{var e=this.F,f=a.getId();if(null!==e&&f in e)throw Error("a`"+f);e[f]=a}lg(a,this);Zf(this.B,c,0,a);a.wa&&this.wa&&a.f==this?(d=this.b,c=d.childNodes[c]||null,c!=a.D()&&d.insertBefore(a.D(),c)):d?(this.b||this.Ib(),c=_.qg(this,c+1),mg(a,this.b,c?c.b:null)):this.wa&&!a.wa&&a.b&&a.b.parentNode&&1==a.b.parentNode.nodeType&&
a.ta()};_.pg=function(a){return a.B?a.B.length:0};_.qg=function(a,c){return a.B?a.B[c]||null:null};_.og=function(a,c,d){a.B&&(0,_.Aa)(a.B,c,d)};_.T.prototype.removeChild=function(a,c){if(a){var d=_.n(a)?a:a.getId();a=this.F&&d?bg(this.F,d)||null:null;if(d&&a){var e=this.F;d in e&&delete e[d];_.de(this.B,a);c&&(a.Ja(),a.b&&_.gf(a.b));lg(a,null)}}if(!a)throw Error("y");return a};

}catch(e){_._DumpException(e)}
try{
var rg,vg,wg,Ag;rg=[1,4,2];_.sg=function(a,c,d,e){d.b(c,e,void 0,a.Y||a,a)};_.tg=function(a){return(_.ee?0==a.Za.button:"click"==a.type?!0:!!(a.Za.button&rg[0]))&&!(_.z&&_.Ta&&a.j)};_.ug=function(a,c,d){for(var e=0;a&&(null==d||e<=d);){if(c(a))return a;a=a.parentNode;e++}return null};vg=function(a){a=a.tabIndex;return _.pa(a)&&0<=a&&32768>a};wg=function(a){a=a.getAttributeNode("tabindex");return null!=a&&a.specified};_.U=function(a,c,d){d?_.R(a,c):_.S(a,c)};
_.xg=function(a,c){var d=a.getAttribute("aria-"+c);return null==d||void 0==d?"":String(d)};_.yg=function(a,c,d,e){if(null!=a)for(a=a.firstChild;a;){if(c(a)&&(d.push(a),e)||_.yg(a,c,d,e))return!0;a=a.nextSibling}return!1};
_.zg=function(a){var c;if((c="A"==a.tagName||"INPUT"==a.tagName||"TEXTAREA"==a.tagName||"SELECT"==a.tagName||"BUTTON"==a.tagName?!a.disabled&&(!wg(a)||vg(a)):wg(a)&&vg(a))&&_.x){var d;!_.pd(a.getBoundingClientRect)||_.x&&null==a.parentElement?d={height:a.offsetHeight,width:a.offsetWidth}:d=a.getBoundingClientRect();a=null!=d&&0<d.height&&0<d.width}else a=c;return a};Ag=function(a,c){var d=[];_.yg(a,c,d,!1);return d};
var Bg,Cg;Bg=function(){};_.V=new Bg;Cg=["click",_.Sa?"keypress":"keydown","keyup"];Bg.prototype.b=function(a,c,d,e,f){var g=function(a){var d=_.ye(c),f=_.qf(a.target)?a.target.getAttribute("role")||null:null;"click"==a.type&&_.tg(a)?d.call(e,a):13!=a.keyCode&&3!=a.keyCode||"keyup"==a.type?32!=a.keyCode||"keyup"!=a.type||"button"!=f&&"tab"!=f||(d.call(e,a),a.preventDefault()):(a.type="keypress",d.call(e,a))};g.j=c;g.b=e;f?f.b(a,Cg,g,d):_.O(a,Cg,g,d)};
var Dg;Dg=function(a){return null!=_.ug(a,function(a){return 1==a.nodeType&&"true"==_.xg(a,"hidden")})};_.Eg=function(a){return a?Ag(a,function(a){return 1==a.nodeType&&_.zg(a)&&!Dg(a)}):[]};
}catch(e){_._DumpException(e)}
try{
_.Fg=!_.x;
}catch(e){_._DumpException(e)}
try{
var Gg=function(a){_.F.call(this);this.w=a;this.o=this.b=null;this.f={};this.B={};this.j={}};_.u(Gg,_.F);var Hg=new Gg(_.J);_.Ub("dd",Hg);
}catch(e){_._DumpException(e)}
try{
var Jg,Mg,Ng,Og,Tg,Ug;_.Ig=function(a){a.b&&a.b.close();a.b=null};Jg=function(a){_.B(this,a,0,-1,null)};_.u(Jg,_.A);_.Kg=function(a,c){if(void 0!==a.f)throw Error("g");a.f=c;_.fc(a)};_.Lg=function(a){return String(a).replace(/([A-Z])/g,"-$1").toLowerCase()};Mg={IMG:" ",BR:"\n"};Ng={SCRIPT:1,STYLE:1,HEAD:1,IFRAME:1,OBJECT:1};Og=function(a,c){return c?_.ug(a,function(a){return!c||_.n(a.className)&&_.We(a.className.split(/\s+/),c)},void 0):null};
_.Pg=function(a,c,d){if(!(a.nodeName in Ng))if(3==a.nodeType)d?c.push(String(a.nodeValue).replace(/(\r\n|\r|\n)/g,"")):c.push(a.nodeValue);else if(a.nodeName in Mg)c.push(Mg[a.nodeName]);else for(a=a.firstChild;a;)_.Pg(a,c,d),a=a.nextSibling};_.Qg=function(a,c){var d=a.getAttribute("aria-"+c);return null==d?d:"boolean"==typeof d?d:"true"==d};
_.Rg=function(a){if(_.Pc&&null!==a&&"innerText"in a)a=a.innerText.replace(/(\r\n|\r|\n)/g,"\n");else{var c=[];_.Pg(a,c,!0);a=c.join("")}a=a.replace(/ \xAD /g," ").replace(/\xAD/g,"");a=a.replace(/\u200B/g,"");_.Pc||(a=a.replace(/ +/g," "));" "!=a&&(a=a.replace(/^\s*/,""));return a};_.Sg=function(a,c){c?a.tabIndex=0:(a.tabIndex=-1,a.removeAttribute("tabIndex"))};Tg=function(a,c){var d=[];return _.yg(a,c,d,!0)?d[0]:void 0};Ug=function(a,c){var d=c.parentNode;d&&d.replaceChild(a,c)};
_.Vg=function(a,c){return _.N(a,c)};_.Wg=function(a,c){var d=c||window.document;return d.querySelectorAll&&d.querySelector?d.querySelectorAll("."+a):_.af(a,c)};_.Yg=function(a,c){_.M.call(this);this.b=a;this.j=Xg(this.b);this.A=c||100;this.o=_.O(a,"resize",this.w,!1,this)};_.u(_.Yg,_.M);_.Yg.prototype.L=function(){_.we(this.o);_.Yg.H.L.call(this)};_.Yg.prototype.w=function(){this.f||(this.f=new _.fg(this.B,this.A,this),_.Wf(this,this.f));this.f.start()}; _.Yg.prototype.B=function(){if(!this.b.Da){var a=this.j,c=Xg(this.b);this.j=c;if(a){var d=!1;a.f!=c.f&&(this.K("b"),d=!0);a.b!=c.b&&(this.K("a"),d=!0);d&&this.K("resize")}else this.K("a"),this.K("b"),this.K("resize")}};
var Zg=function(a){_.M.call(this);this.f=a||window;this.j=_.O(this.f,"resize",this.o,!1,this);this.b=_.mf(this.f)},$g,Xg;_.u(Zg,_.M);_.ah=function(){var a=window,c=_.Yf(a);return $g[c]=$g[c]||new Zg(a)};$g={};Xg=function(a){return a.b?_.Te(a.b):null};Zg.prototype.L=function(){Zg.H.L.call(this);this.j&&(_.we(this.j),this.j=null);this.b=this.f=null};Zg.prototype.o=function(){var a=_.mf(this.f);_.wf(a,this.b)||(this.b=a,this.K("resize"))};
_.bh=function(a){this.f=a;this.b=null};_.ch=function(a){a.b||(a.b=_.O(a.f,"keydown",a.j,!1,a))};_.bh.prototype.j=function(a){9!=a.keyCode||_.Q(this.f,"gb_6")||(_.U(this.f,"gb_6",!0),_.dh(this))};_.dh=function(a){a.b&&(_.we(a.b),a.b=null)};_.eh=function(a,c){_.M.call(this);this.B=a;c&&(this.B.id=c)};_.u(_.eh,_.M);_.eh.prototype.D=function(){return this.B};_.eh.prototype.getId=function(){return this.B.id};_.eh.prototype.U=function(){var a=this.B.id;a||(a="gb$"+_.ig(_.hg.Aa()),this.B.id=a);return a};_.eh.prototype.L=function(){_.gf(this.B);_.eh.H.L.call(this)};
_.fh=function(a){_.eh.call(this,a);_.V.b(a,this.b,!1,this)};_.u(_.fh,_.eh);_.fh.prototype.b=function(a){this.K("click")||a.preventDefault()};_.gh=function(a){return Tg(a,function(a){return _.qf(a)&&_.zg(a)})};_.hh=function(a){(a=_.gh(a))&&a.focus()};var ih=function(){};var jh=function(a,c,d){this.f=a;this.j=c;this.b=d||_.m};var kh=function(){this.b=[]};kh.prototype.f=function(a,c,d){this.w(a,c,d);this.b.push(new jh(a,c,d))};kh.prototype.w=function(a,c,d){d=d||_.m;for(var e=0,f=this.b.length;e<f;e++){var g=this.b[e];if(g.f==a&&g.j==c&&g.b==d){this.b.splice(e,1);break}}};kh.prototype.j=function(a){for(var c=0,d=this.b.length;c<d;c++){var e=this.b[c];"catc"==e.f&&e.j.call(e.b,a)}};
var lh;_.mh=function(a,c,d){this.o=new kh;this.C=a;this.B=c;this.b=lh(a.offsetWidth,this.B);this.F=d||new _.Yg(_.ah(),10);_.O(this.F,"b",function(){window.requestAnimationFrame?window.requestAnimationFrame((0,_.q)(this.A,this)):this.A()},!1,this)};lh=function(a,c){for(var d=0,e=c.length-1,f=c[0];d<e;){if(a<=f.max)return f.id;f=c[++d]}return c[e].id};_.mh.prototype.A=function(){var a=lh(this.C.offsetWidth,this.B);a!=this.b&&(this.b=a,this.j(new ih))};_.mh.prototype.f=function(a,c,d){this.o.f(a,c,d)}; _.mh.prototype.w=function(a,c){this.o.w(a,c)};_.mh.prototype.j=function(a){this.o.j(a)};
var nh={Gh:"gb_1b",Th:"gb_Se",Eh:"gb_3b"};var oh=function(a,c){c||(c=this.createElement(),a.Ec().appendChild(c));_.eh.call(this,c);this.w=new _.Bf(this);_.sg(this.w,this.D(),_.V,this.jg)};_.u(oh,_.eh);_.k=oh.prototype;_.k.createElement=function(){var a=_.ld(window.document,"LI");_.R(a,"gb_8b");_.od(a,"menuitem");return a};
_.k.nh=function(a){if(a){var c=this.D();_.Fg&&c.dataset?c.dataset.item=a:c.setAttribute("data-"+_.Lg("item"),a)}else a=this.D(),_.Fg&&a.dataset?(_.Fg&&a.dataset?"item"in a.dataset:a.hasAttribute?a.hasAttribute("data-"+_.Lg("item")):a.getAttribute("data-"+_.Lg("item")))&&delete a.dataset.item:a.removeAttribute("data-"+_.Lg("item"));return this};_.k.Dc=function(){var a=this.D();return _.Fg&&a.dataset?"item"in a.dataset?a.dataset.item:null:a.getAttribute("data-"+_.Lg("item"))}; _.k.hc=function(a){_.U(this.D(),"gb_9b",a);return this};_.k.focus=function(){_.hh(this.D())};_.k.jg=function(){this.K("click")};
var ph=function(a,c){oh.call(this,a,c);this.o=_.Vg("gb_ac",this.D());this.b=_.N("gb_cc",this.o);this.f=null;this.j=_.N("gb_bc",this.o)};_.u(ph,oh);_.k=ph.prototype;_.k.createElement=function(){var a=ph.H.createElement.call(this);_.R(a,"gb_dc");var c=_.P("A","gb_ac");_.Sg(c,!0);a.appendChild(c);var d=_.P("SPAN","gb_bc");c.appendChild(d);return a};_.k.Dc=function(){return ph.H.Dc.call(this)||this.Oe()};_.k.Oe=function(){return _.Rg(this.j)};_.k.oh=function(a){_.$f(this.j,a);return this};
_.k.Bh=function(a){if(!this.b)if(this.b=_.P("IMG","gb_cc"),this.f)Ug(this.b,this.f),this.f=null;else{var c=this.j;c.parentNode&&c.parentNode.insertBefore(this.b,c)}this.b.setAttribute("src",a);return this};_.k.Ah=function(a){if(!(a instanceof window.Element&&"svg"==a.tagName.toLowerCase()))return this;if(this.b)Ug(a,this.b),this.b=null;else if(this.f)Ug(a,this.f);else{var c=this.j;c.parentNode&&c.parentNode.insertBefore(a,c)}_.R(a,"gb_cc");this.f=a;return this};_.k.focus=function(){this.o.focus()};
_.qh=function(a){_.eh.call(this,a);this.b=[];this.F={}};_.u(_.qh,_.eh);_.eh.prototype.Ec=function(){return this.D()};_.qh.prototype.ka=function(a){var c=this.F[a];if(c)return c;var d=window.document.getElementById(a);if(d)for(var e=0,f=this.b.length;e<f;++e)if(c=this.b[e],c.D()==d)return this.F[a]=c;return null};_.qh.prototype.f=function(a){a.Rb(this);this.b.push(a);var c=a.getId();c&&(this.F[c]=a)};_.qh.prototype.T=function(){for(var a=0,c=this.b.length;a<c;a++)this.b[a].ma();this.F={};this.b=[]};
var rh=function(a,c){_.qh.call(this,c||this.createElement());this.w=a;for(var d=this.D().getElementsByClassName("gb_8b"),e=0;e<d.length;e++){var f=d[e];_.Q(f,"gb_dc")?this.f(new ph(this,f)):this.f(new oh(this,f))}};_.u(rh,_.qh);rh.prototype.createElement=function(){var a=_.ld(window.document,"UL");_.R(a,"gb_7b");return a};rh.prototype.f=function(a){rh.H.f.call(this,a);var c=this.w,d=a.D(),d=d.id||(d.id="gbm"+_.ig(_.hg.Aa()));c.G[d]=a};rh.prototype.j=function(){var a=new oh(this);this.f(a);return a}; rh.prototype.o=function(){var a=new ph(this);this.f(a);return a};
var th=function(a,c){_.qh.call(this,a);this.j=c;this.o=_.N("gb_4b",this.j);this.M=new _.bh(this.o);this.A=_.N("gb_5b",this.o);this.C=_.N("gb_6b",this.o);this.G={};this.J=[];this.w=new _.Bf(this);sh(this);for(var d=this.o.getElementsByClassName("gb_7b"),e=0;e<d.length;e++)this.f(new rh(this,d[e]))},sh;_.u(th,_.qh);var uh="click mousedown scroll touchstart wheel keydown".split(" ");
th.prototype.L=function(){th.H.L.call(this);_.Vf(this.w,window.document.body,uh,this.O,!1,this);_.Vf(this.w,window.document.body,_.xc,this.R)};th.prototype.Ec=function(){return this.o};th.prototype.V=function(){vh(this);return wh(this,this.A)};th.prototype.S=function(){vh(this);return wh(this,this.C)};
var wh=function(a,c){var d=new rh(a),e=d.D();c.appendChild(e);a.f(d);return d},vh=function(a){a.A||(a.A=_.ld(window.document,"DIV"),_.R(a.A,"gb_5b"),a.o.appendChild(a.A),a.C=_.ld(window.document,"DIV"),_.R(a.C,"gb_6b"),a.o.appendChild(a.C))};th.prototype.ha=function(a){_.U(this.j,"gb_2b",1==a)};th.prototype.Ga=function(){return!_.Q(this.D(),"gb_6a")};
th.prototype.close=function(){_.S(this.j,"gb_g");_.K(this.D(),"expanded",!1);window.document.activeElement==this.D()&&this.D().blur();var a=this.M;_.dh(a);_.U(a.f,"gb_6",!1);this.K("close")};_.xh=function(a){return _.Q(a.j,"gb_g")};sh=function(a){_.sg(a.w,a.D(),_.V,a.W);a.D().addEventListener("keydown",function(a){32==a.keyCode&&a.preventDefault()});_.sg(a.w,a.o,_.V,a.Z);a.w.b(a.j,"keydown",a.$);yh(a)};
th.prototype.W=function(){_.xh(this)?this.close():(this.K("beforeshow"),_.R(this.j,"gb_g"),_.K(this.D(),"expanded",!0),_.hh(this.o),_.ch(this.M),this.K("open"))};var zh=function(a){return!_.Q(a.j,"gb_2b")||_.Q(a.j,"gb_1b")||_.Q(a.j,"gb_Se")};th.prototype.$=function(a){if(9===a.keyCode&&_.xh(this)&&zh(this)){var c=a.target,d=_.Eg(this.j);0<d.length&&(c==d[0]&&a.shiftKey?(d[d.length-1].focus(),a.preventDefault()):c!=d[d.length-1]||a.shiftKey||(d[0].focus(),a.preventDefault()))}};
th.prototype.Z=function(a){if(a.target instanceof window.Node){a:{a=a.target;for(var c=this.o;a&&a!==c;){var d=a.id;if(d in this.G){a=this.G[d];break a}a=a.parentNode}a=null}if(a){a=a.Dc();c=0;for(d=this.J.length;c<d;++c){var e=this.J[c];e.b.call(e.f,a)}this.close()}}};
th.prototype.O=function(a){_.xh(this)&&a.target instanceof window.Node&&zh(this)&&("keydown"==a.type?27==a.keyCode&&(a.preventDefault(),a.stopPropagation(),this.close(),this.D().focus()):Og(a.target,"gb_ga")||Og(a.target,"gb_Xb")||_.ff(this.j,a.target)||("touchstart"==a.type&&(a.preventDefault(),a.stopPropagation()),this.close()))};th.prototype.R=function(){_.xh(this)&&(!zh(this)||Og(window.document.activeElement,"gb_0b")||Og(window.document.activeElement,"gb_ga")||_.hh(this.o))}; var yh=function(a){a.w.B(window.document.body,uh,a.O,!1,a);a.w.b(window.document.body,_.xc,a.R)};th.prototype.Y=function(a,c){this.J.push(new Ah(a,c))};var Ah=function(a,c){this.b=a;this.f=c};
_.Bh=function(a){_.eh.call(this,a);_.O(a,"click",this.b,!1,this)};_.u(_.Bh,_.eh);_.Bh.prototype.f=function(){return _.Qg(this.D(),"pressed")||!1};_.Bh.prototype.b=function(a){a=a.b;var c=_.xg(a,"pressed");_.tf(null==c?"":String(c))||"true"==c||"false"==c?_.K(a,"pressed","true"==c?"false":"true"):a.removeAttribute("aria-pressed");this.K("click")};
var Ch,Eh;_.Dh=function(){_.M.prototype.za=_.Ic(Ch,_.M.prototype.Sa);_.M.prototype.zb=_.M.prototype.vc;_.t("gbar.I",_.eh);_.eh.prototype.ia=_.eh.prototype.getId;_.eh.prototype.ib=_.eh.prototype.D;_.eh.prototype.ic=_.eh.prototype.U;_.t("gbar.J",_.qh);_.qh.prototype.ja=_.qh.prototype.ka;_.qh.prototype.jb=_.qh.prototype.T;_.t("gbar.K",_.fh);_.t("gbar.L",_.Bh);_.Bh.prototype.la=_.Bh.prototype.f};Ch=function(a,c,d,e,f){return a.call(this,c,_.Ic(Eh,d),e,f)}; Eh=function(a,c){c.xa=c.type;c.xb=c.target;return a.call(this,c)};
var W=function(a,c,d,e){_.M.call(this);this.f=a;this.C=c;this.M=d;this.T="";this.Y=e;this.A=this.b=null;this.J=!1;this.R=_.N("gb_xc",this.f);this.F=_.G(_.C(c,6),!1);this.W=_.N("gb_yc",this.R);this.j=_.N("gb_ad",this.f);this.w=_.N("gb_bd",this.f);this.G=_.N("gb_gc",this.f);this.o=Array.prototype.slice.call(_.Wg("gb_fd",this.f));this.B=new _.mh(this.f,Fh);Gh(this,this.B.b);this.B.f("catc",this.S,this)};_.u(W,_.M);var Fh=[{id:"gb_1b",max:599},{id:"gb_Se",max:1023},{id:"gb_3b"}];W.prototype.D=function(){return this.f};
W.prototype.ra=function(a){_.$f(this.W,a||"");_.U(this.R,"gb_6a",!a);this.F=!!a;Gh(this,this.B.b)};
var Gh=function(a,c){var d="gb_1b"==c,e="gb_Se"==c,f=_.G(_.C(a.C,5),!1),g=_.G(_.C(a.C,7),!1),h=_.G(_.C(a.C,2),!1),l=_.G(_.C(a.C,1),!1),e=h&&(d||e&&(f||a.F));a.J=!(a.F||d&&(f||g));d=!a.F;e||l?(a.b||((l=_.N("gb_Xb",a.f))?(f=_.N("gb_0b"))?(a.b=new th(l,f),a.b.Sa("open",a.U,!1,a),a.b.Sa("close",a.V,!1,a),_.Dh(),_.t("gbar.C",th),th.prototype.ca=th.prototype.Ec,th.prototype.cb=th.prototype.V,th.prototype.cc=th.prototype.Y,th.prototype.cd=th.prototype.ha,th.prototype.ce=th.prototype.S,_.t("gbar.D",rh),rh.prototype.da=
rh.prototype.j,rh.prototype.db=rh.prototype.o,_.t("gbar.E",oh),oh.prototype.ea=oh.prototype.D,oh.prototype.eb=oh.prototype.hc,oh.prototype.ec=oh.prototype.nh,oh.prototype.ed=oh.prototype.Dc,_.t("gbar.F",ph),ph.prototype.fa=ph.prototype.oh,ph.prototype.fb=ph.prototype.Bh,ph.prototype.fc=ph.prototype.Ah,ph.prototype.fd=ph.prototype.Oe,ph.prototype.ed=ph.prototype.Dc,_.Kg(_.gc.Aa().b,a.b)):a.M.log(Error("z")):a.M.log(Error("A"))),a.b&&!a.b.Ga()&&_.S(a.b.D(),"gb_6a")):a.b&&a.b.Ga()&&(l=a.b,l.close(),
_.R(l.D(),"gb_6a"));a.b&&e?_.Hh(a)||(e=_.N("gb_jd"),a.G.parentNode!=e&&e.insertBefore(a.G,e.childNodes[0]||null),_.Ig(_.qd("dd")),a.K("upi")):_.Hh(a)&&(a.j.appendChild(a.G),_.Ig(_.qd("dd")),a.K("upo"));a.A&&(e=a.A.D(),_.U(e,"gb_6a",!d),d&&a.A.j(a.J));_.Q(a.f,"gb_1b");e=_.Lc(nh);_.Af(a.f,e);_.R(a.f,c);a.b&&(l=a.b.j,_.Af(l,e),_.R(l,c),zh(a.b)?_.N("gb_kd",void 0).appendChild(l):a.f.appendChild(l));_.Ih(a)};W.prototype.S=function(){Gh(this,this.B.b);this.b&&_.Jh(this,_.xh(this.b),!1);this.K("ffc")};
_.Jh=function(a,c,d){a.b&&(zh(a.b)&&(c=!1),a=window.document.body,_.U(a,"gb_od",c),_.U(a,"gb_nd",d))};W.prototype.U=function(){_.Jh(this,!0,!0)};W.prototype.V=function(){_.Jh(this,!1,!0)};_.Hh=function(a){return!!a.b&&a.G.parentNode!=a.j};W.prototype.getHeight=function(){return this.f.offsetHeight};_.Ih=function(a){var c=a.getHeight()+"px";a.T!=c&&(a.T=c,a.Y&&(a.Y.style.height=c),a.K("resize"))};W.prototype.Z=function(){this.w&&_.Ih(this)};
W.prototype.O=function(){if(!this.w){var a=_.ld(window.document,"DIV");_.zf(a,["gb_bd","gb_fd"]);var c;c=this.o[0];c=c.classList.contains("gb_hd")?1:c.classList.contains("gb_gd")?2:0;Kh(a,c);a.style.backgroundColor=this.o[0].style.backgroundColor;this.o.push(a);c=this.j;c.parentNode&&c.parentNode.insertBefore(a,c.nextSibling);this.w=a}return this.w};W.prototype.$=function(){_.gf(this.w);this.w=null;_.Ih(this)};W.prototype.ha=function(a){for(var c=0;c<this.o.length;c++)Kh(this.o[c],a)}; var Kh=function(a,c){_.Af(a,["gb_gd","gb_hd"]);1==c?_.R(a,"gb_hd"):2==c&&_.R(a,"gb_gd")};W.prototype.ka=function(a){for(var c=0;c<this.o.length;c++)this.o[c].style.backgroundColor=a};
var Lh;var Mh=_.N("gb_ec");if(null==Mh)Lh=null;else{var Nh=_.E(_.ic,Jg,6)||new Jg,Oh=new W(Mh,Nh,_.J,_.N("gb_9c"));_.t("gbar.P",W);W.prototype.pa=W.prototype.getHeight;W.prototype.pb=W.prototype.ra;W.prototype.pc=W.prototype.ha;W.prototype.pd=W.prototype.ka;W.prototype.pe=W.prototype.O;W.prototype.pf=W.prototype.Z;W.prototype.pg=W.prototype.$;_.Kg(_.gc.Aa().f,Oh);Lh=Oh}_.X=Lh;

}catch(e){_._DumpException(e)}
try{
var Ph=window.document.querySelector(".gb_eb .gb_b");Ph&&_.Eb(_.sc,Ph,"click");
}catch(e){_._DumpException(e)}
try{
for(var Qh=window.document.querySelectorAll(".gb_Tb"),Rh=0;Rh<Qh.length;Rh++)_.Eb(_.sc,Qh[Rh],"click");
}catch(e){_._DumpException(e)}
try{
var Sh=window.document.querySelector(".gb_pc");if(Sh){var Th=Sh.querySelector(".gb_b");Th&&_.Eb(_.sc,Th,"click")};
}catch(e){_._DumpException(e)}
})(this.gbar_);
// Google Inc.
</script></div></div><meta itemprop="name" content="MC Inquiry report28 08 16_edited_clean.pdf" aria-hidden="true"><meta itemprop="faviconUrl" content="https://ssl.gstatic.com/docs/doclist/images/icon_14_pdf_favicon.ico" aria-hidden="true"><meta itemprop="url" content="https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view?usp=sharing&amp;usp=embed_googleplus" aria-hidden="true"><meta itemprop="embedURL" content="https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/preview?usp=embed_googleplus" aria-hidden="true"><div class="drive-viewer drive-viewer-focus-outlines-disabled drive-viewer-shown drive-viewer-quantum-spinner drive-viewer-v3" aria-label="Showing viewer." tabindex="0"><div class="drive-viewer-shadow drive-viewer-default" tabindex="0" aria-label="Displaying MC Inquiry report28 08 16_edited_clean.pdf."></div><div class="drive-viewer-carousel" style="bottom: 0px;"><div class="drive-viewer-prev-button drive-viewer-button-disabled drive-viewer-button" role="button" aria-disabled="true" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="r,c" data-tooltip-offset="-6" style="-webkit-user-select: none; left: 12px; display: none; opacity: 0;"><div class="drive-viewer-nav-background"><div class="drive-viewer-icon drive-viewer-nav-icon"></div></div></div><div class="drive-viewer-next-button drive-viewer-button-disabled drive-viewer-button" role="button" aria-disabled="true" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="l,c" data-tooltip-offset="-6" style="-webkit-user-select: none; right: 12px; display: none; opacity: 0;"><div class="drive-viewer-nav-background"><div class="drive-viewer-icon drive-viewer-nav-icon"></div></div></div><div class="drive-viewer-toolchest" style="opacity: 0;"><div class="drive-viewer-page-count-v3" style="" aria-label="Page 1 of 47"><div class="drive-viewer-page-count-header">Page</div><div class="drive-viewer-page-count-index">1</div><span class="drive-viewer-page-count-separator">/</span><div class="drive-viewer-page-count-total">47</div></div><div class="drive-viewer-zoom-controls-v3"><div class="drive-viewer-dark-button drive-viewer-zoom-out-button goog-inline-block drive-viewer-button drive-viewer-button-disabled" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="Zoom out" data-tooltip="Zoom out" style="-webkit-user-select: none;" aria-disabled="true"><div class="drive-viewer-icon"></div></div><div class="drive-viewer-button drive-viewer-dark-button drive-viewer-zoom-fit-button goog-inline-block" role="button" tabindex="0" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" style="-webkit-user-select: none;" aria-label="Fit to width" data-tooltip="Fit to width"><div class="drive-viewer-icon"></div></div><div class="drive-viewer-button drive-viewer-dark-button drive-viewer-zoom-in-button goog-inline-block" role="button" tabindex="0" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="Zoom in" data-tooltip="Zoom in" style="-webkit-user-select: none;"><div class="drive-viewer-icon"></div></div></div><div class="drive-viewer-licensebar" style="display: none;"></div></div><div class="drive-viewer-carousel-slide drive-viewer-close-enabled" role="main"><div class="drive-viewer-msg-loading drive-viewer-carousel-loading-message" role="status" tabindex="-1" aria-label="Loading" style="display: none;"><div class="drive-viewer-msg-loading-img drive-viewer-focus-to-default"><div class="drive-spinner"><div class="drive-quantum-spinner active"><div class="spinner-layer spinner-blue"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-red"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-yellow"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-green"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div></div></div></div><span class="drive-viewer-msg-loading-text drive-viewer-focus-to-default" aria-hidden="true">Loading</span></div><div class="drive-viewer-paginated drive-viewer-itemview"><textarea class="drive-viewer-paginated-textarea" aria-hidden="true" tabindex="-1"></textarea><div class="drive-viewer-paginated-scrollable drive-viewer-scrollable" tabindex="-1" style="margin-left: 12px;"><div class="drive-viewer-paginated-pages drive-viewer-layout-transition drive-viewer-paginated-page-cursor" role="document" tabindex="0" style="margin-top: 56px; margin-bottom: 56px; width: 800px; left: 548px;"><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 1 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 8.20452%; width: 69.4118%; height: 4.63734%;">Access to medicinal cannabis:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 23.8655%; top: 13.4364%; width: 52.7731%; height: 5.35077%;">meeting patient needs
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 27.4673%; width: 70.9244%; height: 4.28062%;">All-Party Parliamentary Group for Drug
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 37.8151%; top: 31.629%; width: 24.5378%; height: 4.16171%;">Policy Reform
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.0987%; width: 1.0084%; height: 2.25922%;">
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 36.3025%; top: 48.6326%; width: 27.563%; height: 3.09156%;">Inquiry Report
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 79.6671%; width: 73.1092%; height: 2.0214%;">The enjoyment of the highest attainable standard of health is one of the fundamental
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.2689%; top: 81.5696%; width: 75.9664%; height: 2.0214%;">rights of every human being without distinction of race, religion, political belief, economic
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 41.5126%; top: 83.3532%; width: 17.1429%; height: 1.9025%;">or social condition.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.4538%; top: 86.2069%; width: 71.7647%; height: 2.0214%;">Constitution of the World Health Organisation drawn up in 1946 in conformity with the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 37.8151%; top: 88.1094%; width: 24.5378%; height: 2.0214%;">Charter of the United Nations
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/eda7dd16-17d0-4c62-8193-f159832722e6" class="drive-viewer-paginated-page-img" alt="Page 1 of 47" aria-hidden="true" style="opacity: 1;"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 2 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 49.4118%; top: 92.7467%; width: 1.17647%; height: 1.30797%;">ii
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 45.2101%; top: 8.68014%; width: 13.7815%; height: 2.85375%;">Foreword
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 13.3175%; width: 76.4706%; height: 2.0214%;">For six years, the All-Party Parliamentary Group for Drug Policy Reform has worked for an end
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.22%; width: 76.1345%; height: 2.0214%;">to the war on drugs driven by the USA and supported by the UN. In our Guidance on
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 17.0036%; width: 62.3529%; height: 2.0214%;">Interpreting the UN Drugs Conventions, we called for three major changes:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 19.8573%; width: 26.7227%; height: 2.0214%;">1. evidence-based drugs policy;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.6409%; width: 76.6387%; height: 2.14031%;">2. policy that genuinely promotes the health and welfare of mankind driven by human rights
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 23.5434%; width: 20.6723%; height: 2.0214%;">and public health values;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.4459%; width: 76.6387%; height: 2.0214%;">3. flexibility for Member States to develop drug policy within the UN Conventions based on
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 27.2295%; width: 25.7143%; height: 2.0214%;">our four Guidance principles.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.0832%; width: 76.8067%; height: 2.0214%;">We have had meetings with the President of the UN Economic and Social Council (ECOSOC);
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.8668%; width: 76.8067%; height: 2.14031%;">the Executive Director of the UN Office on Drugs and Crime (UNODC); and the Deputy
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.7693%; width: 76.6387%; height: 2.0214%;">Secretary General of the UN. We have organised international meetings of Ministers and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.5529%; width: 76.6387%; height: 2.14031%;">senior officials in Westminster and spoken at international meetings in New York, Brussels
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.4554%; width: 21.3445%; height: 2.0214%;">and Cartagena, Colombia.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.1902%; width: 76.8067%; height: 2.14031%;">At the UN General Assembly Special Session (UNGASS) held in April 2016, we witnessed both
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.0927%; width: 76.6387%; height: 2.0214%;">the USA and the UN leadership reject a moralistic and prohibitionist approach to the global
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.9952%; width: 76.8067%; height: 1.9025%;">drug problem. Instead, the UN and US leaders called for all our proposed changes to global
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.6599%; width: 10.5882%; height: 2.0214%;">drugs policy.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.5137%; width: 76.8067%; height: 2.0214%;">As far as the UK is concerned, it seems clear that the legalisation of cannabis for medical use
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.2973%; width: 76.8067%; height: 2.0214%;">fulfils the above objectives. There is now a sound evidence base for such a policy. Legalisation
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.1998%; width: 76.8067%; height: 2.0214%;">and licensing will promote the health and welfare of very sick people and the policy respects
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.9834%; width: 76.8067%; height: 2.0214%;">human rights and public health values. The British Government needs to respond to the call
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.7669%; width: 52.437%; height: 2.14031%;">from the UN for drug policies that comply with these principles.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.6207%; width: 76.8067%; height: 2.0214%;">We hope that this report will persuade Government Ministers and politicians of all Parties to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.5232%; width: 76.3025%; height: 2.0214%;">support the proposed reforms. We hope that it will be useful to academics and others
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.3068%; width: 76.6387%; height: 2.0214%;">interested in advancing our knowledge and understanding of medicine, particularly for those
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.2093%; width: 76.8067%; height: 2.0214%;">with chronic conditions; to those concerned about drug policy; and, above all, to those for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.9929%; width: 46.5546%; height: 2.0214%;">whom cannabis has provided some relief from suffering.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.975%; width: 64.0336%; height: 1.78359%;">Caroline Lucas MP Baroness Meacher
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 83.7099%; width: 57.3109%; height: 2.0214%;">Co-chairs of the All-Party Parliamentary Group for Drug Policy Reform
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/bad8223b-3b17-4ce3-b631-be5f950255b8" class="drive-viewer-paginated-page-img" alt="Page 2 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 3 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 49.2437%; top: 92.7467%; width: 1.51261%; height: 1.30797%;">iii
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 38.3193%; top: 8.32342%; width: 27.2269%; height: 3.09156%;">Acknowledgements
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 76.6387%; height: 2.14031%;">The All-Party Parliamentary Group (APPG) for Drug Policy Reform owes a debt of gratitude to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 14.7444%; width: 76.4706%; height: 2.0214%;">Frank Warburton for his major contribution to this report; to Professor Mike Barnes MD FRCP
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.5279%; width: 76.6387%; height: 2.0214%;">and Dr Jennifer Barnes DPsych for their report Cannabis: The Evidence for Medical Use
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.4304%; width: 76.6387%; height: 2.0214%;">produced in response to a very small grant from us; to Jonathan Liebling, Political Officer with
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.214%; width: 76.8067%; height: 2.0214%;">the United Patients Alliance for managing and analysing the results of an online survey of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.1165%; width: 76.6387%; height: 2.0214%;">medicinal cannabis users and; and to the Chronic Pain Coalition who assisted the APPG with
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.9001%; width: 76.8067%; height: 2.14031%;">an online survey of health professionals. Summaries of the key findings from these pieces of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.8026%; width: 36.8067%; height: 2.0214%;">work are included within this Inquiry Report.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.5375%; width: 76.6387%; height: 2.14031%;">We are also most grateful to everyone who gave written and/or oral evidence to the Inquiry
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.44%; width: 60.5042%; height: 2.0214%;">and to APPG members who participated in the hearings (see Appendix 1).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.1748%; width: 76.8067%; height: 2.14031%;">This report has been made possible by the generous support of the Open Society Fund and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.0773%; width: 19.8319%; height: 1.78359%;">the AB Charitable Trust.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 45.5462%; top: 78.3591%; width: 9.07563%; height: 1.30797%;">Disclaimer
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.2773%; top: 80.7372%; width: 74.1176%; height: 2.0214%;">This report has been approved by the officers of the APPG for Drug Policy Reform but does
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.2857%; top: 82.5208%; width: 71.9328%; height: 2.0214%;">not necessarily represent the views of each individual member of the Group. It does not
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 25.7143%; top: 84.4233%; width: 48.4034%; height: 2.0214%;">represent the views of the Houses of Parliament in general.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/9eba0f96-6f45-42e0-9ce6-5ca141388b9e" class="drive-viewer-paginated-page-img" alt="Page 3 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 4 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 49.2437%; top: 92.7467%; width: 1.68067%; height: 1.30797%;">iv
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 12.9412%; height: 2.73484%;">Contents
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 14.7444%; width: 75.9664%; height: 1.30797%;">Foreword....................................................................................................................................ii
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.2414%; width: 76.1345%; height: 1.54578%;">Acknowledgements................................................................................................................... iii
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 19.2628%; width: 75.9664%; height: 2.0214%;">Executive summary.................................................................................................................... v
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 22.1165%; width: 75.9664%; height: 1.42687%;">1. Introduction ........................................................................................................................9
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.1379%; width: 76.1345%; height: 2.0214%;">2. Developments in the regulation of medicinal cannabis elsewhere in the world.............12
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.635%; width: 76.1345%; height: 2.0214%;">3. Conducting the Inquiry and taking evidence....................................................................18
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.132%; width: 76.1345%; height: 1.78359%;">4. Medicinal cannabis: the evidence ....................................................................................19
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.629%; width: 76.1345%; height: 1.78359%;">5. The use of medicinal cannabis in the UK..........................................................................21
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.126%; width: 76.1345%; height: 2.0214%;">6. Results of the survey of health professionals...................................................................27
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.5042%; width: 76.1345%; height: 1.78359%;">7. Case studies......................................................................................................................30
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.0012%; width: 76.1345%; height: 2.0214%;">8. Current scheduling of cannabis: implications for research..............................................32
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.4982%; width: 76.1345%; height: 2.0214%;">9. Models of regulation for medicinal purposes ..................................................................34
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 43.9952%; width: 75.9664%; height: 1.66468%;">10. Conclusions and recommendations .................................................................................38
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.3734%; width: 76.1345%; height: 2.0214%;">Appendix 1: Those giving evidence and the APPG panel ........................................................39
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.7515%; width: 76.1345%; height: 2.14031%;">Appendix 2: Survey of those who use medicinal cannabis......................................................41
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.2485%; width: 76.1345%; height: 2.0214%;">Appendix 3: Brief Survey for health professionals on the medicinal use of cannabis ............43
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.7455%; width: 76.1345%; height: 2.0214%;">Appendix 4: Marks medications prior to starting treatment with cannabis..........................44
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 56.7182%; width: 75.9664%; height: 1.30797%;">Endnotes..................................................................................................................................45
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/60a694c3-f338-495a-8d59-5f37b744fea5" class="drive-viewer-paginated-page-img" alt="Page 4 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"><a href="http://www.endourpain.org/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.endourpain.org" style="left: 50.7563%; top: 41.9738%; width: 18.4874%; height: 1.66468%;"></a></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 5 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 49.4118%; top: 92.9845%; width: 1.34454%; height: 1.07015%;">v
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 26.7227%; height: 3.09156%;">Executive summary
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 31.2605%; height: 2.0214%;">Medicinal cannabis: the way forward
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 15.6956%; width: 76.6387%; height: 2.0214%;">Many jurisdictions across the world have either already introduced systems that allow lawful
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.4792%; width: 76.8067%; height: 2.14031%;">access to medicinal cannabis or are in the process of so doing. At least 11 European countries
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.3817%; width: 76.8067%; height: 2.0214%;">already ensure access to it including: Austria, the Czech Republic, Finland, Belgium, Germany,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 21.1653%; width: 76.6387%; height: 2.0214%;">Italy, the Netherlands, Romania, Portugal and Switzerland. Twenty-four States in the USA also
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.0678%; width: 76.8067%; height: 2.0214%;">ensure access, with more states due to vote on the matter. Canada, Israel, Jamaica and many
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 24.8514%; width: 76.4706%; height: 2.0214%;">Latin American countries, including Uruguay, Chile and Colombia join the countries that allow
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.7539%; width: 35.1261%; height: 2.0214%;">access to cannabis for medicinal purposes.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 29.4887%; width: 76.1345%; height: 2.0214%;">However, the UK lags behind. Indeed, in the UK cannabis and its derivatives are listed under
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.3912%; width: 76.8067%; height: 2.0214%;">Schedule 1, the Schedule for dangerous drugs with no medicinal value. At the same time, the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 33.1748%; width: 76.6387%; height: 2.14031%;">UK Government has approved nabiximols (trade name Sativex) and nabilone (trade name
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.0773%; width: 72.9412%; height: 2.0214%;">Cesamet), which seems irrational and contrary to the Governments scheduling decision.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.8121%; width: 76.8067%; height: 2.14031%;">This issue matters to a substantial number of patients (and their families) across the UK. One
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.7146%; width: 76.8067%; height: 2.0214%;">estimate of current users of medicinal cannabis in the UK puts the figure at 30,000 daily.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 41.4982%; width: 76.6387%; height: 2.14031%;">However, the campaign group End Our Pain (www.endourpain.org) puts the estimate at
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.4007%; width: 76.6387%; height: 2.0214%;">approaching 1,000,000 in total. This is based on the fact that Home Office figures put the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.1843%; width: 76.8067%; height: 2.0214%;">number of UK cannabis takers (both recreational and medicinal) at 3,000,000, and figures
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.9679%; width: 76.6387%; height: 2.0214%;">from the USA suggest that approaching 1 in 3 will be for primarily medical reasons. If this
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.7515%; width: 76.6387%; height: 2.14031%;">figure seems high, it is interesting to note that Germany, which is currently introducing
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.654%; width: 76.8067%; height: 2.0214%;">legislation to allow legal access to medicinal cannabis estimates that nearly 800,000 of its
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.4376%; width: 36.1345%; height: 2.0214%;">citizens may be eligible under their scheme.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.2913%; width: 76.6387%; height: 2.0214%;">Against this background, the APPG convened the most in-depth parliamentary inquiry into
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.0749%; width: 76.6387%; height: 2.14031%;">this issue ever undertaken. Alongside their inquiry, the APPG commissioned the most
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.9774%; width: 51.7647%; height: 1.78359%;">extensive review of evidence in the literature in modern times.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.7122%; width: 9.91597%; height: 2.0214%;">The inquiry
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.566%; width: 76.6387%; height: 2.0214%;">The inquiry learnt that the reputation of cannabis as a medicine, particularly for treating the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.4685%; width: 76.6387%; height: 2.0214%;">symptoms of chronic conditions, and the failure of prescription medicines to relieve their
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.2521%; width: 76.6387%; height: 2.0214%;">symptoms, has led patients to try herbal cannabis even though access to it is not lawful and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.0357%; width: 76.6387%; height: 2.14031%;">even though they cannot generally get expert medical guidance or supervision to cover its
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 71.9382%; width: 76.6387%; height: 2.0214%;">use. The APPG has heard and assembled compelling stories of the dramatic improvements to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.7218%; width: 76.6387%; height: 2.14031%;">their health that some cannabis users have experienced. Many spoke of the ways in which
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.6243%; width: 76.6387%; height: 2.0214%;">cannabis had enabled them to stop using pharmaceutical drugs with serious side effects, or
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 77.5268%; width: 76.6387%; height: 2.0214%;">to get their lives back. People without experience of medicinal cannabis told the Inquiry
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.3103%; width: 76.6387%; height: 2.0214%;">about the desperation they felt in experiencing the pain and suffering of a chronic illness.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 81.2128%; width: 76.4706%; height: 2.0214%;">Many who were taking cannabis to help with their symptoms told of the added stress and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.9964%; width: 76.6387%; height: 2.0214%;">worry induced by having to risk prosecution. They expressed sincere hope that cannabis might
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.78%; width: 50.9244%; height: 2.0214%;">be made legally available and would prove effective for them.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/e3566b93-a9b5-4159-8144-668c68178a9b" class="drive-viewer-paginated-page-img" alt="Page 5 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 6 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 49.2437%; top: 92.7467%; width: 1.51261%; height: 1.30797%;">vi
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.6387%; height: 2.0214%;">As a part of this inquiry, we undertook a small online survey of health professionals with the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 76.6387%; height: 2.14031%;">help of the Chronic Pain Policy Coalition. They had prescribed or knew of prescriptions for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.0095%; width: 76.6387%; height: 2.0214%;">cannabis-based treatments for chronic pain arising from many different conditions. The
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.912%; width: 76.6387%; height: 2.0214%;">majority were positive about the role of cannabis-based medicines for reducing pain. At the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.6956%; width: 76.6387%; height: 2.0214%;">very least, cannabis-based treatment can provide significant benefit for a small group of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.4792%; width: 47.563%; height: 2.14031%;">chronic pain patients where other treatments have failed.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 76.8067%; height: 2.0214%;">We commissioned an online survey of medicinal cannabis use in the UK. This revealed
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.2354%; width: 76.6387%; height: 2.0214%;">cannabis use for a considerable range of conditions: for example, chronic and severe pain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.019%; width: 76.8067%; height: 2.0214%;">(24% of respondents); arthritis (12%); insomnia (21%); fibromyalgia (9%); post-traumatic
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.8026%; width: 76.6387%; height: 2.14031%;">stress disorder (PTSD) (7%); depression (30%); and anxiety (26%). Very similar results were
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.7051%; width: 33.9496%; height: 2.0214%;">found among cannabis users in Australia.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.44%; width: 76.8067%; height: 2.14031%;">With regard to reported efficacy, cannabis was perceived to provide great relief overall by
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.3424%; width: 76.6387%; height: 2.0214%;">86% of patients, and substantial relief of specific symptoms such as pain, nausea and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.2449%; width: 76.6387%; height: 2.0214%;">insomnia. Over 90% reported no or mild side effects from cannabis treatment. By contrast,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.0285%; width: 76.6387%; height: 2.0214%;">respondents experienced significant, severe and very severe side effects from
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.8121%; width: 19.1597%; height: 2.14031%;">prescribed medication.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.6659%; width: 76.8067%; height: 2.0214%;">A majority of respondents (63%) have discussed using a cannabis-based treatment with their
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.5684%; width: 76.6387%; height: 2.0214%;">GP or Consultant, but 72% of patients had obtained their cannabis on the street, directly or
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.352%; width: 76.6387%; height: 1.9025%;">indirectly. Some respondents reported stress and anxiety associated with obtaining cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.4923%; width: 6.89076%; height: 1.66468%;">illegally.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.8704%; width: 71.4286%; height: 2.0214%;">Review of the evidence of the effectiveness of medicinal cannabis by Professor Mike
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.7729%; width: 25.5462%; height: 1.78359%;">Barnes and Dr Jennifer Barnes
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.5077%; width: 76.8067%; height: 2.0214%;">The review was based on a literature search producing over 20 000 references. The evidence
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.4102%; width: 76.8067%; height: 2.0214%;">was graded according to the system used by the American Academy of Neurology (AAN),
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.1938%; width: 76.6387%; height: 2.0214%;">based on the robustness of the research methodology. The evidence for particular medical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 59.0963%; width: 76.8067%; height: 2.0214%;">applications of cannabis was then grouped into three categories: good, moderate and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.3555%; width: 6.89076%; height: 1.30797%;">some.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.7337%; width: 76.8067%; height: 2.0214%;">The theoretical basis for consideration of cannabis as a medicinal product is strong. The
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.5172%; width: 76.6387%; height: 2.0214%;">natural endocannabinoid system has a range of important natural functions, including
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.4197%; width: 76.6387%; height: 2.0214%;">modulation of pain, control of movement, protection of nerve cells and a role in natural brain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.2033%; width: 76.6387%; height: 2.0214%;">adaptability, as well as a role in various metabolic immune and inflammatory processes and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 71.1058%; width: 39.1597%; height: 2.0214%;">a possible role in the control of tumour growth.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.8407%; width: 26.3866%; height: 2.0214%;">The review found the following:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.6944%; width: 76.6387%; height: 2.0214%;"> There is good evidence for one or more of the cannabis products or natural cannabis in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 78.5969%; width: 73.6134%; height: 2.0214%;">the management of chronic pain, including neuropathic pain; spasticity; nausea and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 80.3805%; width: 73.1092%; height: 2.0214%;">vomiting, particularly in the context of chemotherapy; and in the management of anxiety.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.283%; width: 76.6387%; height: 2.14031%;"> There is moderate evidence for the use of cannabis in sleep disorders; appetite
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 84.1855%; width: 73.6134%; height: 2.0214%;">stimulation in the context of chemotherapy; fibromyalgia; PTSD; and for some symptoms
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 85.9691%; width: 18.8235%; height: 1.9025%;">of Parkinsons disease.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 87.9905%; width: 61.6807%; height: 2.0214%;"> There is some limited evidence of efficacy for a further list of disorders.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/85cb1b8d-c3c7-4a42-8257-8efbbbdc21d6" class="drive-viewer-paginated-page-img" alt="Page 6 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 7 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 48.9076%; top: 92.7467%; width: 2.18487%; height: 1.30797%;">vii
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 17.479%; height: 1.78359%;">Potential downsides
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 11.1772%; width: 76.8067%; height: 2.0214%;">As with the adoption of any substance in a medical environment, it is vital to consider any
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.9608%; width: 76.6387%; height: 2.0214%;">potential downsides and put them in context. The short-term side effects of cannabis are
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 76.6387%; height: 2.14031%;">generally mild and well tolerated. There is probably a small link between cannabis and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.6468%; width: 76.1345%; height: 2.0214%;">schizophrenia for those who start using cannabis at an early age and if the individual has a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.5493%; width: 76.6387%; height: 2.0214%;">genetic predisposition to psychosis. There is a small dependency rate of around 9%. This
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 76.8067%; height: 2.0214%;">compares with 32% for tobacco use and 15% for alcohol use. Researchers recommend caution
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.2354%; width: 76.8067%; height: 2.0214%;">in prescribing cannabis to younger people, given the possible susceptibility of the developing
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.4946%; width: 5.04202%; height: 1.30797%;">brain.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.8728%; width: 76.6387%; height: 2.0214%;">Overall, Professor Barnes concludes that there is a considerable literature demonstrating the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.6564%; width: 76.6387%; height: 2.0214%;">efficacy of cannabis and/or available cannabis products in a number of important indications.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 30.44%; width: 76.6387%; height: 2.14031%;">Much further research on cannabis is needed in relation to a range of diseases. According to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.3424%; width: 76.8067%; height: 2.0214%;">our survey of medicinal cannabis users, 54% of respondents reported significant to very
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.2449%; width: 76.6387%; height: 2.0214%;">severe side effects from prescription medicines compared to 8.5% reporting such side effects
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.0285%; width: 29.0756%; height: 1.78359%;">from their medicinal cannabis use.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.8823%; width: 76.6387%; height: 2.0214%;">The Drug Policy Alliance (DPA) in the USA has reviewed the evidence of the benefits of access
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.6659%; width: 76.6387%; height: 2.0214%;">to medicinal cannabis since its legalisation in many US States over recent years. Their findings
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.9251%; width: 7.89916%; height: 1.42687%;">included:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 45.3032%; width: 76.4706%; height: 1.9025%;">1. Medical benefits. The most obvious benefit is to patients. Cannabis has been shown to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 47.0868%; width: 21.0084%; height: 2.0214%;">alleviate their symptoms.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.8704%; width: 76.8067%; height: 2.0214%;">2. Crime. Studies evaluating the effect on crime rates have concluded that the legalization
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 50.7729%; width: 73.6134%; height: 2.0214%;">of marijuana for medical purposes is not predictive of higher crime rates and may be
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 52.5565%; width: 45.3782%; height: 1.78359%;">related to reductions in rates of homicide and assault.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.459%; width: 76.6387%; height: 2.0214%;">3. Levels of social use. Passing State medicinal marijuana laws does not affect marijuana use
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 56.2426%; width: 47.8992%; height: 2.0214%;">or perceived riskiness of use among adolescents or adults.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.1451%; width: 76.6387%; height: 2.0214%;">4. Traffic safety. A 2012 meta-analysis of 66 studies of drug-positive drivers and crash risk
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 59.9287%; width: 73.6134%; height: 2.0214%;">found that the risk of marijuana-positive drivers was statistically comparable to that
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 61.8312%; width: 52.2689%; height: 2.0214%;">associated with penicillin, antihistamines and antidepressants.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.6147%; width: 76.8067%; height: 2.0214%;">5. Overdose prevention. Recent studies document a relationship between medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 65.5172%; width: 58.4874%; height: 2.0214%;">marijuana laws and a significant reduction in opioid overdose fatalities.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.3008%; width: 76.6387%; height: 2.0214%;">6. Alcohol substitution. When people have access to marijuana through legal means, they
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 69.2033%; width: 61.5126%; height: 2.0214%;">consume less alcohol and the social consequences of alcohol use decrease.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.9869%; width: 76.6387%; height: 2.0214%;">7. Reduction in suicides. Medicinal marijuana leads to an improvement in the psychological
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 72.8894%; width: 42.8571%; height: 2.0214%;">wellbeing of young adult males and fewer suicides.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.6243%; width: 47.563%; height: 2.0214%;">Models of regulation of cannabis for medicinal purposes
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.478%; width: 76.8067%; height: 2.0214%;">We have considered different models of regulation for cannabis. Examples from elsewhere in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 80.2616%; width: 76.4706%; height: 2.0214%;">Europe, Australia, Canada, Israel, Uruguay, the USA and other countries show that there is a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.1641%; width: 76.8067%; height: 2.0214%;">place within state health programmes for making herbal cannabis available for a designated
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 83.9477%; width: 69.916%; height: 2.0214%;">number of conditions based on the best available evidence, to be reviewed regularly.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.8014%; width: 76.8067%; height: 2.0214%;">There are challenges in terms of ensuring the strength, quality and purity of herbal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 88.585%; width: 76.1345%; height: 2.0214%;">for medicinal purposes. These seem to be best met by controlling supply via regulated outlets,
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/2f461aff-0289-4c8b-bc7f-f4d274cc3287" class="drive-viewer-paginated-page-img" alt="Page 7 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 8 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 48.7395%; top: 92.7467%; width: 2.52101%; height: 1.30797%;">viii
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">such as pharmacies, and cultivation by licenced growers. However, cost and a limited variety
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 76.6387%; height: 2.14031%;">of strains being made available in such outlets may restrict patient access to the best
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.0095%; width: 76.6387%; height: 2.0214%;">medicinal cannabis product to meet their needs. This is why some jurisdictions have opted
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.7931%; width: 63.8655%; height: 2.14031%;">for programmes where patients can grow a limited amount for their own use.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.1225%; width: 10.2521%; height: 1.30797%;">Conclusions
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.5006%; width: 76.6387%; height: 2.0214%;"> There is a sizeable population of patients in the UK who have found that medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 21.4031%; width: 73.6134%; height: 2.0214%;">cannabis works for them. For many, it is the only substance that brings them relief from
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 23.1867%; width: 13.6134%; height: 2.0214%;">their symptoms.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.0892%; width: 76.8067%; height: 2.0214%;"> As access to medicinal cannabis is not lawful in the UK, these patients have to suffer the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 26.9917%; width: 58.6555%; height: 2.0214%;">added stress of breaking the law to obtain what for them is a medicine.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.8942%; width: 76.8067%; height: 2.0214%;"> The review of the literature clearly shows that there is a broad range of evidence that
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 30.6778%; width: 73.6134%; height: 2.14031%;">medicinal cannabis works for a range of conditions, which means that the continued
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 32.5803%; width: 39.8319%; height: 2.0214%;">listing of cannabis under Schedule 1 is irrational.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.4828%; width: 76.6387%; height: 2.0214%;"> The fact that so many countries now have or are introducing a form of cannabis regulation
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 36.3853%; width: 73.6134%; height: 2.0214%;">to ensure access to herbal cannabis to help those with serious chronic conditions, where
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 38.1688%; width: 73.7815%; height: 2.0214%;">prescription medicines have been ineffective, further undermines the UK Governments
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 40.0713%; width: 13.9496%; height: 2.0214%;">current position.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.9738%; width: 76.6387%; height: 2.0214%;"> The issue of medicinal cannabis should be treated as a matter of compassion and be
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 43.7574%; width: 50.7563%; height: 1.9025%;">viewed separately from the wider issue of drug policy reform.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.849%; width: 16.1345%; height: 1.42687%;">Recommendations
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.2271%; width: 18.1513%; height: 2.0214%;">That the government:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 52.0809%; width: 76.4706%; height: 2.0214%;">1. accepts the evidence from this inquiry, from the associated Barnes report and from
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 53.8644%; width: 73.6134%; height: 2.0214%;">around the world that medicinal cannabis works and has a role to play in the treatment
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 55.7669%; width: 20.1681%; height: 2.0214%;">of a range of conditions;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.5505%; width: 76.6387%; height: 2.0214%;">2. moves to introduce a system that allows lawful access to medicinal cannabis in the UK.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 59.453%; width: 59.1597%; height: 2.0214%;">This will involve the relisting of cannabis from Schedule 1 to Schedule 4;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.2366%; width: 76.8067%; height: 1.78359%;">3. carries out an assessment of the various models used across the world to allow lawful
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 63.1391%; width: 55.2941%; height: 2.0214%;">access to medicinal cannabis and draw up options for consultation;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.9227%; width: 76.8067%; height: 2.0214%;">4. notes our preference for a system based on the proposed German model which we
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 66.8252%; width: 73.6134%; height: 2.0214%;">believe has characteristics that ensure much wider availability of medicinal cannabis to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 68.6088%; width: 11.0924%; height: 2.0214%;">patients; and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.5113%; width: 76.6387%; height: 2.0214%;">5. that the Government decriminalises home growing of small quantities of cannabis for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 72.2949%; width: 52.2689%; height: 2.0214%;">medicinal purposes as witnessed in Uruguay and some US state
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/b82c732e-a27c-4969-86e3-b0fa7aced5f3" class="drive-viewer-paginated-page-img" alt="Page 8 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 9 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 49.4118%; top: 92.8656%; width: 1.17647%; height: 1.18906%;">9
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.68014%; width: 23.5294%; height: 2.85375%;">1. Introduction
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.3175%; width: 13.4454%; height: 1.78359%;">The UN context
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.1712%; width: 76.8067%; height: 2.0214%;">The recent UNGASS meeting on global drug policy held in New York in April 2016 marked the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.0737%; width: 76.8067%; height: 2.0214%;">beginning of the end of the war on drugs. Although the Drugs Convention framework
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.8573%; width: 76.8067%; height: 2.0214%;">remains in place for the time being, the rhetoric of UN leaders and organisations now reflects
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.7598%; width: 76.8067%; height: 2.0214%;">an entirely new interpretation of the Conventions. In New York, they emphasised human
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.5434%; width: 76.6387%; height: 2.0214%;">rights, sustainable development, the primacy of health and the need for policy to be based
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.4459%; width: 76.8067%; height: 2.0214%;">upon evidence. This breakthrough at the UN reflects actions taken by Member States in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 27.2295%; width: 76.4706%; height: 2.0214%;">Europe, South America, the Caribbean and States within the USA to find better and more
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.132%; width: 76.8067%; height: 2.0214%;">humane ways to respond to drug use. This report proposes that law reform relating to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.9156%; width: 76.6387%; height: 2.0214%;">medicinal cannabis should be the first UK response to the new UN focus on the need for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.8181%; width: 24.5378%; height: 2.0214%;">evidence-based drug policies.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.5529%; width: 33.7815%; height: 2.0214%;">History of the medicinal use of cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.4067%; width: 76.8067%; height: 2.0214%;">The medical use of cannabis dates back to about 4000 BC. More recently, in the 19th century
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.1902%; width: 76.6387%; height: 2.0214%;">cannabis was used throughout Europe for migraine, neuropathic and musculoskeletal pain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.0927%; width: 76.8067%; height: 2.0214%;">and as an aid to childbirth. At that time, the noted physicians of the age supported its
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.8763%; width: 76.6387%; height: 1.9025%;">medicinal use. Indeed, Sir John Russell Reynolds recommended it for various conditions
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.6599%; width: 63.0252%; height: 2.0214%;">ranging from insomnia to dysmenorrhea and prescribed it to Queen Victoria.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 48.3948%; width: 76.4706%; height: 2.0214%;">In the UK, cannabis remained clinically available until 1971 when it was banned under the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 50.2973%; width: 76.4706%; height: 2.0214%;">Misuse of Drugs Act. This Act made possession and supply of controlled drugs, including
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.0809%; width: 16.1345%; height: 2.0214%;">cannabis, unlawful.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.9346%; width: 76.8067%; height: 2.0214%;">The Act introduced three classes of controlled drugs: Class A drugs (including morphine,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.7182%; width: 76.6387%; height: 2.0214%;">diamorphine (heroin), cocaine and LSD) are deemed the most harmful with the highest
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.6207%; width: 76.6387%; height: 2.0214%;">penalties for possession or sale; Class B (including cannabis, amphetamines and barbiturates)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.4043%; width: 76.1345%; height: 2.0214%;">are an intermediate category; Class C are deemed the least harmful and carry lesser penalties.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.3068%; width: 76.1345%; height: 2.0214%;">These include anabolic steroids, benzodiazepines and growth hormones. There is no
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.0904%; width: 41.5126%; height: 1.78359%;">consistent scientific basis for these classifications.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.9441%; width: 76.8067%; height: 2.0214%;">This has remained the case to this day, although cannabis was reclassified as a Class C drug
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.7277%; width: 76.6387%; height: 2.0214%;">for five years in 2004 on the advice of the Advisory Council on the Misuse of Drugs. For no
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.6302%; width: 55.4622%; height: 2.0214%;">good reason, it was reclassified to the more serious Class B in 2009.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 75.1486%; width: 76.6387%; height: 2.0214%;">In 2006, the UK Parliamentary Science and Technology Select Committee produced a report
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.9322%; width: 76.6387%; height: 2.14031%;">that concluded that the present classification was arbitrary and unscientific and suggested
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.8347%; width: 76.6387%; height: 2.0214%;">improvements. There has not yet been a change in the law as a result of their
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.0939%; width: 15.7983%; height: 1.30797%;">recommendations.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/cad08821-078a-4a87-8628-5beafbe0d1a9" class="drive-viewer-paginated-page-img" alt="Page 9 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 10 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 49.0756%; top: 92.8656%; width: 2.01681%; height: 1.18906%;">10
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 41.8487%; height: 1.78359%;">Box 1: What are cannabis and medicinal cannabis?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.1023%; width: 29.2437%; height: 2.0214%;">Schedules of drugs for medical use
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.956%; width: 76.6387%; height: 2.0214%;">The Misuse of Drugs Regulations 2001, which amend and update the Misuse of Drugs
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 58.7396%; width: 75.9664%; height: 2.14031%;">Regulations 1985, currently define the categories of people authorised to supply and possess
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.6421%; width: 76.6387%; height: 2.0214%;">controlled drugsfor medicinal use. Schedule 1, which includes drugs such as cannabis, are not
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.5446%; width: 76.1345%; height: 2.0214%;">conventionally used for medicinal purposes and are deemed to have no medicinal value.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 64.3282%; width: 76.4706%; height: 2.0214%;">Possession and supply is prohibited without specific Home Office approval. Schedule 2
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.1118%; width: 76.6387%; height: 2.14031%;">includes morphine and diamorphine and those drugs are subject to special requirements
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.0143%; width: 76.6387%; height: 2.0214%;">relating to their legal prescription, including safe custody and the need to maintain registers.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 69.7979%; width: 76.4706%; height: 2.14031%;">Nabiximols (Sativex) is marketed under Schedule 4. These drugs are available on prescription
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 71.7004%; width: 76.6387%; height: 2.0214%;">in certain circumstances and are not subject to the strictest safe custody requirements. CBD
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.4839%; width: 71.2605%; height: 2.14031%;">in isolation is not proscribed (see Section 6  Results of survey of health professionals).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 76.3377%; width: 76.6387%; height: 2.0214%;">In the UK, even the established medicinal applications of cannabis are only partly recognised.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 78.2402%; width: 76.6387%; height: 2.0214%;">Dronabinol has never been licenced. Nabilone was licenced in 1982 as a hospital-only
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.0238%; width: 76.8067%; height: 2.0214%;">prescription indicated by the National Institute for Health and Care Excellence (NICE) for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.9263%; width: 75.4622%; height: 3.80499%;">nausea and vomiting caused by cytotoxic chemotherapy, unresponsive to conventional anti-
emetics (under close observation, preferably within a hospital setting).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 69.4118%; top: 83.7099%; width: 19.3277%; height: 2.0214%;">1 Sativex has only been
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 85.6124%; width: 76.8067%; height: 2.0214%;">approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) as an extra
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 87.396%; width: 76.6387%; height: 2.0214%;">treatment for patients with spasticity due to multiple sclerosis. It is not indicated as a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 11.7717%; width: 7.89916%; height: 1.30797%;">Cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 13.0797%; width: 74.6218%; height: 2.0214%;">Cannabis is a very hardy plant that grows throughout the world. The plant produces over
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 14.7444%; width: 74.7899%; height: 2.14031%;">10 natural cannabinoids called phytocannabinoids. These are found in the greatest
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 16.5279%; width: 74.6218%; height: 2.0214%;">concentration in the unfertilised flower heads. The main psychoactive component of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 18.3115%; width: 74.7899%; height: 2.0214%;">cannabis, tetrahydrocannabinol (THC), was isolated and synthesised in Israel in 1964. Of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.7731%; top: 19.9762%; width: 74.958%; height: 2.14031%;">the other phytocannabinoids, cannabidiol (CBD) has along with THC been identified as
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 21.7598%; width: 74.7899%; height: 2.0214%;">having strong medical potential. As our knowledge of phytocannabinoids and the human
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 23.5434%; width: 74.7899%; height: 2.0214%;">endocannabinoid system develops, the medical use of some of the other cannabinoids may
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 25.2081%; width: 74.7899%; height: 2.14031%;">also be recognized. There is interaction between phytocannabinoids. CBD can reduce the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 26.9917%; width: 23.1933%; height: 2.0214%;">psychoactive effects of THC.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.7731%; top: 30.44%; width: 74.958%; height: 2.0214%;">The ratio of THC to CBD appears to be important in terms of medicinal use and has a bearing
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 32.2235%; width: 74.7899%; height: 2.0214%;">on the side effect profile. It is also possible that the overall efficacy of the natural plant in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 34.0071%; width: 74.7899%; height: 2.0214%;">medicinal terms depends not only on THC and CBD and the other phytocannabinoids, but
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 35.6718%; width: 49.0756%; height: 2.0214%;">also on the entourage effect of the other plant chemicals.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 39.239%; width: 16.4706%; height: 1.78359%;">Medicinal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.7731%; top: 40.9037%; width: 74.958%; height: 2.0214%;">There are a range of interpretations of the term medicinal cannabis. It can mean a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 42.6873%; width: 74.7899%; height: 2.0214%;">specific medical intervention from a healthcare professional using a pharmaceutical grade
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 44.4709%; width: 74.7899%; height: 1.9025%;">drug, containing a synthesised cannabinoid, licenced by a national health authority.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.7731%; top: 46.0166%; width: 74.958%; height: 2.0214%;">Alternatively the term can refer to self-medication by individuals using street herbal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.9412%; top: 47.8002%; width: 74.6218%; height: 2.0214%;">cannabis or resin. These two interpretations and others within that range are examined in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.7731%; top: 49.5838%; width: 9.57983%; height: 2.0214%;">this report.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/ad90ed91-aefa-4f2a-94e2-a1caf133631f" class="drive-viewer-paginated-page-img" alt="Page 10 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 11 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 49.0756%; top: 92.8656%; width: 2.01681%; height: 1.18906%;">11
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">recommended treatment by NICE partly because of its high cost, although it is available on
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 18.1513%; height: 2.0214%;">prescription in Wales.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 14.7444%; width: 74.4538%; height: 2.0214%;">It is very difficult, although not impossible, to undertake studies of cannabis because of its
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.5279%; width: 60.3361%; height: 2.0214%;">Schedule 1 status. Clearly, at least in the UK, this has hampered research.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/e7fd2854-1ffe-4538-ba00-6d0e0c1074ba" class="drive-viewer-paginated-page-img" alt="Page 11 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 12 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.68014%; width: 66.0504%; height: 3.21046%;">2. Developments in the regulation of medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 18.1513%; top: 11.8906%; width: 43.8655%; height: 2.73484%;">cannabis elsewhere in the world
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.5279%; width: 76.8067%; height: 2.0214%;">The list of countries that have some form of regulation for medicinal use now includes 24
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.3115%; width: 76.8067%; height: 2.0214%;">States in the USA with more due to vote on the issue; Canada, Israel and in Europe, Austria,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 20.214%; width: 76.6387%; height: 2.0214%;">Belgium, the Czech Republic, the Netherlands, Romania and Portugal. Bedrocan, herbal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.9976%; width: 76.8067%; height: 2.0214%;">cannabis grown under licence for medical use in the Netherlands, is available on prescription
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.9001%; width: 76.1345%; height: 2.0214%;">in a number of European countries including: Finland, Germany, Italy and Switzerland.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.6837%; width: 76.1345%; height: 2.0214%;">Countries that have recently decided to introduce a system of regulation include Australia
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.5862%; width: 76.8067%; height: 2.0214%;">and Jamaica, and in South America, Chile, Colombia and Uruguay. In a number of other South
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.3698%; width: 42.1849%; height: 2.0214%;">American countries, personal use is decriminalised.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.6992%; width: 7.56303%; height: 1.54578%;">Uruguay
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 34.9584%; width: 76.6387%; height: 2.0214%;">Uruguay is the only country in the world to regulate cannabis supply for social use at the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.8609%; width: 76.6387%; height: 2.0214%;">national level. Its system has not yet been fully implemented and the impact has not been
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.6445%; width: 76.8067%; height: 2.0214%;">assessed. The Uruguayan law has introduced a system of licences for individuals and clubs to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.547%; width: 76.6387%; height: 2.0214%;">grow their own. The law refers to a limit of six plants for individuals, more for clubs. It is also
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.3306%; width: 76.6387%; height: 2.0214%;">intended to grant licences to commercial growers whose product will then be sold via
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.2331%; width: 76.8067%; height: 1.9025%;">registered pharmacies. It is expected that cannabis will begin to be sold in pharmaciesin 2016
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.8977%; width: 76.1345%; height: 2.0214%;">and will be exempt from VAT.2 Cannabis for medicinal purposes will be grown under licence
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.8002%; width: 76.6387%; height: 2.0214%;">separately and under stricter conditions to ensure purity and quality. This will be reflected in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.5838%; width: 7.89916%; height: 2.0214%;">its price.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 52.4376%; width: 75.9664%; height: 2.0214%;">It is likely that the Uruguayan initiative has encouraged the schemes for medicinal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.2212%; width: 18.6555%; height: 1.78359%;">in Colombia and Chile.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.5505%; width: 3.86555%; height: 1.30797%;">USA
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 59.8098%; width: 75.9664%; height: 2.0214%;">In the USA, California was the first State to approve a regulatory system for cannabis in 1996.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.7122%; width: 76.8067%; height: 2.0214%;">This has been regarded as a loose model of regulation. Since then, 24 States, as well as the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 63.4958%; width: 76.6387%; height: 2.0214%;">District of Columbia and the Island Territory of Guam have regulated medical use. More
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.3983%; width: 76.8067%; height: 2.0214%;">recently, States have tended to follow tighter models of regulation that include restrictions
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.1819%; width: 76.8067%; height: 2.0214%;">on the conditions for which a cannabis prescription can be provided and the systems for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.0844%; width: 34.6218%; height: 2.0214%;">authorising and supervising dispensaries.3
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 71.8193%; width: 76.6387%; height: 2.0214%;">In those States where medicinal cannabis is available,systems vary but the common elements
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 74.0785%; width: 7.56303%; height: 1.42687%;">include:4
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 76.4566%; width: 76.4706%; height: 2.0214%;">1. Physicians can recommend rather than prescribe cannabis if they think it will be beneficial.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 78.2402%; width: 73.7815%; height: 2.0214%;">As cannabis remains within the US Schedule 1 at federal level (which determines that it
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 80.0238%; width: 39.4958%; height: 2.0214%;">has no medicinal value) it cannot be prescribed.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.6885%; width: 76.8067%; height: 2.0214%;">2. An identity card is issued to the patient and/or caregiver. A caregiver can be a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 83.4721%; width: 73.7815%; height: 2.0214%;">dispensary or someone who undertakes to grow cannabis for a patient under a more
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 85.2556%; width: 18.9916%; height: 2.0214%;">informal arrangement.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.9203%; width: 71.7647%; height: 2.0214%;">3. Many states, although not all, have a system of approved dispensaries for cannabis.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/67a87d14-1143-40d3-bce2-f27561a00542" class="drive-viewer-paginated-page-img" alt="Page 12 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 13 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 75.2941%; height: 1.78359%;">4. Most states restrict the conditions for which cannabis can be recommended. The list of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 10.107%; width: 40.5042%; height: 2.0214%;">conditions can vary considerably between states.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 55.1261%; top: 10.107%; width: 33.4454%; height: 2.0214%;">5 A quite short and specific list has been
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 11.7717%; width: 26.7227%; height: 2.0214%;">drawn up by the State of Maine:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 15.3389%; width: 73.4454%; height: 2.0214%;">Epilepsy and other disorders characterized by seizures; glaucoma; multiple sclerosis and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 17.0036%; width: 73.6134%; height: 2.0214%;">other disorders characterized by muscle spasticity; nausea or vomiting as a result of AIDS
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 18.7872%; width: 30.2521%; height: 2.0214%;">or cancer chemotherapy; and PTSD.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 22.2354%; width: 45.2101%; height: 2.0214%;">The New Hampshire list of conditions is more detailed:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 25.8026%; width: 73.4454%; height: 2.0214%;">(1) Cancer, glaucoma, positive status for human immunodeficiency virus, acquired
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 27.4673%; width: 73.6134%; height: 2.0214%;">immune deficiency syndrome, hepatitis C currently receiving antiviral treatment,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 29.2509%; width: 73.7815%; height: 2.0214%;">amyotrophic lateral sclerosis, muscular dystrophy, Crohns disease, multiple sclerosis,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 30.9156%; width: 73.6134%; height: 2.14031%;">chronic pancreatitis, spinal cord injury or disease, traumatic brain injury, epilepsy, lupus,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 32.6992%; width: 73.7815%; height: 2.0214%;">Parkinsons disease, Alzheimers disease, or one or more injuries that significantly
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 34.4828%; width: 62.521%; height: 2.0214%;">interferes with daily activities as documented by the patients provider; AND
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 37.931%; width: 73.6134%; height: 2.0214%;">(2) A severely debilitating or terminal medical condition or its treatment that has produced
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 39.7146%; width: 73.7815%; height: 3.68609%;">at least one of the following: elevated intraocular pressure, cachexia, chemotherapy-
induced anorexia, wasting syndrome, agitation of Alzheimers disease, severe pain that
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 43.1629%; width: 73.6134%; height: 2.0214%;">has not responded to previously prescribed medication or surgical measures or for which
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 44.9465%; width: 73.7815%; height: 1.9025%;">other treatment options produced serious side effects, constant or severe nausea,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 46.4923%; width: 62.521%; height: 2.0214%;">moderate to severe vomiting, seizures, or severe, persistent muscle spasms.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 50.0595%; width: 73.6134%; height: 2.0214%;">A number of States allow that other conditions, not specified, may be treated subject to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 51.843%; width: 73.6134%; height: 2.0214%;">the approval of the State health authorities. A few allow for physician discretion in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 53.7455%; width: 73.7815%; height: 2.0214%;">recommending cannabis as a treatment. For example, in Massachusetts this is set out as
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 56.0048%; width: 6.72269%; height: 1.30797%;">follows:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 58.3829%; width: 73.4454%; height: 2.0214%;">Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 60.0476%; width: 73.7815%; height: 2.0214%;">deficiency syndrome (AIDS), hepatitis C, amyotrophic lateral sclerosis (ALS), Crohns
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 61.8312%; width: 73.6134%; height: 2.0214%;">disease, Parkinsons disease, multiple sclerosis and other conditions as determined in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 63.6147%; width: 35.7983%; height: 2.0214%;">writing by a qualifying patients physician.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.063%; width: 76.8067%; height: 2.0214%;">5. Fourteen states specify a possession limit for medicinal cannabis which includes a specific
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 68.8466%; width: 73.7815%; height: 2.0214%;">number of cannabis plants indicating that private growing of cannabis plants is within
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 70.5113%; width: 73.7815%; height: 2.0214%;">their laws. Other states set out possession limits that are couched in terms of the usable
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 72.2949%; width: 73.6134%; height: 2.0214%;">weight of cannabis or in terms of supply over a fixed time period. For example,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 73.9596%; width: 62.8571%; height: 2.14031%;">Massachusetts specifies a limit of a 60-day supply which is set at 10 ounces.6
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 77.5268%; width: 61.5126%; height: 2.0214%;">What has been the impact of medicinal marijuana legislation in the USA?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.6183%; width: 76.8067%; height: 2.14031%;">The most obvious impact of developments in the USA is much improved access to medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.5208%; width: 76.6387%; height: 2.0214%;">cannabis by patients; cannabis has been used to treat a range of conditions. However, there
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.3044%; width: 76.8067%; height: 1.78359%;">have been a number of other benefits to communities in those States where cannabis is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.2069%; width: 76.8067%; height: 2.0214%;">legally available for medical use. The APPG sent a call for evidence to the DPA, the leading
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 87.9905%; width: 76.8067%; height: 2.14031%;">organisation in the USA promoting drug policies that are grounded in science, compassion,
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/1b4a32e4-f023-43c6-bd77-00b904e65626" class="drive-viewer-paginated-page-img" alt="Page 13 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 14 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">health and human rights. The response from the DPA included a review of research into the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 76.6387%; height: 2.14031%;">wider impacts of medicinal cannabis regulation. This covered issues of crime, overall cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.0095%; width: 64.0336%; height: 2.0214%;">consumption, driving, overdose, alcohol and suicide and is reproduced below.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 75.6303%; top: 12.3662%; width: 1.17647%; height: 0.951249%;">7
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.5279%; width: 60.8403%; height: 2.0214%;">DPA: Review of wider impacts from the regulation of medicinal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.7384%; width: 76.6387%; height: 2.0214%;">Crime rates: Studies evaluating the association between state medical marijuana laws and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.4031%; width: 76.8067%; height: 2.14031%;">crime rates have found that legalization of marijuana for medical purposes is not predictive
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.1867%; width: 75.4622%; height: 2.0214%;">of higher crime rates and may be related to reductions in rates of homicide and assault.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 87.0588%; top: 23.5434%; width: 1.17647%; height: 0.951249%;">8
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 24.9703%; width: 76.4706%; height: 2.0214%;">Recent studies have specifically examined the location of medical marijuana dispensaries and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.635%; width: 76.6387%; height: 2.14031%;">violent or property crime rates and concluded that robbery and burglary rates were
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.4185%; width: 38.9916%; height: 2.0214%;">unaffected by medicinal marijuana legislation.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 50.5882%; top: 28.7753%; width: 1.0084%; height: 0.951249%;">9
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.8668%; width: 76.6387%; height: 2.0214%;">Youth and adult use of marijuana: Studies demonstrate that the passage of state medical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.7693%; width: 76.6387%; height: 2.0214%;">marijuana laws does not affect marijuana use or perceived riskiness of use among
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.5529%; width: 76.6387%; height: 2.0214%;">adolescents or adults.10,11 Specifically, research shows that youth marijuana use rates
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.4554%; width: 76.6387%; height: 2.0214%;">typically decrease in the year following medical legalization12 and that in the subsequent next
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.239%; width: 76.6387%; height: 2.14031%;">few years, youth do not significantly increase the prevalence or frequency of their marijuana
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.4982%; width: 5.04202%; height: 1.42687%;">use.13
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.8763%; width: 76.8067%; height: 2.0214%;">Traffic safety: The issue of marijuana consumption and road safety has received considerable
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.6599%; width: 76.6387%; height: 2.0214%;">scrutiny, particularly in the last decade. The preponderance of evidence indicates that the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.4435%; width: 76.6387%; height: 2.14031%;">risks of further reforming marijuana laws are quite low. The largest review of the scientific
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.346%; width: 76.8067%; height: 2.0214%;">data by fara 2012 meta-analysis of 66 studies of drug-positive drivers and crash riskfound
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.1296%; width: 76.6387%; height: 2.0214%;">marijuana-positive drivers risk among the lowest of any drugs; the risk was statistically
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.0321%; width: 76.8067%; height: 2.0214%;">comparable to that associated with penicillin, antihistamines and antidepressants.14 (See also
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.8157%; width: 17.8151%; height: 2.0214%;">Alcohol substitution.)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.6694%; width: 76.8067%; height: 2.0214%;">Overdose prevention: A striking study published last year in the Journal of the American
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 59.453%; width: 76.6387%; height: 2.14031%;">Medical Association documents a relationship between medical marijuana laws and a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.3555%; width: 76.8067%; height: 2.0214%;">significant reduction in opioid overdose fatalities. States with medical cannabis laws had a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.1391%; width: 76.6387%; height: 2.14031%;">24.8% lower mean annual opioid overdose mortality rate compared with states without
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.0416%; width: 76.8067%; height: 2.0214%;">medical cannabis laws, an association that generally strengthened over time.15 The
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.8252%; width: 76.8067%; height: 2.14031%;">authors hypothesize this relationship results from patients successfully substituting marijuana
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.7277%; width: 76.6387%; height: 2.0214%;">for analgesic opioids, which is particularly noteworthy as opioid overdose has surpassed auto
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.5113%; width: 76.8067%; height: 2.14031%;">accidents as the leading cause of accidental death in the country.16 (More recently, academics
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.4138%; width: 76.8067%; height: 2.0214%;">at the University of Georgia have found that between 2010 and 2013, for Medicare Part D
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 74.1974%; width: 76.1345%; height: 2.14031%;">enrollees (seniors), the use of prescription drugs for which marijuana could serve as a clinical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.0999%; width: 76.6387%; height: 2.0214%;">alternative fell significantly once a medical marijuana law was implemented. They calculate
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 77.8835%; width: 66.0504%; height: 2.14031%;">that on a national level this saved an estimated $165.2 million per year in 2013.)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 77.6471%; top: 78.2402%; width: 1.68067%; height: 0.951249%;">17
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.5208%; width: 76.6387%; height: 2.0214%;">Alcohol substitution: A recent review of research has demonstrated that marijuana is a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.3044%; width: 76.6387%; height: 2.0214%;">substitute for alcoholwhen people have access to marijuana through legal means, they
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.2069%; width: 76.8067%; height: 2.0214%;">consume less alcohol and the social consequences of alcohol decrease.18 The potential
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 87.9905%; width: 76.6387%; height: 2.0214%;">implications of marijuana-for-alcohol substitution are further illustrated by a study that
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/99a8a560-33d0-4586-b2cc-dbd09dfb6c72" class="drive-viewer-paginated-page-img" alt="Page 14 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 15 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">associated marijuana use with lower incidents of intimate partner violence.19 And multiple
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 76.6387%; height: 2.14031%;">traffic safety studies demonstrate that drivers under the influence of THC are able to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.0095%; width: 72.605%; height: 2.0214%;">compensate for their impairment, while drivers under the influence of alcohol are not.20
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 76.6387%; height: 2.14031%;">Suicide: A recent Colorado study demonstrated that there is no known association between
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.6468%; width: 76.6387%; height: 2.0214%;">marijuana use and suicide rates.21 Meanwhile a national study concluded that medical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.5493%; width: 76.6387%; height: 2.0214%;">marijuana leads to an improvement in the psychological wellbeing of young adult males, an
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 41.6807%; height: 2.0214%;">improvement that is reflected in fewer suicides.22
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.3971%; width: 6.55462%; height: 1.30797%;">Canada
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.6564%; width: 76.6387%; height: 2.14031%;">Canada introduced a system for the regulation of cannabis in 2001. The system allows for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.5589%; width: 76.6387%; height: 2.0214%;">medical professionals to prescribe cannabis at their own discretion under two broad
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.4614%; width: 76.1345%; height: 2.0214%;">categories. The categories cover any symptoms treated as part of providing compassionate
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.2449%; width: 76.8067%; height: 2.0214%;">end-of-life care or the symptoms associated with the following medical conditions (Category
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 36.5042%; width: 2.35294%; height: 1.54578%;">1):
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.0012%; width: 76.8067%; height: 2.0214%;"> severe pain and/or persistent muscle spasms from multiple sclerosis, from a spinal cord
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 40.6659%; width: 28.0672%; height: 2.0214%;">injury or from spinal cord disease;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.5684%; width: 76.8067%; height: 2.0214%;"> severe pain, cachexia, anorexia, weight loss, and/or severe nausea from cancer or
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 44.2331%; width: 15.9664%; height: 1.9025%;">HIV/AIDS infection;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.0166%; width: 40.3361%; height: 2.0214%;"> severe pain from severe forms of arthritis; or
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.8002%; width: 22.0168%; height: 2.0214%;"> seizures from epilepsy.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.2485%; width: 76.8067%; height: 2.0214%;">They also cover patients who have debilitating symptoms from conditions, other than those
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.151%; width: 21.1765%; height: 2.0214%;">listed above (Category 2).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.3615%; width: 4.87395%; height: 1.30797%;">Israel
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 58.7396%; width: 76.6387%; height: 2.0214%;">Medical use has been permitted since the early 1990s. In 2013, 13 000 patients had been
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.5232%; width: 76.6387%; height: 2.0214%;">given a state license to use cannabis for medical purposes.23 It is currently being used to treat
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.4257%; width: 20.6723%; height: 2.0214%;">the following conditions:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.2794%; width: 19.6639%; height: 1.9025%;"> Parkinsons disease;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.063%; width: 17.9832%; height: 2.0214%;"> multiple sclerosis;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.8466%; width: 16.6387%; height: 2.0214%;"> Crohns disease;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.7491%; width: 25.7143%; height: 1.9025%;"> other chronic illnesses; and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.0083%; width: 8.06723%; height: 1.30797%;"> PTSD.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.2188%; width: 6.38655%; height: 1.54578%;">Europe
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 78.478%; width: 76.4706%; height: 2.0214%;">In Europe, a clear distinction needs to be made between systems for the regulation of herbal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.3805%; width: 76.8067%; height: 2.0214%;">cannabis as a medicine and those for cannabis synthetics and derivatives that have gone
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.1641%; width: 76.8067%; height: 2.0214%;">through the clinical trials normally necessary for a medicine to be approved. Sativex
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.0666%; width: 76.6387%; height: 2.0214%;">(nabiximols), which has gone through this process, is currently approved for medical use in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 85.8502%; width: 10.7563%; height: 1.78359%;">17 countries.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 22.6891%; top: 86.2069%; width: 1.68067%; height: 0.951249%;">24
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/0b014a88-1f36-483f-adad-e8f5078f99a8" class="drive-viewer-paginated-page-img" alt="Page 15 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 16 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 14.2857%; height: 1.78359%;">The Netherlands
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 11.1772%; width: 76.6387%; height: 2.0214%;">The Netherlands has the longest-standing scheme for medicinal cannabis in Europe.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 12.9608%; width: 76.4706%; height: 2.0214%;">Medicinal herbal cannabis in the form of florets or powder has been available since 2001 on
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 76.6387%; height: 2.14031%;">prescription from pharmacies. Its production is controlled by the Office for Medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.6468%; width: 76.8067%; height: 2.0214%;">Cannabis which is responsible for ensuring supply and quality control. Cultivation is licenced
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.5493%; width: 76.6387%; height: 2.0214%;">and monitored by the Office and the products should contain no pesticides, heavy metals,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 72.605%; height: 2.0214%;">fungi or bacteria. The Office supplies a variety of strains of cannabis as shown in Table 1.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 84.2017%; top: 20.6897%; width: 1.84874%; height: 0.951249%;">25
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.1867%; width: 60.5042%; height: 2.0214%;">Table 1: Strains of cannabis supplied by the Office for Medicinal Cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 26.635%; width: 60.3361%; height: 2.0214%;">Variety THC content CBD content
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 28.4185%; width: 53.4454%; height: 1.9025%;">Bedrocan About 19% &lt;1%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 30.321%; width: 53.4454%; height: 1.78359%;">Bedrobinol About 12% &lt;1%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 32.1046%; width: 59.4958%; height: 1.78359%;">Bediol About 6% About 7.5%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.6718%; width: 76.6387%; height: 1.78359%;">The Dutch health authorities have carried out an extensive review of the scientific literature
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.4554%; width: 76.6387%; height: 2.0214%;">and consequently made a limited list of the conditions where the use of medicinal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.239%; width: 25.7143%; height: 1.9025%;">can be indicated. This includes:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.2117%; width: 76.6387%; height: 2.0214%;"> pain and muscle spasms or cramps associated with multiple sclerosis or spinal cord
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 44.352%; width: 7.39496%; height: 1.54578%;">damage;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.6599%; width: 65.042%; height: 2.0214%;"> nausea, loss of appetite, weight loss and debilitation due to cancer or AIDS;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.4435%; width: 76.6387%; height: 2.0214%;"> nausea and vomiting associated with chemotherapy or radiotherapy used in the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 49.2271%; width: 47.8992%; height: 2.0214%;">treatment of cancer, hepatitis C or HIV infection and AIDS;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.0107%; width: 76.8067%; height: 2.0214%;"> chronic pain (mainly pain associated with the nervous system, for example, that caused
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 52.7943%; width: 73.7815%; height: 2.0214%;">by a damaged nerve, phantom pain, facial neuralgia or chronic pain that remains after the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 54.459%; width: 20%; height: 2.0214%;">recovery from shingles);
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.2426%; width: 19.6639%; height: 2.14031%;"> Tourette syndrome;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.1451%; width: 26.3866%; height: 2.0214%;"> therapy-resistant glaucoma.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 37.9832%; top: 58.5018%; width: 1.68067%; height: 0.951249%;">26
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.5933%; width: 76.8067%; height: 2.0214%;">The reason for this limited list of indications is that the efficacy of the medicinal use of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.4958%; width: 76.6387%; height: 2.0214%;">cannabis for other medical conditions has not yet been properly studied in convincing clinical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.2794%; width: 76.8067%; height: 2.0214%;">trials. The list is subject to change based on the findings of new studies. In terms of cost,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.1819%; width: 76.6387%; height: 2.0214%;">medicinal cannabis is not automatically covered by healthcare insurers. Some will provide
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.9655%; width: 76.8067%; height: 2.0214%;">limited cover through supplementary insurance. The number of people using herbal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.868%; width: 76.6387%; height: 2.0214%;">supplied by the Dutch authorities has increased from 1300 patients in 2010 to 4000 patients
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.6516%; width: 8.23529%; height: 1.78359%;">in 2015.27
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.981%; width: 8.06723%; height: 1.54578%;">Germany
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 78.2402%; width: 76.6387%; height: 2.0214%;">In Germany, the Federal Institute for Drugs and Medical Devices has authorised the medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.1427%; width: 76.8067%; height: 2.0214%;">use of cannabis for special compassion cases, mainly patients with terminal cancer. There
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.9263%; width: 76.6387%; height: 2.0214%;">are currently a few hundred such cases who can purchase, at their own cost, cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 83.7099%; width: 76.1345%; height: 2.14031%;">imported from the Netherlands primarily for pain relief. The issues for patients have included:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.6825%; width: 40.6723%; height: 2.0214%;"> availability of cannabis from the Netherlands;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 88.4661%; width: 29.5798%; height: 2.0214%;"> quality of the cannabis on offer;
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/a8b23d12-f675-417b-92c0-abeaf8b12489" class="drive-viewer-paginated-page-img" alt="Page 16 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 17 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.44233%; width: 71.2605%; height: 2.0214%;"> cost (palliative cannabis treatment can cost between 800 and 1,000 per month,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 82.8571%; top: 8.44233%; width: 5.88235%; height: 1.78359%;">28 and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 10.107%; width: 38.9916%; height: 2.0214%;">is not covered by the health insurance system).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 13.6742%; width: 76.4706%; height: 2.0214%;">Legislation is now being introduced by the Federal Government into Parliament which
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.4578%; width: 76.8067%; height: 2.0214%;">addresses these issues by setting up a system to license the production of herbal cannabis on
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.3603%; width: 76.8067%; height: 2.0214%;">German soil and to ensure that its provision to patients is covered by the German health
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.1439%; width: 76.8067%; height: 2.0214%;">insurance scheme. The initial number of beneficiaries from this legislation is likely to be small.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.0464%; width: 76.6387%; height: 2.0214%;">They will be limited to those judged to have no other treatment options or where existing
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.83%; width: 76.8067%; height: 2.0214%;">treatments have been ineffective. However, it has been estimated that in due course 800,000
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.7325%; width: 46.2185%; height: 2.0214%;">patients may gain access to cannabis under the scheme.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 57.8151%; top: 24.9703%; width: 1.84874%; height: 1.07015%;">29
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.9429%; width: 4.03361%; height: 1.54578%;">Italy
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.321%; width: 76.8067%; height: 2.0214%;">Since 2013, it has been possible for those in possession of a valid prescription from a licenced
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.1046%; width: 76.8067%; height: 2.0214%;">physician to be treated with medicinal cannabis. Patients can obtain medicinal cannabis from
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.0071%; width: 76.8067%; height: 2.0214%;">licenced pharmacies, which have imported cannabis from the Netherlands. This is expensive
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.7907%; width: 20.1681%; height: 2.0214%;">at up to 38 per gram.30
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 38.6445%; width: 76.4706%; height: 2.0214%;">In response, Italy has recently licenced the production of herbal cannabis at a facility within a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.4281%; width: 76.8067%; height: 2.0214%;">military compound in Florence, which is expected to produce up to 100 kg of cannabis per
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.3306%; width: 76.8067%; height: 2.0214%;">year. About half of Italys regions have agreed to supply medicinal cannabis free or at low
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.1141%; width: 70.7563%; height: 1.9025%;">cost. Even if charges are imposed, the price would be in the region of 515 per gram.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 82.521%; top: 44.4709%; width: 1.68067%; height: 0.951249%;">31
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.3246%; width: 4.87395%; height: 1.54578%;">Spain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.5838%; width: 76.6387%; height: 2.0214%;">A limited amount of cannabis that is used for therapeutic purposes is available via Spains
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.4863%; width: 76.8067%; height: 2.0214%;">Cannabis Social Clubs. Although Nabilone and nabiximols (Sativex) are authorised for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.2699%; width: 76.3025%; height: 2.0214%;">prescription, herbal cannabis is not. The Cannabis Social Clubs operate in a legal grey area. A
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.1724%; width: 76.6387%; height: 2.0214%;">successful defence against prosecution by individuals and members of Cannabis Social Clubs
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.956%; width: 76.8067%; height: 1.78359%;">has been that the cultivation of cannabis has not been for sale but is available to members
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.8585%; width: 76.6387%; height: 2.0214%;">for therapeutic purposes. This has not stopped crackdowns on the Clubs and the attitude of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.6421%; width: 34.6218%; height: 2.0214%;">the authorities can vary region by region.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/39c34899-b3db-416f-9743-57dc204db8b9" class="drive-viewer-paginated-page-img" alt="Page 17 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 18 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 64.5378%; height: 3.09156%;">3. Conducting the Inquiry and taking evidence
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 12.8419%; width: 44.0336%; height: 2.0214%;">In January 2016, the APPG began its Inquiry to clarify:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.6956%; width: 76.6387%; height: 2.14031%;"> whether switching the medical status of cannabis from Schedule 1 to a less restrictive
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 17.4792%; width: 24.5378%; height: 2.0214%;">schedule would be beneficial;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.2628%; width: 65.2101%; height: 2.14031%;"> the range and extent of the unofficial use of cannabis for medical purposes;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.1653%; width: 76.1345%; height: 2.0214%;"> the impact of the current Schedule 1 status on research into the medical uses of cannabis;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.9489%; width: 76.8067%; height: 2.0214%;"> whether useful evidence is emerging from the regulation of cannabis in over 20 US States
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 24.7325%; width: 73.7815%; height: 2.0214%;">and elsewhere (the implications of licensing cannabis for medical use following a change
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 26.3971%; width: 10.7563%; height: 2.0214%;">in Schedule).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.8454%; width: 44.0336%; height: 2.14031%;">The Inquiry has taken evidence in the following ways:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.8181%; width: 76.6387%; height: 2.0214%;"> a call for evidence to a range of bodies and individuals including government agencies,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 34.4828%; width: 73.6134%; height: 2.14031%;">experts in the field of medicinal cannabis, voluntary organisations and individuals who use
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 36.2663%; width: 31.2605%; height: 2.0214%;">cannabis to treat a medical condition;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.0499%; width: 76.6387%; height: 2.0214%;"> a series of four hearings held at the Houses of Parliament to probe some of the written
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 39.8335%; width: 52.7731%; height: 2.0214%;">evidence received and to hear oral evidence on the main issues;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.6171%; width: 76.6387%; height: 2.0214%;"> the commissioning of a systematic literature review of medical applications of cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 43.4007%; width: 73.6134%; height: 2.0214%;">by Professor Mike Barnes, Honorary Professor of Neurological Rehabilitation, Newcastle
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 45.1843%; width: 73.4454%; height: 1.9025%;">University and Dr Jennifer Barnes, DPsych, Clinical Psychologist, Northumberland, Tyne &amp;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 46.7301%; width: 73.6134%; height: 1.78359%;">Wear NHS Foundation Trust. Professor Barnes has been Clinical Director of Rehabilitation
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 48.5137%; width: 73.6134%; height: 2.0214%;">North within the NHS, President of the World Federation for NeuroRehabilitation,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 50.2973%; width: 73.7815%; height: 2.0214%;">Chairman of the Royal College of Physicians Rehabilitation Committee. He is currently
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 51.962%; width: 62.3529%; height: 2.0214%;">Clinical Director of Neurological Rehabilitation with the Christchurch Group;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.7455%; width: 29.5798%; height: 2.14031%;"> carrying out two online surveys:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 17.9832%; top: 55.5291%; width: 70.5882%; height: 2.0214%;">o one of users of cannabis for medicinal purposes who were contacted by Jonathan
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 21.1765%; top: 57.3127%; width: 67.563%; height: 2.0214%;">Liebling, Political Officer from the United Patients Alliance (UPA), and a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 21.0084%; top: 58.9774%; width: 66.3866%; height: 2.0214%;">representative body for medicinal cannabis users. Jonathan analysed the results;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 17.9832%; top: 60.761%; width: 70.5882%; height: 2.0214%;">o also, a survey of health professionals who were alerted to the survey by the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 21.0084%; top: 62.5446%; width: 67.563%; height: 2.0214%;">Chronic Pain Coalition, a forum for patients, professionals and parliamentarians
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 21.0084%; top: 64.2093%; width: 41.0084%; height: 2.14031%;">who are concerned with the issue of chronic pain.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.7765%; width: 76.1345%; height: 2.0214%;">The work of the Inquiry was carried out between January and the end of May 2016. The APPG
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.56%; width: 76.6387%; height: 2.0214%;">received 12 formal responses to its call for evidence and had many more exchanges with other
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 71.4625%; width: 76.6387%; height: 2.0214%;">interested parties about the issues involved. It held hearings on the 10 and 24 February and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.2461%; width: 76.1345%; height: 2.0214%;">on the 2 and 9 March 2016. Sixteen experts gave evidence to a panel of APPG members.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 75.1486%; width: 76.6387%; height: 2.0214%;">Between six and nine panel members were present at each hearing. For details of those giving
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.9322%; width: 37.8151%; height: 2.0214%;">evidence and panel members see Appendix 1.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/84201e7e-1bf5-4cdd-bffb-035507af4542" class="drive-viewer-paginated-page-img" alt="Page 18 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011465/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011465/" style="left: 18.3193%; top: 46.849%; width: 42.3529%; height: 1.54578%;"></a></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 19 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 51.2605%; height: 2.73484%;">4. Medicinal cannabis: the evidence
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 76.6387%; height: 2.14031%;">The medicinal cannabis environment is bedevilled by claim and counterclaim about the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 76.6387%; height: 2.0214%;">benefits or dangers of using cannabis. To assess the evidence and bring a dispassionate view
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.5279%; width: 76.8067%; height: 2.0214%;">of what is known about current and potential applications of cannabis-based treatments, the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.4304%; width: 76.8067%; height: 2.0214%;">APPG commissioned Professor Mike Barnes32 and Dr Jennifer Barnes to prepare an up-to-date
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.214%; width: 76.6387%; height: 2.0214%;">review of the current evidence and to grade the evidence in terms of its quality. Specifically
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.1165%; width: 16.4706%; height: 2.0214%;">they were asked to:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.9703%; width: 76.8067%; height: 2.0214%;"> examine those diseases and conditions where cannabis is identified as having an
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 26.7539%; width: 45.7143%; height: 2.0214%;">established or credible potential treatment application;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.5375%; width: 76.6387%; height: 2.0214%;"> assess and grade the quality of the research related to each of those diseases and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 30.6778%; width: 9.41176%; height: 1.54578%;">conditions;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.1046%; width: 38.4874%; height: 2.0214%;"> document the side effects of cannabis; and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.8882%; width: 76.8067%; height: 2.0214%;"> comment on the impact of the potential legalisation of cannabis in the UK on potential
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 35.6718%; width: 32.437%; height: 2.0214%;">medicinal use and supporting research.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.1201%; width: 76.6387%; height: 2.0214%;">The work was carried out in April and May 2016. It involved a literature search producing over
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.0226%; width: 43.3613%; height: 1.78359%;">20 000 references. The results are summarised here.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 54.958%; top: 41.0226%; width: 33.1092%; height: 2.0214%;">33 Evidence was graded according to the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.8062%; width: 76.8067%; height: 2.0214%;">system used by the American Academy of Neurology (AAN), particularly in the systematic
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.7087%; width: 76.1345%; height: 1.9025%;">review of medicinal marijuana for neurological conditions by the Academy (Koppel et al.,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.3734%; width: 76.8067%; height: 2.0214%;">2014; www.ncbi.nlm.nih.gov/pmc/articles/PMC4011465/). The AAN grading scheme
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.2759%; width: 76.6387%; height: 2.0214%;">(paraphrased) divides the quality of research into four classes depending on how robust the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.0595%; width: 76.8067%; height: 2.0214%;">research methodology is. The classes range from 1 to 4, Class 1 being a randomised, controlled
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.962%; width: 76.1345%; height: 2.0214%;">clinical trial with a masked or objective outcome assessment, in a representative population.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.7455%; width: 76.1345%; height: 2.0214%;">Class 4 includes trials that may not use controls. The evidence for particular medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.648%; width: 76.1345%; height: 2.0214%;">applications of cannabis was grouped into three categories: good, moderate or some
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.9073%; width: 6.05042%; height: 1.30797%;">where:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.2854%; width: 61.5126%; height: 2.0214%;"> good represents at least two Class 1 studies plus studies in Class 2/3/4;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.3068%; width: 76.6387%; height: 2.0214%;"> moderate represents one Class 1 or at least two Class 2 studies backed by Class 3/4
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 64.0904%; width: 10.2521%; height: 2.0214%;">studies; and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.1118%; width: 54.958%; height: 2.0214%;"> some represents one Class 2 study backed by Class 3/4 studies.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.9655%; width: 76.6387%; height: 2.0214%;">A lack of a categorisation for a particular or potential medicinal application of cannabis may
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.7491%; width: 38.9916%; height: 2.0214%;">simply mean that further research is necessary.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.6029%; width: 76.8067%; height: 2.0214%;">Cannabis has been used as a medical product for many centuries. In recent decades, it has
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.3864%; width: 76.8067%; height: 2.0214%;">been discovered that the human brain and other organs contain naturally occurring
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 77.2889%; width: 76.6387%; height: 2.0214%;">cannabinoid receptors and chemicals that bind to those receptors. This is called the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.0725%; width: 76.6387%; height: 2.0214%;">endocannabinoid system. The endocannabinoid system has a range of important natural
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.975%; width: 76.8067%; height: 2.0214%;">functions, including modulation of pain, control of movement, protection of nerve cells and a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.7586%; width: 76.6387%; height: 2.14031%;">role in natural brain adaptability (plasticity), as well as a role in various metabolic, immune
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.6611%; width: 66.3866%; height: 2.0214%;">and inflammatory processes and a possible role in the control of tumour growth.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 87.396%; width: 76.4706%; height: 2.14031%;">Plant cannabis probably works in man by mimicking the effects of the human
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 89.2985%; width: 76.6387%; height: 2.0214%;">endocannabinoid system. The main plant cannabinoids (phytocannabinoids) studied and
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/80c94862-a5fb-44f4-9acb-7aa8431a8783" class="drive-viewer-paginated-page-img" alt="Page 19 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 20 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.6387%; height: 2.0214%;">thought to be the most important in terms of efficacy, are THC and CBD, although many
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 52.1008%; height: 2.0214%;">others exist and a role for them may become clearer with time.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.9608%; width: 76.8067%; height: 2.0214%;">The paper has provided an analysis and has graded the evidence for the efficacy of cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 76.8067%; height: 2.14031%;">and various licensed cannabis products for a number of different indications. The findings are
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.6468%; width: 10.7563%; height: 1.78359%;">that there is:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.5006%; width: 76.8067%; height: 2.0214%;"> good evidence for one or more of the cannabis products or natural cannabis in the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 21.2842%; width: 73.7815%; height: 2.0214%;">management of chronic pain, including neuropathic pain,spasticity, nausea and vomiting,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 22.9489%; width: 65.7143%; height: 2.14031%;">particularly in the context of chemotherapy, and in the management of anxiety;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.8514%; width: 76.6387%; height: 2.0214%;"> moderate evidence in sleep disorders, appetite stimulation in the context of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 26.5161%; width: 68.4034%; height: 2.0214%;">chemotherapy, fibromyalgia, PTSD, and for some symptoms of Parkinsons disease;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.4185%; width: 76.8067%; height: 2.0214%;"> some limited evidence of efficacy, but further studies are required, in the management of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 30.0832%; width: 73.7815%; height: 2.0214%;">agitation in dementia, epilepsy, particularly drug-resistant childhood epilepsies, bladder
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 31.8668%; width: 73.6134%; height: 2.0214%;">dysfunction, glaucoma and Tourettes syndrome. There is a theoretical basis, but so far
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 33.6504%; width: 73.7815%; height: 2.0214%;">no convincing evidence, of efficacy for the management of dystonia, Huntingtons
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 35.3151%; width: 73.1092%; height: 2.0214%;">disease, headache, brain protection in the context of traumatic brain injury, depression,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 37.0987%; width: 73.7815%; height: 2.0214%;">obsessive compulsive disorder, gastrointestinal disorders, psychoses (CBD), and a role in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 38.8823%; width: 19.4958%; height: 1.9025%;">cancer/tumour control.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 42.3306%; width: 76.6387%; height: 2.0214%;">In summary, the review found that the short-term side effects of cannabis are generally mild
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.1141%; width: 76.8067%; height: 1.66468%;">and well tolerated. An assessment of the evidence for a causal link between cannabis use and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.8977%; width: 76.6387%; height: 2.0214%;">schizophrenia indicates that there is probably a link in those who start using cannabis at an
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.6813%; width: 76.8067%; height: 2.14031%;">early age and also if the individual has a genetic predisposition to psychosis. There should be
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.5838%; width: 76.8067%; height: 2.0214%;">caution with regard to prescription of cannabis for such individuals. There is a small
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.3674%; width: 76.6387%; height: 2.14031%;">dependency rate with cannabis at around 9%, which needs to be taken seriously but
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.2699%; width: 76.8067%; height: 2.0214%;">compares to around 32% for tobacco use and 15% for alcohol use. There may be a, as yet
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.0535%; width: 76.6387%; height: 2.14031%;">unproven, risk of respiratory cancer for smoked cannabis. This route of administration is not
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.956%; width: 76.8067%; height: 2.0214%;">recommended. The evidence for cognitive impairment in long-term users is not clear but it is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.7396%; width: 76.6387%; height: 2.14031%;">wise to be cautious in prescribing cannabis to younger people, given the possible
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.6421%; width: 31.0924%; height: 2.0214%;">susceptibility of the developing brain.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.3769%; width: 76.6387%; height: 2.14031%;">Overall, there is a considerable literature demonstrating the efficacy of cannabis and/or
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.2794%; width: 76.3025%; height: 2.0214%;">available cannabis products in a number of important indications. Clearly much further work
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.063%; width: 76.6387%; height: 2.14031%;">is needed with regard to the formulation of cannabis and the best THC:CBD ratio for different
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.9655%; width: 76.8067%; height: 2.0214%;">conditions. Better and further studies are also needed on both its short- and, more
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.7491%; width: 26.8908%; height: 2.0214%;">particularly, longer-term effects.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/d04d34a4-e2b1-419a-820e-2f30d8c7124f" class="drive-viewer-paginated-page-img" alt="Page 20 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 21 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 59.6639%; height: 2.73484%;">5. The use of medicinal cannabis in the UK
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 76.8067%; height: 2.14031%;">The extent of cannabis use for medicinal purposes in the UK is unclear. Much of it, necessarily
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 76.8067%; height: 2.0214%;">and regrettably, involves obtaining cannabis from illegal sources so it is, as a rule, hidden.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 16.5279%; width: 76.6387%; height: 2.0214%;">Estimates of the level of cannabis use suggest that 30,000 patients in this country are using
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.4304%; width: 16.1345%; height: 2.0214%;">cannabis each day.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 27.7311%; top: 18.4304%; width: 61.0084%; height: 2.0214%;">34 If medicinal cannabis were legalised, we might expect the number of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.214%; width: 29.916%; height: 2.0214%;">users to increase to over 1,000,000.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 41.6807%; top: 20.214%; width: 46.8908%; height: 2.0214%;">35 The 1,000,000 estimate is based on the proportion of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.1165%; width: 76.8067%; height: 2.0214%;">those using cannabis for medicinal compared with overall use within US states where
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.9001%; width: 29.916%; height: 2.0214%;">medicinal use is legal and regulated.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.7539%; width: 76.6387%; height: 2.0214%;">Alongside evidence presented to the Inquiry from individuals and experts on what medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.5375%; width: 76.1345%; height: 2.0214%;">cannabis users have faced and risked to use it for treatment, the APPG commissioned an
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.44%; width: 76.6387%; height: 2.0214%;">online survey in the UK of those who use cannabis medicinally. The survey was administered
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.2235%; width: 76.8067%; height: 2.14031%;">and analysed by Jonathan Liebling from the UPA, a body representing those who use cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.126%; width: 76.6387%; height: 2.0214%;">medicinally. It was completed between March and April 2016 by those who were contacted
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.9096%; width: 76.6387%; height: 2.14031%;">through social media and a number of medically focused cannabis support groups and health
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.8121%; width: 13.2773%; height: 2.0214%;">support groups.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 40.547%; width: 76.6387%; height: 2.14031%;">Respondents were given the choice to submit their answers anonymously and the analysis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.4495%; width: 76.6387%; height: 2.0214%;">was carried out after the answers had been anonymised. The questionnaire comprised 25
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.2331%; width: 76.6387%; height: 2.0214%;">questions which sought to capture the experience of using cannabis medicinally. (The
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.0166%; width: 76.1345%; height: 2.0214%;">questionnaire used is shown in Appendix 2.) Six hundred and twenty-three questionnaires
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.8002%; width: 76.6387%; height: 2.14031%;">were received. Those using the survey were self-selecting in that they had to be in a position
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.7027%; width: 76.6387%; height: 2.0214%;">to know about the survey, principally via the UPA, and to be motivated to spend the time
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.4863%; width: 76.8067%; height: 2.14031%;">completing it. We do not claim that the sample is representative. Those who responded to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.3888%; width: 76.8067%; height: 2.0214%;">the survey are more likely to be those who have had a positive experience of cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.1724%; width: 76.6387%; height: 2.14031%;">treatment. Finally, the descriptions of conditions and the impact of medicines including
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.0749%; width: 64.5378%; height: 2.0214%;">cannabis are those of the respondents and not independent clinical diagnoses.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 59.8098%; width: 75.9664%; height: 2.14031%;">However, despite these limitations, it is important to consider the results of this survey as an
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.7122%; width: 76.8067%; height: 2.0214%;">indication of the experience of some cannabis user patients. Also, the number of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.6147%; width: 76.6387%; height: 2.0214%;">questionnaires received has allowed for both a range of experiences to be described and for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.3983%; width: 57.8151%; height: 2.0214%;">a number of common issues within those experiences to be identified.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.1332%; width: 17.8151%; height: 2.14031%;">Results of the survey
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.7218%; width: 28.7395%; height: 2.14031%;">Characteristics of the respondents
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 76.9322%; width: 75.9664%; height: 2.0214%;">Respondents included 447 (71%) males and 176 (28.3%) females. Their ages ranged from 16
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.8347%; width: 76.6387%; height: 2.0214%;">to 75 years with a mean age of 37.1 years. The majority of male respondents were between
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.6183%; width: 76.6387%; height: 2.0214%;">20 and 40 years old (61.3%), while less than half (43.8%) of female respondents were from
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.5208%; width: 50.7563%; height: 2.0214%;">that age group. Respondents came from all regions of the UK.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/504e9015-4213-4864-b760-f16e1e936f66" class="drive-viewer-paginated-page-img" alt="Page 21 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 22 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 51.4286%; height: 2.0214%;">Conditions for which medical cannabis is used as a treatment
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 11.5339%; width: 76.8067%; height: 2.0214%;">According to respondents, cannabis was used medicinally to treat a wide range of conditions,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.3175%; width: 76.8067%; height: 2.0214%;">for example, chronic and severe pain (24.1%), arthritis (12%), insomnia (21%), fibromyalgia
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.1011%; width: 44.0336%; height: 2.14031%;">(9%), PTSD (7%), depression (30%) and anxiety (26%).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.7384%; width: 76.6387%; height: 2.0214%;">This compares with some previous studies. For example, a 2005 study of medicinal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.522%; width: 25.3782%; height: 1.78359%;">users in Australia36 found that:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.3757%; width: 76.6387%; height: 2.0214%;">Long term and regular medical cannabis use was frequently reported for multiple medical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.0404%; width: 76.6387%; height: 2.14031%;">conditions including chronic pain (57%), depression (56%), arthritis (35%), persistent nausea
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.824%; width: 24.8739%; height: 2.0214%;">(27%) and weight loss (26%).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.2723%; width: 46.2185%; height: 2.14031%;">How long had patients suffered from these conditions?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.4828%; width: 76.6387%; height: 2.0214%;">Over half of respondents (53.1%) had suffered the conditions described for between 10 and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.3853%; width: 76.6387%; height: 2.0214%;">30 years. This indicates that cannabis is being used to treat and provide relief, in most cases,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.1688%; width: 76.6387%; height: 2.0214%;">from the symptoms of long-term, chronic conditions. Even for those reporting that they had
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.0713%; width: 76.8067%; height: 2.0214%;">had their condition for between 1 and 5 years the majority (64.8%) had suffered from it for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.8549%; width: 13.1092%; height: 2.0214%;">at least 3 years.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.7647%; top: 44.7087%; width: 57.1429%; height: 1.9025%;">At what point did patients start treating themselves with cannabis?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.6813%; width: 76.1345%; height: 2.0214%;">Although some respondents had treated themselves with cannabis before or at the same time
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.5838%; width: 76.6387%; height: 2.0214%;">as they had been treated with conventional medicines, the majority (67.1%) only turned to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.3674%; width: 76.6387%; height: 2.0214%;">cannabis after being prescribed conventional medicines. Nearly half (48.1%) persevered with
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.2699%; width: 76.8067%; height: 2.0214%;">prescription medicines for at least one year before beginning a cannabis treatment. The list
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.0535%; width: 76.8067%; height: 2.0214%;">of medications prescribed includes some significantly intrusive and in some cases, addictive
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.956%; width: 76.8067%; height: 2.0214%;">preparations. The list includes: analgesics (23% of cases), antidepressants, sedatives,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.7396%; width: 76.6387%; height: 2.0214%;">antipsychotics, steroids and anticonvulsants. One witness heard by the group listed 34
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.6421%; width: 76.8067%; height: 2.0214%;">medications prescribed for their condition before they tried treating their condition with
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.4257%; width: 76.6387%; height: 2.0214%;">cannabis. (See Appendix 4 for an example of the kind of prescription medicines that have
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.3282%; width: 9.91597%; height: 2.0214%;">been used.)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 67.063%; width: 73.7815%; height: 2.0214%;">What had been the experience with prescribed medicines and with cannabis treatment?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 70.2735%; width: 76.6387%; height: 2.0214%;">Many patients responding to the survey clearly suffer from conditions that are resistant to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.0571%; width: 76.6387%; height: 2.14031%;">prescribed medicines: 41.9% of respondents reported that their condition was not relieved
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.9596%; width: 76.8067%; height: 2.0214%;">or in some way their situation was worse after taking prescribed medication; 45.9% reported
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.7432%; width: 76.1345%; height: 2.14031%;">a modest improvement in their condition while the proportion of respondents reporting some
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 77.6457%; width: 76.6387%; height: 2.0214%;">improvement in their condition was 10.9%. Only 1.4% felt that their prescribed medication
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.4293%; width: 26.2185%; height: 2.0214%;">had been completely effective.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.283%; width: 76.8067%; height: 2.0214%;">The experience reported for cannabis treatment was far more positive. A strong majority of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.0666%; width: 76.6387%; height: 2.14031%;">respondents (89.9%) reported some improvement in their condition and no zero or negative
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 85.9691%; width: 76.8067%; height: 2.0214%;">effects were reported. Cannabis was perceived to provide great relief overall (86%), and
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/8d499855-310c-49a7-b4bf-705cba815982" class="drive-viewer-paginated-page-img" alt="Page 22 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 23 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.6387%; height: 2.0214%;">substantial relief of specific symptoms such as pain, nausea and insomnia. Again this
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 62.6891%; height: 2.0214%;">compares very closely to the Australian study cited earlier which found that:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 12.9608%; width: 71.7647%; height: 2.0214%;">Cannabis was perceived to provide great relief overall (86%), and substantial relief of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 45.3782%; height: 2.0214%;">specific symptoms such as pain, nausea and insomnia.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 56.9748%; top: 15.1011%; width: 1.84874%; height: 0.951249%;">37
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 18.1926%; width: 75.4622%; height: 2.0214%;">What were the side effects reported for prescribed medicines and for cannabis treatment?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 21.4031%; width: 76.6387%; height: 2.0214%;">Fifty-four per cent of respondents experienced significant, severe and very severe side effects
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.1867%; width: 76.8067%; height: 2.0214%;">from prescribed medication. To describe their side effects respondents used terms including
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.0892%; width: 76.8067%; height: 2.0214%;">sickness, nightmares, severe headaches (significant); a number of negative effects, suicidal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.8728%; width: 76.8067%; height: 2.0214%;">thoughts, vomiting (severe); and severe suicidal thoughts, seizures, blackouts (extremely
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.132%; width: 6.89076%; height: 1.54578%;">severe).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 31.5101%; width: 76.4706%; height: 2.0214%;">By comparison, 8.5% of respondents reported significant or severe side effects from cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.4126%; width: 76.8067%; height: 2.0214%;">treatment. That is, over 90% of respondents report no or mild side effects. Those patients
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.1962%; width: 76.6387%; height: 3.9239%;">who experienced side effects from cannabis reported drowsiness, the munchies, being too-
high, nausea and dizziness, paranoia, anxiety and a dry mouth. Cannabis is a thoroughly
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.8823%; width: 76.6387%; height: 2.0214%;">researched drug in terms of its potential harms, so this list is not surprising. However, it is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.7848%; width: 76.8067%; height: 2.0214%;">important to note that these side effects were considered mild compared with many of those
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.5684%; width: 76.6387%; height: 2.0214%;">reported for prescribed medicines and were to some extent mitigated by patients learning
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.4709%; width: 73.6134%; height: 1.66468%;">which strains of cannabis and which combinations of cannabinoids worked best for them.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 47.0868%; width: 75.9664%; height: 2.0214%;">However, there was an effect reported which resulted from the illicit status of cannabis;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.9893%; width: 76.6387%; height: 2.0214%;">35.6% of respondents reported illegality as being a concern arising from their use of cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.7729%; width: 76.6387%; height: 2.0214%;">as a treatment. In some this led to experiences of paranoia and anxiety; others were
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.6754%; width: 76.6387%; height: 2.0214%;">concerned about the stigma associated with taking a controlled substance or the problems of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.459%; width: 76.8067%; height: 2.0214%;">obtaining cannabis on the illicit market. Finally, there were issues around not being able to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.3615%; width: 76.6387%; height: 2.0214%;">guarantee quality or safety in a product obtained on the illicit market combined with a high
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.7396%; width: 4.20168%; height: 1.18906%;">cost.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.9988%; width: 76.6387%; height: 2.0214%;">The problems with obtaining illicit cannabis can also affect the family. In giving oral evidence
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.7824%; width: 76.8067%; height: 2.0214%;">to the Inquiry, representatives of Law Enforcement Against Prohibition (LEAP) described the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.6849%; width: 41.5126%; height: 2.0214%;">situation of many people in their 20s, 30s and 40s.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.4197%; width: 75.4622%; height: 2.0214%;">They still have to live with their parents. Whoevers roof you are living under, they face the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.2033%; width: 70.9244%; height: 2.0214%;">same level of prosecution as you. Not only are you putting yourself at risk, but you are
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.7647%; top: 70.9869%; width: 72.605%; height: 2.0214%;">putting your family and support groups at risk. That of course causes stress and a whole
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.6516%; width: 57.8151%; height: 2.0214%;">other realm of family fallout from criminalisation. (Neil Woods, LEAP)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 76.0999%; width: 57.9832%; height: 2.14031%;">What was the view of the medical profession to cannabis treatment?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 79.3103%; width: 76.4706%; height: 2.0214%;">Not all but a majority of respondents (63%) have discussed using a cannabis treatment with
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.2128%; width: 76.8067%; height: 2.0214%;">their GP or Consultant. Of this group, only a small proportion of prescribers (28%) have taken
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.9964%; width: 76.8067%; height: 2.0214%;">a negative view of their cannabis treatment with a higher proportion (41.3%) being actively
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.8989%; width: 76.6387%; height: 2.0214%;">positive. Over one-third of respondents (37%) had not discussed using cannabis to treat their
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.6825%; width: 76.6387%; height: 2.0214%;">condition with their GP or Consultant. This group are likely to have been put off doing so by
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/32635dd1-fefc-4685-bc38-34e0fea1a1b6" class="drive-viewer-paginated-page-img" alt="Page 23 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 24 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.6387%; height: 2.0214%;">the current illegal status of cannabis which thus acts as a barrier to finding the most effective
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 26.3866%; height: 2.0214%;">way to meet their health needs.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 12.9608%; width: 48.7395%; height: 2.0214%;">Where do people using cannabis as a treatment obtain it?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.1712%; width: 76.8067%; height: 2.0214%;">Of the 80.9% of respondents who answered this question, a clear majority (72%) obtained
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.9548%; width: 76.6387%; height: 2.0214%;">their cannabis on the street or from a friend. As a friend will almost certainly obtain cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.8573%; width: 49.5798%; height: 2.0214%;">from the street, this ultimately amounts to the same thing.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 61.1765%; top: 19.8573%; width: 27.563%; height: 2.0214%;">38 Other sources involved grow
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.6409%; width: 76.8067%; height: 2.0214%;">your own either by the patient themselves or by their friends or Clubs. Alternatively, the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.5434%; width: 40.1681%; height: 2.0214%;">cannabis was obtained via the internet (Table 2).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.2782%; width: 29.4118%; height: 2.0214%;">Table 2: Sources of cannabis supply
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.9496%; top: 29.8454%; width: 67.395%; height: 1.9025%;">Did not answer 19.1%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 32.2235%; width: 67.563%; height: 1.30797%;">Street 52.6%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.9496%; top: 34.0071%; width: 67.395%; height: 1.42687%;">Friends 19.4%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 35.9096%; width: 67.563%; height: 1.30797%;">GYO 10.7%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 37.6932%; width: 67.0588%; height: 1.42687%;">GYO-Friends 6.7%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 39.5957%; width: 67.0588%; height: 1.30797%;">GYO-Club 2.0%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.9496%; top: 41.4982%; width: 66.8908%; height: 1.30797%;">Internet 7.3%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 43.2818%; width: 67.0588%; height: 1.42687%;">Abroad 1.2%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 46.2545%; width: 76.4706%; height: 2.14031%;">Users who presently access cannabis for medicinal purposes receive significant advice and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.157%; width: 71.4286%; height: 2.0214%;">guidance from their suppliers, including instructions on strains, dosage and indications.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.8918%; width: 17.9832%; height: 2.14031%;">Proposals for change
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 54.1023%; width: 76.4706%; height: 2.0214%;">Not surprisingly, none of the respondents were happy with the status quo in terms of the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.0048%; width: 76.8067%; height: 2.0214%;">current schedule and control of cannabis as a Class B drug. They split into three groups either
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.7883%; width: 76.8067%; height: 2.0214%;">calling for legalisation of cannabis with regulation of supply, its legalisation for medicinal use
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 59.6908%; width: 76.8067%; height: 2.0214%;">or the decriminalisation of users of cannabis. The proportion supporting each option is given
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.4744%; width: 8.7395%; height: 1.78359%;">in Table 3.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.3282%; width: 35.7983%; height: 2.0214%;">Table 3: Proportion supporting each option
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 67.8954%; width: 65.2101%; height: 2.0214%;">Law change Respondents
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 69.7979%; width: 62.3529%; height: 2.0214%;">Full legalisation 58.9%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 71.5815%; width: 62.3529%; height: 2.0214%;">Legalise for medicinal use only 31.6%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 73.9596%; width: 61.8487%; height: 1.30797%;">Decriminalise use 9.5%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 75.3864%; width: 62.8571%; height: 1.78359%;">Grand total 100.0%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.9536%; width: 26.7227%; height: 2.0214%;">The emerging market in CBD oil
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.6885%; width: 76.8067%; height: 2.0214%;">The Inquiry has also heard evidence of a cannabis-based product which has emerged recently:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 83.591%; width: 76.6387%; height: 2.0214%;">CBD oil. CBD oil is extracted from hemp plants which are a form of cannabis grown legally as
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 85.3746%; width: 76.6387%; height: 2.0214%;">they contain a minimal amount of THC (&lt;2%). CBD oil is sold mainly over the internet. Nick
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 87.2771%; width: 76.4706%; height: 2.0214%;">Ellis, the Chief Executive of CBDUK Ltd, himself a user of CBD oil medicinally for ulcerative
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 89.0606%; width: 56.6387%; height: 2.0214%;">colitis and fibromyalgia, described to our Inquiry what was involved.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/e28c86e4-5809-4958-bc9e-1dda07aad69c" class="drive-viewer-paginated-page-img" alt="Page 24 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 25 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 76.4706%; height: 2.0214%;">His company sells a range of cannabis oil products which are classed as dietary supplements
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 76.6387%; height: 2.14031%;">and the company is not allowed to give medical advice or make any claims as to the medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.0095%; width: 76.8067%; height: 2.0214%;">efficacy of the products. It seemed, however, that 90 % of customers are buying the products
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.7931%; width: 15.6303%; height: 1.9025%;">for health reasons.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.6468%; width: 76.6387%; height: 2.0214%;">There are concerns from government agencies that the trade in CBD oil is not strongly
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.5493%; width: 76.8067%; height: 2.0214%;">regulated. In 2015, the US Federal Food and Drug Administration wrote to six companies
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 76.8067%; height: 2.0214%;">selling CBD products.39 The problems they cited included medicinal claims being made for the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.1165%; width: 76.1345%; height: 2.14031%;">CBD oil product being sold and an absence of any CBD content. They informed one company:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 24.9703%; width: 76.6387%; height: 2.0214%;">Your product is offered for conditions that are not amenable to self-diagnosis and treatment
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.7539%; width: 76.6387%; height: 2.0214%;">by individuals who are not medical practitioners; therefore, adequate directions for use cannot
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.4185%; width: 66.3866%; height: 2.0214%;">be written so that a layperson can use this drug safely for its intended purposes.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 77.8151%; top: 28.7753%; width: 1.84874%; height: 0.951249%;">40
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.9857%; width: 76.8067%; height: 2.0214%;">Another issue with CBD oil is the cost. Although the medicinal use of legally sold CBD is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.7693%; width: 76.8067%; height: 2.0214%;">obscured, and details of the cost of medicinal use are anecdotal, an example of the daily cost
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.6718%; width: 76.6387%; height: 2.0214%;">of using CBD oil medicinally is $18 per day.41 For a chronic condition continued use for over
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.4554%; width: 34.1176%; height: 1.9025%;">two months could cost more than $1000.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.3092%; width: 76.8067%; height: 2.0214%;">The results of research into the efficacy of medicinal cannabis are increasingly known. It is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.0927%; width: 76.6387%; height: 2.0214%;">reasonable to assume that the market in CBD oil in the UK is driven at least in part by the fact
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.9952%; width: 76.6387%; height: 1.9025%;">that herbal cannabis is not legally available for medicinal use. A regime of regulated herbal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.6599%; width: 76.3025%; height: 2.0214%;">cannabis as available in Europe would seem to offer the best prospect for patients to access
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.5624%; width: 76.6387%; height: 2.0214%;">medicinal grade cannabis at a reasonable cost and with the benefit of professional advice
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.346%; width: 12.1008%; height: 1.78359%;">from a doctor.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.5565%; width: 10.2521%; height: 1.42687%;">Conclusions
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.9346%; width: 76.6387%; height: 2.0214%;">The survey has identified users experiences with medicinal cannabis taken to treat a wide
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.8371%; width: 76.6387%; height: 2.0214%;">range of conditions. For some of these conditions, our review of evidence suggested that
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.6207%; width: 76.6387%; height: 2.0214%;">there is a good evidence base for the effectiveness of cannabis. For others the evidence base
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.5232%; width: 55.4622%; height: 2.0214%;">is not so strong but the respondents have reported positive results.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.258%; width: 76.8067%; height: 2.0214%;">Those using medicinal cannabis are not doing so lightly. Typically, they will have been
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.1605%; width: 62.6891%; height: 2.0214%;">prescribed a range of medications for at least a year before trying cannabis.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 67.8954%; width: 76.4706%; height: 2.0214%;">Respondents report a generally positive experience with cannabis by contrast with their
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.7979%; width: 76.6387%; height: 2.0214%;">mixed experience of previously tried prescription drugs. The positive experience includes an
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 71.5815%; width: 76.8067%; height: 2.0214%;">experience of the side effects of cannabis relatively less serious than those of prescription
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.4839%; width: 76.6387%; height: 2.0214%;">drugs. However, a side effect of cannabis that needs to be acknowledged is the stress and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.2675%; width: 37.3109%; height: 2.0214%;">anxiety caused by having to obtain it illegally.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 78.1213%; width: 76.6387%; height: 2.0214%;">In the main, respondents experience with the medical profession is that in their main doctors
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.9049%; width: 76.8067%; height: 2.0214%;">are not opposed to self-medication with cannabis. However, it is a matter of concern that an
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.8074%; width: 76.8067%; height: 2.0214%;">exchange between health professionals and cannabis users does not take place in 37% of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.3044%; width: 5.21008%; height: 1.07015%;">cases.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 86.4447%; width: 76.4706%; height: 2.0214%;">Not surprisingly, respondents are in favour of a change in the law. It is a reasonable
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 88.2283%; width: 76.8067%; height: 2.0214%;">assumption that they speak for the estimated 30 000 who use medicinal cannabis daily. Such
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/ff68b801-9120-47c7-859a-eb128b128c82" class="drive-viewer-paginated-page-img" alt="Page 25 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 26 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">a change would also benefit those who are currently seeking treatment from the legal, but
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 36.3025%; height: 2.0214%;">costly and poorly regulated, CBD oil market.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 36.1345%; top: 16.2901%; width: 1.17647%; height: 2.73484%;">
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/718de63e-cfb4-4aab-a96d-3b43c48adcce" class="drive-viewer-paginated-page-img" alt="Page 26 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 27 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 65.3782%; height: 3.09156%;">6. Results of the survey of health professionals
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 12.8419%; width: 76.6387%; height: 2.14031%;">In order to get a picture of how medicinal cannabis is viewed by health professionals, a short
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 76.1345%; height: 2.0214%;">online survey was undertaken with the assistance of the Chronic Pain Policy Coalition. The
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.5279%; width: 76.6387%; height: 2.0214%;">Coalition is a forum established in 2006 to unite patients, professionals and parliamentarians
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.4304%; width: 76.6387%; height: 2.0214%;">in a mission to develop an improved strategy for the prevention, treatment and management
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.214%; width: 76.6387%; height: 2.0214%;">of chronic pain and its associated conditions.42 The Coalition notified the health professionals
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.1165%; width: 76.8067%; height: 2.0214%;">with whom it is in touch that we had set up an online survey. Between 26 February and 13
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.9001%; width: 76.8067%; height: 2.14031%;">April 2016, 126 replies were received. This is a strong response from busy and senior health
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.8026%; width: 76.6387%; height: 2.0214%;">professionals. It indicates a lot of interest in the issue by a group of health professionals
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.5862%; width: 76.8067%; height: 2.0214%;">working in the field of chronic pain, a field where our evidence review has demonstrated that
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.4887%; width: 76.8067%; height: 2.0214%;">there is good evidence for the use of cannabis to contribute to treatment plans. How far the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.2723%; width: 66.5546%; height: 2.0214%;">comments of this group represent the medical profession as a whole is untested.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.126%; width: 76.6387%; height: 2.0214%;">The majority of respondents were Consultants, mainly working in the field of pain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.9096%; width: 57.3109%; height: 2.0214%;">management. The full breakdown of respondents is shown in Table 4.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.7634%; width: 29.5798%; height: 2.0214%;">Table 4: Breakdown of respondents
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 41.6171%; width: 23.0252%; height: 2.0214%;">Breakdown of respondents
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 43.4007%; width: 66.5546%; height: 1.9025%;">Academics 5 4%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 45.1843%; width: 67.0588%; height: 1.78359%;">Consultants 86 68%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.9496%; top: 47.4435%; width: 66.3866%; height: 1.30797%;">Doctors 8 6%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.9496%; top: 49.2271%; width: 66.8908%; height: 1.30797%;">Nurses 12 10%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.9496%; top: 50.5351%; width: 66.3866%; height: 2.0214%;">Physiotherapists 5 4%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 52.3187%; width: 66.5546%; height: 1.78359%;">Other 10 8%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 13.7815%; top: 54.1023%; width: 67.563%; height: 1.9025%;">Total 126 100%
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.7396%; width: 58.6555%; height: 2.0214%;">Knowledge of cannabis being used by patients to treat their condition
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 61.5933%; width: 76.6387%; height: 2.0214%;">Ninety-seven (77%) of those responding were aware of patients being prescribed or making
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.3769%; width: 76.6387%; height: 2.0214%;">use of cannabis or cannabis-based medicines to treat their condition, either in the form of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.2794%; width: 76.8067%; height: 2.0214%;">synthetic cannabinoids or cannabis derivatives such as nabilone or Sativex (nabiximols); or
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.063%; width: 67.563%; height: 2.0214%;">imported from the Netherlands (Bedrocan); or cannabis obtained by other means.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.9168%; width: 76.8067%; height: 2.0214%;">Of these, half described the prescription of Sativex for pain management. Specialist pain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 71.7004%; width: 76.1345%; height: 2.0214%;">consultants are one of the groups within the medical profession that can prescribe Sativex
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.6029%; width: 76.8067%; height: 2.0214%;">although not all prescribing committees authorise its prescription. A smaller group had made
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.3864%; width: 76.6387%; height: 2.0214%;">use of synthetic THC in the form of nabilone. Such drugs are licenced for the reduction of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 77.2889%; width: 76.6387%; height: 2.0214%;">spasticity in multiple sclerosis sufferers but in some cases were being prescribed off licence
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.0725%; width: 76.6387%; height: 2.0214%;">for the treatment of pain. Some health professionals have anything up to 100 patients being
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.975%; width: 76.8067%; height: 2.0214%;">treated with Sativex. The numbers reported as being treated with nabilone are much lower,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.7586%; width: 8.23529%; height: 1.78359%;">under 10.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 85.6124%; width: 76.6387%; height: 2.0214%;">It was clear from the responses that many health professionals are aware of patients taking
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 87.396%; width: 76.8067%; height: 2.0214%;">cannabis obtained from the street in addition to prescriptions of Sativex or nabilone. The
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 89.2985%; width: 76.6387%; height: 2.0214%;">numbers involved could be as many as 150 per respondent, but the number varies from this
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/11e70821-133a-4a4c-a5cd-7d58186fd32c" class="drive-viewer-paginated-page-img" alt="Page 27 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 28 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">figure to a very few. This can depend on whether patients feel confident to talk to their
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 33.1092%; height: 2.0214%;">Consultant or other health professional.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.9608%; width: 76.6387%; height: 3.9239%;">As the health professionals were pain specialists they reported their experience of cannabis-
based treatments in this area. The types of pain where they had either prescribed or had
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.6468%; width: 76.8067%; height: 2.0214%;">knowledge of the prescription of cannabis-based treatment included: pain associated with
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.5493%; width: 76.6387%; height: 2.0214%;">multiple sclerosis, neuropathic or nerve pain, severe musculoskeletal pain from degenerative
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 76.8067%; height: 2.0214%;">changes, back pain, cancer pain, pain due to spinal cord injury, fibromyalgia, chronic migraine
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.2354%; width: 76.6387%; height: 3.80499%;">and cluster headaches, atypical facial pain, chronic visceral and pelvic pain syndromes, post-
amputation phantom pain, failed back surgery syndrome, nociceptive pain (caused by
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.8026%; width: 76.8067%; height: 2.14031%;">damage to body tissue), demyelinating polyneuropathy, complex regional pain syndrome and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.7051%; width: 52.2689%; height: 2.0214%;">deafferentation pain (based on interruption of nerve impulses).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 30.44%; width: 76.6387%; height: 2.14031%;">In summary, as one respondent put it, every kind of pain you can mention and according to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.3424%; width: 37.3109%; height: 2.0214%;">another pain resistant to other treatments.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.0773%; width: 45.3782%; height: 1.9025%;">Perceived effectiveness of cannabis based medication
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.931%; width: 76.6387%; height: 2.0214%;">One hundred and eight replies were obtained to the question What in your experience has
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.8335%; width: 76.8067%; height: 2.0214%;">been the impact of using cannabis medicinally on the conditions listed? Of these, 72 were
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.6171%; width: 76.6387%; height: 2.0214%;">positive about the role of cannabis-based medicines for the conditions they were involved in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.4007%; width: 21.5126%; height: 2.14031%;">researching. For example:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 46.6112%; width: 7.56303%; height: 1.30797%;">Nabilone
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 48.9893%; width: 75.9664%; height: 2.0214%;">Nabilone seems to be a useful drug, generally well tolerated and does not seem to suffer from
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.7647%; top: 50.7729%; width: 64.7059%; height: 2.0214%;">problems with tolerance and analgesic (pain causing) side effects like opioids.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.1023%; width: 6.21849%; height: 1.30797%;">Sativex
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 56.4804%; width: 76.4706%; height: 2.0214%;">Sativex is a very useful addition to the menu of treatments for spasticity and neuropathic
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.7647%; top: 58.7396%; width: 5.54622%; height: 1.54578%;">pain.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.5933%; width: 14.6218%; height: 1.30797%;">Street cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 63.9715%; width: 74.7899%; height: 2.0214%;">Those who report using cannabis report that they find it either reduces pain or helps them
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.874%; width: 14.4538%; height: 2.0214%;">to tolerate pain.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 68.7277%; width: 76.6387%; height: 2.0214%;">Negative comments often referred to applications of a particular cannabis-based treatment
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.5113%; width: 76.8067%; height: 2.0214%;">for particular conditions where very limited or no benefit had been observed, for example, in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.4138%; width: 76.8067%; height: 2.0214%;">a trial for the treatment of diabetes. Other reports included observations that benefits were
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 74.1974%; width: 76.8067%; height: 2.0214%;">short term or that cannabis-based medicines can have negative psychoactive effects. But
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.0999%; width: 76.6387%; height: 2.0214%;">other patients reported to respondents that the relaxing experience from taking cannabis was
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 77.8835%; width: 36.4706%; height: 2.0214%;">helpful to them in managing their condition.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.7372%; width: 76.8067%; height: 2.0214%;">A number of positive comments were qualified by comments that cannabis-based treatment
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.5208%; width: 76.6387%; height: 2.0214%;">did not work for all patients and could have less of an impact on some patients than other
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.4233%; width: 76.6387%; height: 2.0214%;">drugs. However, health professionals were clear that cannabis definitely works for some
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.2069%; width: 76.8067%; height: 2.0214%;">people and according to one respondent, it works in the most difficult cases. For another
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/9c976d3b-e084-445d-af04-7d3118a522d2" class="drive-viewer-paginated-page-img" alt="Page 28 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 29 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.6387%; height: 2.0214%;">respondent, cannabis-based treatment can provide significant benefit for a small group of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 44.5378%; height: 2.0214%;">chronic pain patients where other agents have failed.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.9608%; width: 75.6303%; height: 2.0214%;">Also the fact that a drug does not work for all patients is not, in itself, a reason to exclude it
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.8633%; width: 73.1092%; height: 2.0214%;">from the formulary. As one respondent commented, I probably see an equal number of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.7647%; top: 16.7658%; width: 73.2773%; height: 2.0214%;">patients who report that they tried cannabis but found that it didn't help. (This is true for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.7647%; top: 18.5493%; width: 23.1933%; height: 2.0214%;">prescribed pain meds too.)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.8787%; width: 9.41176%; height: 1.30797%;">Conclusion
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.2568%; width: 76.6387%; height: 2.0214%;">A group of senior health professionals have given their views on the current and potential use
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.0404%; width: 51.0924%; height: 2.0214%;">of cannabis-based treatment in the treatment of chronic pain.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.8942%; width: 76.8067%; height: 2.0214%;">While some have been negative about the value of any of the cannabis treatments available,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.6778%; width: 76.6387%; height: 2.0214%;">a much larger group have been positive about the role of cannabis, mainly in terms of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.5803%; width: 76.8067%; height: 2.0214%;">nabilone and Sativex (nabiximols) but in some cases in terms of herbal street cannabis as
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.8395%; width: 4.20168%; height: 1.30797%;">well.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.2176%; width: 76.6387%; height: 2.0214%;">There were a number of calls among respondents for cannabis-based treatment to be more
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.0012%; width: 46.7227%; height: 2.0214%;">widely and more easily available. Typical examples were:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 41.8549%; width: 69.7479%; height: 2.0214%;">Some patients claim to have benefited significantly but at present we cannot legally
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.7574%; width: 72.605%; height: 1.9025%;">support the use of illicit substances, therefore potentially stopping patients getting their
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.7647%; top: 45.541%; width: 16.1345%; height: 1.9025%;">perceived benefit.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 48.2759%; width: 74.7899%; height: 2.0214%;">Not magic, safe, well worth a try in these awful chronic pain problems where we have few
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.654%; width: 7.73109%; height: 1.54578%;">options.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/72cbe653-cf41-480f-b52d-9c3cc9196996" class="drive-viewer-paginated-page-img" alt="Page 29 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 30 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 23.5294%; height: 2.73484%;">7. Case studies
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 28.0672%; height: 2.0214%;">Chronic neuropathic pain  Jacob
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.6956%; width: 76.8067%; height: 2.0214%;">Jacob is 28 years of age. He has been battling chronic and neuropathic pain for eight years,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.4792%; width: 76.8067%; height: 2.14031%;">having been born with a diaphragmatic hernia and initially needing life-saving corrective
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.3817%; width: 76.6387%; height: 2.0214%;">surgery. He had surgery on several occasions and in 2007 was found unconscious due to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.1653%; width: 76.6387%; height: 2.0214%;">extreme pain and internal bleeding. Surgery was again necessary to remove adhesions and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.0678%; width: 76.6387%; height: 2.0214%;">scarring of his abdomen and bowel. But he continued to struggle with intense pain, spasms
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.8514%; width: 76.1345%; height: 2.0214%;">and digestion and mobility problems. After trying various antispasmodics and opiates,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.7539%; width: 76.8067%; height: 2.0214%;">including oxycodone (OxyNorm), pregabalin (Lyrica) and amitriptyline which all caused very
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.5375%; width: 76.8067%; height: 2.14031%;">severe side effects, he was given nabilone and Sativex (nabiximols). Neither of these
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.44%; width: 76.8067%; height: 2.0214%;">medications was effective in combating his symptoms. He is currently trying to obtain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 32.2235%; width: 71.7647%; height: 2.0214%;">Bedrocan legally and relies on herbal and extracted cannabis as his sole source of relief.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.0773%; width: 21.1765%; height: 2.0214%;">Multiple sclerosis  Clark
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.8121%; width: 76.6387%; height: 2.14031%;">Clark was diagnosed with multiple sclerosis in 2010 at the age of 24. He took many
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.7146%; width: 76.6387%; height: 2.0214%;">prescription medications to control his symptoms, but they all had severe side effects, leaving
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.4982%; width: 31.2605%; height: 2.0214%;">him feeling worse than without them.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.352%; width: 76.8067%; height: 1.9025%;">Clark had watched his stepfather slowly deteriorate from the same disease. Clark does qualify
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.0166%; width: 76.8067%; height: 2.14031%;">for Sativex but his primary care trust/ clinical commissioning group refused to pay for it. Clark
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.9191%; width: 76.6387%; height: 2.0214%;">has two doctors recommendations from the USA after a recent trip there and now consumes
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.7027%; width: 76.6387%; height: 2.14031%;">cannabis almost exclusively to treat his multiple sclerosis, saving the NHS the cost of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.6052%; width: 76.6387%; height: 2.0214%;">medications which is about 30k per year. The benefits he experiences include: reduced
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.3888%; width: 76.6387%; height: 2.14031%;">spasticity, pain relief, increased appetite, reduced bladder and bowel problems, less nausea
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.2913%; width: 76.6387%; height: 2.0214%;">and very little side effects and means he can walk further and does not need the aid of a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.5505%; width: 9.7479%; height: 1.30797%;">wheelchair.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 59.9287%; width: 72.9412%; height: 2.0214%;">Degenerative disc disease/osteoarthritis and stenosis in lumber and cervical spine, and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.7122%; width: 37.6471%; height: 2.0214%;">arthritis in knees and right hip  Anonymous
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.566%; width: 76.6387%; height: 2.0214%;">This anonymous patient is a 42-year-old mother of three and former paediatric nurse. Last
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.4685%; width: 76.8067%; height: 2.0214%;">year she underwent major spinal surgery to replace two discs in her neck. She suffers constant
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.2521%; width: 76.6387%; height: 2.0214%;">pain and is unable to work. Indeed, the neuropathic pain is much worse than before the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.6302%; width: 8.90756%; height: 1.42687%;">operation.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.8894%; width: 76.6387%; height: 2.0214%;">Over the past 15 years she has been prescribed over 34 different medications, including
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 74.673%; width: 76.1345%; height: 2.14031%;">opiates, anti-inflammatories, anti-epileptic medication, antispasmodics, antidepressants and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.5755%; width: 76.6387%; height: 2.0214%;">anti-emetics. Most of the medications have had intolerable side effects including nausea,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.3591%; width: 76.6387%; height: 2.14031%;">vomiting, sedation, arrhythmia, dizziness, severe headaches and a marked reduction in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.2616%; width: 76.8067%; height: 2.0214%;">appetite; also severe withdrawal symptoms when she stopped taking opiate medication. She
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.0452%; width: 38.8235%; height: 2.14031%;">has also had epidural and facet joint injections.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.8989%; width: 76.6387%; height: 2.0214%;">Today she relies on Bedrocan, a licenced cannabis medicine, which she buys in the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 86.8014%; width: 76.6387%; height: 2.0214%;">Netherlands. This involves a painful journey four times a year to get a Dutch prescription and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 88.585%; width: 76.6387%; height: 2.0214%;">to purchase the cannabis medication in person from a pharmacy. She pays 2130 a year for
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/d8faa353-8dce-41c4-86e3-88d59f89e678" class="drive-viewer-paginated-page-img" alt="Page 30 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 31 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">her cannabis. This dose of Sativex would cost more than 49 000 per year. Her consultant has
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 45.2101%; height: 2.0214%;">discussed increasing her dose, but she cannot afford it.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.9608%; width: 76.6387%; height: 2.0214%;">She is clear that cannabis has not cured her but it alleviates her neuropathic pain, spasms and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.7444%; width: 76.8067%; height: 2.14031%;">stiffness. It also helps reduce the nausea which she experiences when in pain and improves
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.6468%; width: 76.8067%; height: 2.0214%;">her appetite. She says that for those in severe pain, cannabis does not cause a high. It simply
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.4304%; width: 74.4538%; height: 2.14031%;">restores the patient to a normal mental state. She is not aware of any adverse side effects.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.2842%; width: 28.7395%; height: 1.78359%;">Brain tumour and seizures  Mark
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 24.019%; width: 76.4706%; height: 2.14031%;">Mark had 24/7 headaches for seven years and had five or more seizures per day. He had lost
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.9215%; width: 76.6387%; height: 2.0214%;">the sight in his left eye and lost his driving license. He was prescribed a long list of medications
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.824%; width: 76.8067%; height: 2.0214%;">which were generally not effective and caused a number of severe side effects. (See Appendix
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.6076%; width: 76.6387%; height: 2.0214%;">4 for list of medications and side effects.) He spent a year researching the endocannabinoid
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.5101%; width: 76.6387%; height: 2.0214%;">system and the use of cannabis oil to treat cancers and seizures. He finally made some
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.2937%; width: 76.1345%; height: 2.0214%;">cannabis oil and took it. Within 10 minutes he says his headache stopped. After three days,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.1962%; width: 76.6387%; height: 2.0214%;">he noticed that his seizures had also stopped, along with the pain behind his left eye. His eye
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.9798%; width: 76.6387%; height: 2.0214%;">then began to focus. He told his neurologist about these changes. He has since stopped all
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.8823%; width: 76.8067%; height: 2.0214%;">other medications and has his driving license back. He continues to take cannabis and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.6659%; width: 10.4202%; height: 1.78359%;">cannabis oil.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.4007%; width: 23.6975%; height: 2.14031%;">Neuropathic pain  Caroline
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.1356%; width: 76.6387%; height: 2.0214%;">Caroline has not had one night of sound sleep in the UK in 15 years, due to neuropathic pain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.038%; width: 76.6387%; height: 2.0214%;">and spasms. She describes her neuropathic pain as covering all of her body. It is burning,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.8216%; width: 76.6387%; height: 2.0214%;">scalding pain. Neuropathic pain does not respond to usual pain killers due to its aetiology and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.6052%; width: 37.479%; height: 2.14031%;">yet cannabinoids have been proven to work.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.459%; width: 76.6387%; height: 2.0214%;">Caroline refers to the repeated GP and hospital appointments and hospital admissions, all of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.3615%; width: 76.6387%; height: 2.0214%;">which are very costly and could be avoided if cannabis were available on prescription, she
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.1451%; width: 76.8067%; height: 2.0214%;">says. Caroline is critical of the limitation on prescribing of cannabis medications to multiple
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.0476%; width: 76.6387%; height: 2.0214%;">sclerosis sufferers. She argues that this discriminates against others with similar symptoms
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.8312%; width: 76.6387%; height: 2.0214%;">but with a different diagnosis. Caroline has had to give up work as a dual qualified nurse
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 63.7337%; width: 76.6387%; height: 2.0214%;">10 years before retirement because of her symptoms. She tried cannabis in Amsterdam and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.5172%; width: 76.1345%; height: 2.0214%;">is clear that she could have continued working if she were able to access cannabis in the UK.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.4197%; width: 76.6387%; height: 2.0214%;">She experienced her first night of sound sleep in Amsterdam. There, she did not have to get
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.2033%; width: 69.5798%; height: 2.0214%;">up 10 times in the night because of bladder spasms which keep her awake for hours.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.0571%; width: 76.8067%; height: 2.0214%;">I also suffer from emotional problems says Caroline. This is because of her multiple sclerosis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.8407%; width: 76.8067%; height: 2.0214%;">lesions that are so severe that when they start she has to drive her carto somewhere secluded
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.7432%; width: 57.3109%; height: 2.0214%;">and scream for up to 3 hours until they subside, not to disturb others.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.478%; width: 76.6387%; height: 2.0214%;">This issue is about the morality of the government, and how it defends and cares for those
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.3805%; width: 52.1008%; height: 2.0214%;">it represents, says Caroline. I want my life back  its simple.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/87fd1cfe-f5f5-4b90-bee5-4a5758c955aa" class="drive-viewer-paginated-page-img" alt="Page 31 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 32 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 70.4202%; height: 3.09156%;">8. Current scheduling of cannabis: implications for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 18.1513%; top: 11.415%; width: 12.437%; height: 2.73484%;">research
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.0523%; width: 76.6387%; height: 2.0214%;">The implications for research of the current Schedule 1 status for cannabis are that to obtain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.8359%; width: 76.8067%; height: 2.0214%;">the necessary permissions remains a costly obstacle course. Getting a Schedule 1 licence for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.7384%; width: 76.8067%; height: 2.0214%;">research in the UK takes about a year and costs around 5000. This sum includes 3000 for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.522%; width: 76.6387%; height: 2.0214%;">the licence and 2000 for the other requirements (extra security for the drug cabinets, police
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.4245%; width: 76.8067%; height: 2.0214%;">checks, etc.). For cannabis trials involving a placebo, cannabis placebo is held to be a Schedule
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 25.2081%; width: 41.6807%; height: 2.0214%;">1 substance so these costs are reproduced again.43
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 28.0618%; width: 76.4706%; height: 2.0214%;">Import licences are only granted for 12 weeks by the Home Office and can expire before all
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.8454%; width: 76.6387%; height: 2.0214%;">the arrangements (e.g. export licence from the Netherlands and approval by the Dutch
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 31.7479%; width: 76.6387%; height: 2.0214%;">Medical Cannabis Office) are made. As a result of these restrictions, it has been calculated
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.5315%; width: 76.6387%; height: 2.0214%;">that research involving Schedule 1 drugs takes significantly longer and costs about 10 times
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.434%; width: 76.6387%; height: 2.0214%;">that of research into other drugs. Researchers not only have to consider the cost but also the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.2176%; width: 52.437%; height: 2.0214%;">uphill administrative struggle if they are to pursue their studies.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.0713%; width: 76.6387%; height: 2.0214%;">A further consequence of Schedule 1 status is that only four hospitals have been granted a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.8549%; width: 76.8067%; height: 2.0214%;">licence to hold stocks of cannabis although all of them can hold heroin.44 Only a handful of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 43.7574%; width: 58.1513%; height: 1.78359%;">UK universities hold a Home Office Licence to do research on cannabis.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 46.3734%; width: 76.4706%; height: 2.0214%;">Research into cannabis can take place in a number of different ways with different objectives.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 48.2759%; width: 76.6387%; height: 2.0214%;">It can explore the characteristics and impact of the many different cannabinoids and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.0595%; width: 76.6387%; height: 2.0214%;">terpenes. (Terpenes are organic molecules which are understood to contribute to the smell
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.962%; width: 76.8067%; height: 2.0214%;">and taste of plants, e.g. the distinctive smell of turpentine derived from pine resin.) It can
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.7455%; width: 76.6387%; height: 2.0214%;">involve pre-clinical trials of individual cannabinoids or particular combinations of one or two
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.648%; width: 76.8067%; height: 2.0214%;">cannabinoids conducted in vitro or by means of animal testing. As the review conducted by
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 57.4316%; width: 76.6387%; height: 2.0214%;">Mike Barnes has shown, there is a lot of documentation from these pre-clinical trials.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 59.3341%; width: 57.6471%; height: 2.0214%;">However, many of the results are yet to be tested in a full clinical trial.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.069%; width: 76.8067%; height: 2.0214%;">The experience of conducting clinical trials was described in evidence given by representatives
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.9715%; width: 76.6387%; height: 2.0214%;">of GW Pharmaceuticals who developed Sativex (nabiximols). They argued that in this process
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.7551%; width: 76.6387%; height: 2.0214%;">the demands of the clinical trials pose more of a challenge than overcoming the difficulties
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.6576%; width: 76.6387%; height: 2.0214%;">presented by Schedule 1 status. This point of view was also put forward by Gerald Heddell
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.4411%; width: 76.6387%; height: 2.0214%;">from MHRA. The situation of GW Pharmaceuticals may have been made easier after they
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 71.3436%; width: 76.6387%; height: 2.0214%;">were able to establish the cultivation of their own supply of cannabis which others who
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.1272%; width: 76.6387%; height: 2.0214%;">engage in cannabis research in the UK cannot do. But the initial negotiations with the Home
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.0297%; width: 76.6387%; height: 2.0214%;">Office to establish their own supply were extensive, and the installation of the necessary
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.8133%; width: 31.0924%; height: 2.0214%;">security equipment took five months.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.6671%; width: 76.8067%; height: 2.0214%;">While it is accepted that as far as medicine development is concerned, for those with
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.4507%; width: 76.6387%; height: 2.14031%;">considerable infrastructure and resources, the schedule question may not be so acute, it still
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 83.3532%; width: 76.6387%; height: 2.0214%;">seems to be a major obstacle for academic and pre-clinical research in the UK. And as our
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 85.1367%; width: 76.8067%; height: 2.0214%;">evidence review indicates, there are still some major gaps in our understanding of the medical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 87.0392%; width: 17.9832%; height: 2.0214%;">potential of cannabis.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/1032d374-3e76-40be-843d-85b5b9bacf7d" class="drive-viewer-paginated-page-img" alt="Page 32 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 33 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 75.9664%; height: 2.0214%;">In order to resolve some of the problems, a rescheduling of cannabis is recommended.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 10.107%; width: 76.4706%; height: 2.14031%;">Rescheduling to Schedule 2 puts cannabis on a par with heroin where there is a recognised
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.0095%; width: 76.6387%; height: 2.0214%;">therapeutic application, although heroin is characterised as being highly addictive.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.912%; width: 76.6387%; height: 2.0214%;">Accordingly, Schedule 2 drugs are subject to strict controls about the security of stocks kept
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.6956%; width: 76.8067%; height: 2.0214%;">for medicinal purposes. Our evidence review found that cannabis has a small dependency
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.5981%; width: 76.6387%; height: 2.0214%;">rate compared to tobacco and alcohol and the experience of the regulation of medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.3817%; width: 76.6387%; height: 2.0214%;">cannabis in the USA involves little leakage of cannabis stocks into the illegal market. A more
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.1653%; width: 76.3025%; height: 2.14031%;">appropriate schedule, given these factors, would be Schedule 4 alongside Sativex
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.0678%; width: 76.1345%; height: 2.0214%;">(nabiximols). The requirements for the security of medical stocks would then be less strict,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.8514%; width: 41.8487%; height: 2.14031%;">more proportionate to any risk and less expensive.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/3003d1c2-3e80-4f8e-88cd-fff73020f23e" class="drive-viewer-paginated-page-img" alt="Page 33 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 34 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 65.8824%; height: 3.09156%;">9. Models of regulation for medicinal purposes
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 76.8067%; height: 2.14031%;">The models of regulation for medicinal cannabis currently in operation fall into three broad
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.4578%; width: 6.38655%; height: 1.30797%;">groups:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 17.4792%; width: 76.4706%; height: 2.0214%;">1. the licensing of cannabis-based drugs which have been shown in clinical trials to pass the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 19.3817%; width: 73.7815%; height: 2.0214%;">appropriate tests for a medicine to be approved by national health authorities for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 21.8787%; width: 9.91597%; height: 1.42687%;">treatments;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.1867%; width: 76.6387%; height: 2.0214%;">2. models which allow herbal cannabis to be prescribed for a limited number of conditions
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 25.0892%; width: 73.7815%; height: 2.0214%;">and where cannabis is supplied via regulated outlets, such as pharmacies, and cultivated
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 26.8728%; width: 73.7815%; height: 2.0214%;">by licenced growers. This is the model adopted or being proposed by many European
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 28.7753%; width: 32.1008%; height: 2.0214%;">countries, Australia, Canada and Israel.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.6778%; width: 76.6387%; height: 2.0214%;">3. models similar to model 2 but with the added provision that individuals and/or informal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 32.5803%; width: 73.7815%; height: 2.0214%;">caregivers can grow a limited number of cannabis plants for medical use. This is the model
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 34.4828%; width: 53.9496%; height: 2.0214%;">in place in a number of the States within the USA and in Uruguay.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.2176%; width: 7.22689%; height: 1.9025%;">Model 1
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 40.0713%; width: 76.6387%; height: 2.0214%;">Most countries in Europe, Australia, Canada, the USA and many others have approved the use
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.9738%; width: 76.8067%; height: 2.0214%;">of cannabis-based drugs including Dronabinol and Sativex (nabiximols). The process by which
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.7574%; width: 76.6387%; height: 1.9025%;">these drugs have been developed and approved has been the standard one for the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 45.541%; width: 76.8067%; height: 2.0214%;">development of medicines with an additional struggle to get government consent and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.3246%; width: 76.8067%; height: 2.0214%;">licences to carry out the tests. The clinical trials properly involve stringent tests over a period
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.1082%; width: 76.8067%; height: 2.14031%;">of time and are very expensive. They require major investment, the cost of which is reflected
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.0107%; width: 76.8067%; height: 2.0214%;">in the price of the drugs. Importantly, these drugs have been developed while cannabis and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.7943%; width: 53.4454%; height: 1.78359%;">cannabis derivatives remained within the UN Schedules 1 and IV.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.648%; width: 76.8067%; height: 2.0214%;">The UN Schedule 1 is for substances that are highly addictive and liable to abuse ... and which
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.5505%; width: 76.6387%; height: 2.0214%;">have no medicinal value and Schedule IV is for certain drugs with particularly dangerous
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.7647%; top: 59.3341%; width: 37.3109%; height: 2.0214%;">properties and little or no therapeutic value.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.1879%; width: 76.8067%; height: 2.0214%;">The national scheduling of cannabis in Europe and elsewhere generally follows the UN
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.9715%; width: 76.8067%; height: 2.0214%;">position. This has led to anomalies where the particular approved cannabis-based drugs have
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.7551%; width: 76.6387%; height: 2.14031%;">been rescheduled to recognise their status as medicines while cannabis and its derivatives
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.6576%; width: 76.6387%; height: 2.0214%;">remain in the no medicinal value category. As described above, it also means that further
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.4411%; width: 52.1008%; height: 2.14031%;">research into the medicinal properties of cannabis is restricted.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.2949%; width: 76.6387%; height: 2.0214%;">A change in the medicinal schedule of cannabis would free up a wide range of research and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 74.1974%; width: 76.1345%; height: 2.0214%;">could lead to the development and approval of further medicines. As recommended earlier,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.981%; width: 76.8067%; height: 2.0214%;">the change of schedule should be from Schedule 1 to Schedule 4. Schedule 2 is for high harm
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 77.8835%; width: 76.8067%; height: 2.0214%;">drugs, such as opiates, which nonetheless have a medical application but where the security
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.6671%; width: 76.6387%; height: 2.0214%;">of medical stocks needs to be at the highest level. Schedule 4 acknowledges that drug harms
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.4507%; width: 54.7899%; height: 2.14031%;">are at a lower level and the same level of security is not necessary.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 84.3044%; width: 76.6387%; height: 2.0214%;">Rescheduling cannabis with no other reform would continue to leave the majority of patients
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.2069%; width: 46.2185%; height: 2.0214%;">needing medicinal cannabis with a number of problems:
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/228588da-3bb5-4398-acc7-8611eb1ffe15" class="drive-viewer-paginated-page-img" alt="Page 34 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 35 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 76.4706%; height: 2.0214%;">1. The availability of medicinal cannabis will not improve in the short term and it is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 10.2259%; width: 73.6134%; height: 2.0214%;">questionable whether any new cannabis-based drugs which might be developed and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 12.0095%; width: 73.7815%; height: 2.14031%;">approved sometime in the future will be easily available. As in the case of Sativex
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 13.912%; width: 71.0924%; height: 2.0214%;">(nabiximols) a NICE recommendation for availability on prescription is not guaranteed.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.8145%; width: 71.0924%; height: 2.0214%;">2. Many will not be able to afford a private prescription. The costs will be prohibitive.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.717%; width: 76.1345%; height: 2.0214%;">3. Many will continue to have problems with the approved cannabis-based drugs. For some,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 19.6195%; width: 73.6134%; height: 2.0214%;">the strength is too low. For others, the form of administration of the drug (such as the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 21.522%; width: 24.2017%; height: 2.0214%;">Sativex spray) is problematic.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.3056%; width: 69.5798%; height: 2.0214%;">4. For others, the proportion of THC and CBD will not been right for their condition.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 26.1593%; width: 75.9664%; height: 2.0214%;">In order to meet the needs of this large group of patients we need to consider other models.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.0131%; width: 7.22689%; height: 1.78359%;">Model 2
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 31.8668%; width: 76.4706%; height: 2.0214%;">In Europe, the system of regulation where herbal cannabis can be made available on
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.6504%; width: 71.2605%; height: 2.0214%;">prescription to patients was initially adopted by the Netherlands. The key features are:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.5042%; width: 69.5798%; height: 2.0214%;"> the creation of a special cannabis agency (a requirement of the UN conventions);
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.5256%; width: 53.9496%; height: 2.0214%;"> the cultivation of cannabis restricted to licenced growers; and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.4281%; width: 76.8067%; height: 2.0214%;"> a list of conditions for which herbal cannabis can be prescribed. The Netherlands has
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 42.3306%; width: 73.7815%; height: 2.0214%;">based this list on a literature review of the evidence and their system allows for the list of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 44.2331%; width: 50.2521%; height: 1.9025%;">approved conditions to expand should the evidence justify it.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.849%; width: 76.8067%; height: 2.14031%;">A number of other countries in Europe including Finland, Germany and Italy have set up
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.7515%; width: 76.8067%; height: 2.0214%;">systems where particular conditions can be treated with herbal cannabis. However, there is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.654%; width: 76.8067%; height: 2.0214%;">considerable room for improvement. Eligibility criteria can vary considerably. In Israel, the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.5565%; width: 76.8067%; height: 2.0214%;">scheme has granted licences for cannabis treatment to over 13 000 patients. Finlands system
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.459%; width: 76.8067%; height: 2.0214%;">is so restricted that there are less than a hundred registered patients. The registration
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.3615%; width: 76.6387%; height: 2.0214%;">procedure can be complex and difficult to navigate. In Europe, the supply from the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 58.1451%; width: 76.6387%; height: 2.0214%;">Netherlands has not kept up with the demand. The range of herbal cannabis strains is too
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.0476%; width: 76.6387%; height: 2.0214%;">limited and there are concerns about quality. Another issue is cost. Although the cost of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.9501%; width: 76.3025%; height: 2.0214%;">herbal cannabis from the Netherlands is significantly lower than Dronabinol and Sativex
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.8526%; width: 60.5042%; height: 2.0214%;">(nabiximols), it could be cheaper to grow it under licence in each country.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.7063%; width: 76.6387%; height: 2.0214%;">Some of the drawbacks to this model will be removed in Germany if its scheme for medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.4899%; width: 20.3361%; height: 2.0214%;">marijuana becomes law:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 71.3436%; width: 72.605%; height: 2.0214%;"> Treatment will be based on a doctors prescription. Registration will not be required.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.365%; width: 59.1597%; height: 2.0214%;"> Over 60 conditions will be eligible for medicinal cannabis treatment.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 70.7563%; top: 73.7218%; width: 1.84874%; height: 0.951249%;">45
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.2675%; width: 76.6387%; height: 2.0214%;"> While in the first instance herbal cannabis will be imported, Germany intends to produce
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 77.17%; width: 35.1261%; height: 2.0214%;">a range of pharmaceutical grade products.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.0725%; width: 70.2521%; height: 2.14031%;"> The cost will be at least partly covered by the German health insurance scheme.46
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.0939%; width: 76.8067%; height: 2.0214%;"> The cost of herbal cannabis is considerably less than that of Sativex. In the UK, the cost of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 82.9964%; width: 73.1092%; height: 2.0214%;">Sativex, where available, is over 150 per week whereas the weekly cost of Bedrocan
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 84.78%; width: 73.7815%; height: 2.14031%;">(supplied from the Netherlands and having a comparable balance of THC and CBD) is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 87.0392%; width: 5.37815%; height: 1.42687%;">20.47
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/d291c913-dd57-426b-95a5-c60f6b48049b" class="drive-viewer-paginated-page-img" alt="Page 35 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 36 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.44233%; width: 76.6387%; height: 2.0214%;"> A particular feature of the German proposal is a requirement for patients receiving
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 10.2259%; width: 73.7815%; height: 2.0214%;">medicinal cannabis paid for by the health insurance scheme to agree to take part in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 12.1284%; width: 61.3445%; height: 2.0214%;">research trials. It is not proposed that this practice be replicated in the UK.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.9822%; width: 76.8067%; height: 2.0214%;">One of the drivers of this model is that the State concerned is trying to reduce patient reliance
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.8847%; width: 76.8067%; height: 2.0214%;">not only on street cannabis but also grow your own. This is based on a perspective that the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.6683%; width: 76.6387%; height: 2.0214%;">state should not be sanctioning or condoning use of a treatment product where quality,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.5707%; width: 76.6387%; height: 2.0214%;">impurities and dosage cannot be controlled. The other concern is that there may be an
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.3543%; width: 76.8067%; height: 2.0214%;">overlap between grow your own and the illicit drugs trade. All current examples of the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.2568%; width: 76.8067%; height: 2.0214%;">regulation of forms of medicinal cannabis apart from Uruguay, some American States and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.0404%; width: 76.8067%; height: 2.0214%;">perhaps Spain, retain laws where trade in cannabis for recreational use is illegal. Concern
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.9429%; width: 76.8067%; height: 2.0214%;">about quality where the cultivation of cannabis for personal use is permitted was expressed
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.7265%; width: 51.0924%; height: 2.0214%;">by one of the expert witnesses giving evidence to the hearing.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 32.5803%; width: 76.6387%; height: 2.0214%;">My personal view is that growth should be controlled, as opposed to some of the States in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.3639%; width: 76.6387%; height: 2.0214%;">the United States where you can grow your own in your backyard. That is not satisfactory,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.2663%; width: 76.6387%; height: 2.0214%;">because it allows so many different varieties, types and impurities to be incorporated. I would
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.1688%; width: 76.6387%; height: 2.0214%;">like to see growth controlled, such as the Bedrocan initiative and Sativex. It allows for quality
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.0713%; width: 26.3866%; height: 1.78359%;">control. Professor Mike Barnes
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 42.9251%; width: 76.6387%; height: 2.0214%;">In order to ensure much wider availability of pharmaceutical grade herbal cannabis, it is
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.7087%; width: 76.6387%; height: 1.9025%;">recommended that a scheme incorporating the main features of the proposed German
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.4923%; width: 31.4286%; height: 2.0214%;">legislation are introduced into the UK.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.2271%; width: 72.605%; height: 2.0214%;">Model 3: availability of herbal cannabis for medicinal purposes including provision for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.1296%; width: 32.2689%; height: 2.0214%;">individuals to grow their own supplies
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.8644%; width: 76.8067%; height: 2.0214%;">Schemes allowing individuals to grow their own medicinal supplies are present in Uruguay
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.7669%; width: 76.8067%; height: 2.0214%;">and some American States; here, the option for grow your own can operate alongside
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.5505%; width: 76.6387%; height: 2.0214%;">models 1 and 2 and in some cases within the context of the regulation of cannabis for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 59.453%; width: 76.6387%; height: 2.0214%;">recreational use. In Spain, Cannabis Social Clubs are the only way in which medicinal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 61.2366%; width: 76.6387%; height: 2.0214%;">users can access herbal cannabis. There is some evidence that those jurisdictions intending
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.1391%; width: 76.8067%; height: 2.0214%;">to introduce a scheme for regulating herbal cannabis by means of a licenced supplier are
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.9227%; width: 76.1345%; height: 2.0214%;">doing so, in part, because of concerns that there is more of a risk that a grow your own
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.8252%; width: 76.6387%; height: 2.0214%;">scheme will leak into the illicit recreational market. Germany and the regional government in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.6088%; width: 76.8067%; height: 2.0214%;">Catalonia, Spain who have been considering a scheme for licenced commercial growers on
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.5113%; width: 44.7059%; height: 2.0214%;">behalf of the State are two examples of this approach.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.2461%; width: 76.8067%; height: 2.0214%;">A key issue that patients may consider is cost. Even at 20 a week the cost of herbal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.1486%; width: 76.8067%; height: 2.0214%;">for the treatment of a chronic condition where the patient is not able to work is a significant
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.9322%; width: 76.6387%; height: 2.0214%;">financial burden. In Uruguay, medicinal cannabis sold via pharmacies is likely to be more
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.8347%; width: 76.6387%; height: 2.0214%;">expensive than recreational cannabis as it is grown under stricter conditions and will have a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 80.6183%; width: 76.6387%; height: 2.0214%;">greater variety of strains. This may well encourage the numbers registering to grow their own.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.5208%; width: 76.6387%; height: 2.0214%;">An important feature of any state scheme for regulated access to herbal cannabis will be to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.3044%; width: 43.6975%; height: 2.0214%;">subsidise it through a state health insurance scheme.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/345db964-9305-4fad-945a-994bc57fe9ae" class="drive-viewer-paginated-page-img" alt="Page 36 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 37 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">Testimony from the users of medicinal cannabis at the hearings, case studies and the survey
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 10.107%; width: 76.6387%; height: 2.14031%;">of users of medicinal cannabis suggests that some at least try different strains of cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.0095%; width: 76.6387%; height: 2.0214%;">until they find the ones that work best for them. Decriminalisation of home growing of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.7931%; width: 73.6134%; height: 2.14031%;">medicinal cannabis would allow more flexibility in determining the type of cannabis used.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.6468%; width: 76.1345%; height: 2.0214%;">A system of state-controlled, licenced production can guarantee quality, ensure the product
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.5493%; width: 76.8067%; height: 2.0214%;">is free from pesticides and other impurities and ensure specified levels of the main
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 76.8067%; height: 2.0214%;">cannabinoids in the particular strains selected. However, lower cost, avoiding the illicit market
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.2354%; width: 76.6387%; height: 2.0214%;">and flexibility for users in experimenting with the strain and dosage that works best for them
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.019%; width: 76.8067%; height: 2.0214%;">are more easily achieved in a system of decriminalised grow your own. A state-sponsored
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.8026%; width: 76.6387%; height: 2.14031%;">resource could be made available to growers advising on growing methods and quality
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.1807%; width: 6.72269%; height: 1.30797%;">control.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/3f58cbc6-262c-4e1f-a387-04a3afb41cc0" class="drive-viewer-paginated-page-img" alt="Page 37 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 38 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 53.6134%; height: 2.73484%;">10. Conclusions and recommendations
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.3175%; width: 10.2521%; height: 1.30797%;">Conclusions
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.6956%; width: 76.8067%; height: 2.0214%;">This Inquiry has produced strong evidence from Mike Barnes, Professor of Neurological
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 17.4792%; width: 76.4706%; height: 2.14031%;">Rehabilitation; senior health professionals; patients taking cannabis to control chronic pain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.3817%; width: 76.6387%; height: 2.0214%;">and other debilitating symptoms; the MHRA and others to prove that policy reform in this
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.1653%; width: 17.3109%; height: 2.0214%;">field is long overdue.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.019%; width: 27.563%; height: 2.0214%;">The Inquiry Panel concludes that:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 26.7539%; width: 76.4706%; height: 2.0214%;">1. Patients suffering chronic severe conditions should not risk arrest if they obtain cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 28.6564%; width: 73.1092%; height: 2.0214%;">as a treatment, when other treatments have failed or generate unacceptable side effects.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.5589%; width: 76.8067%; height: 2.0214%;">2. The inclusion of cannabis in Schedule 1 (the schedule for substances with no medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 32.4614%; width: 73.6134%; height: 2.0214%;">value) is no longer sustainable. There is now a sound evidence base showing cannabis to
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 34.3639%; width: 37.479%; height: 2.0214%;">be effective for a range of chronic conditions.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.1474%; width: 76.8067%; height: 2.0214%;">3. Some estimated 30,000 patients in the UK use cannabis or cannabis-based products as
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 38.0499%; width: 60.6723%; height: 2.0214%;">medicines on a daily basis. This could entail as much as 1,000,000 in total.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.9524%; width: 76.6387%; height: 2.0214%;">4. Cannabis-based medicines have an established place in the management of chronic pain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 41.8549%; width: 8.40336%; height: 1.78359%;">in the UK.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.7574%; width: 76.6387%; height: 1.9025%;">5. Many countries now have or are introducing a form of cannabis regulation to ensure
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 45.541%; width: 73.6134%; height: 1.9025%;">access to herbal cannabis to help those with serious chronic conditions, where
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 47.3246%; width: 37.479%; height: 2.0214%;">prescription medicines have been ineffective.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.654%; width: 16.1345%; height: 1.30797%;">Recommendations
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 52.9132%; width: 76.4706%; height: 2.14031%;">1. Cannabis should be included in Schedule 4 rather than Schedule 1, thus promoting
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 55.2913%; width: 7.89916%; height: 1.30797%;">research.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.7182%; width: 76.1345%; height: 2.0214%;">2. A scheme incorporating the main features of the proposed German legislation should be
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 58.6207%; width: 73.7815%; height: 2.0214%;">introduced into the UK to ensure much wider availability of medicinal cannabis. Herbal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 60.4043%; width: 73.6134%; height: 2.0214%;">cannabis would thus be available on prescription for the treatment of specified
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 62.3068%; width: 73.6134%; height: 2.0214%;">conditions, paid for by the NHS for those conditions. Medicinal cannabis would be
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 64.0904%; width: 71.7647%; height: 2.0214%;">produced by licenced producers and sold through licenced outlets, such as pharmacies.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.9929%; width: 76.6387%; height: 2.0214%;">3. The Government should decriminalise home growing of small quantities of cannabis for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 67.7765%; width: 59.4958%; height: 2.0214%;">medicinal purposes as is the case in Uruguay and some American States.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/9cb04ad1-d3ce-474f-aa38-c06061a901b9" class="drive-viewer-paginated-page-img" alt="Page 38 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 39 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 73.7815%; height: 3.09156%;">Appendix 1: Those giving evidence and the APPG panel
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 14.7899%; height: 1.9025%;">Written evidence
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.409%; width: 66.0504%; height: 2.0214%;">Written evidence was received from the following organisations and individuals:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.1439%; width: 28.5714%; height: 1.78359%;">The National Police Chiefs Council
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.8787%; width: 56.3025%; height: 2.14031%;">The Medicines and Health Care Products Regulatory Agency (MHRA)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.7325%; width: 47.7311%; height: 2.0214%;">GW Pharmaceuticals (developers and suppliers of Sativex)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.5862%; width: 45.7143%; height: 2.0214%;">The Drug Policy Alliance (DPA), a US-based organisation
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.321%; width: 28.5714%; height: 2.0214%;">The United Patients Alliance (UPA)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.1748%; width: 53.4454%; height: 2.0214%;">The UK Law Enforcement Against Prohibition (LEAP) organisation
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 35.9096%; width: 27.563%; height: 2.0214%;">Cannabis Law Reform UK (CLEAR)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 38.7634%; width: 16.9748%; height: 1.78359%;">Professor Val Curran
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 41.4982%; width: 76.4706%; height: 2.0214%;">Professor Les Iverson, Chair of the Advisory Council for the Misuse of Drugs (in a personal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.7574%; width: 7.73109%; height: 1.66468%;">capacity)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 46.0166%; width: 18.8235%; height: 2.0214%;">Patients: LS, CS and NE
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.5351%; width: 11.9328%; height: 1.78359%;">Oral evidence
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 53.3888%; width: 75.9664%; height: 2.0214%;">Four hearings were arranged on the 10 and 24 February and the 2 and 9 March 2016 in
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.1724%; width: 74.6218%; height: 2.0214%;">Committee Rooms at the House of Lords. At each hearing, those giving oral evidence were:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 58.0262%; width: 14.958%; height: 2.0214%;">10 February 2016
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 61.1177%; width: 67.8992%; height: 2.0214%;">Professor Val Curran, Professor of Psychopharmacology, University College London
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 63.9715%; width: 76.6387%; height: 2.0214%;">Professor Les Iverson, Chair of the Advisory Council for the Misuse of Drugs (in a personal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.2307%; width: 7.73109%; height: 1.54578%;">capacity)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.6088%; width: 37.479%; height: 2.0214%;">Jonathan Liebling, Political Officer of the UPA
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 71.3436%; width: 38.6555%; height: 1.9025%;">LS  a user of medicinal cannabis for treatment
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 74.1974%; width: 39.1597%; height: 1.78359%;">CS  a user of medicinal cannabis for treatment
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 77.0511%; width: 14.958%; height: 2.0214%;">24 February 2016
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 80.1427%; width: 76.6387%; height: 2.0214%;">Professor Mike Barnes, Honorary Professor of Neurological Rehabilitation, Newcastle
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 82.5208%; width: 8.57143%; height: 1.54578%;">University
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 84.78%; width: 71.5966%; height: 2.0214%;">Dr David Potter JP, Director of Botanical Research and Cultivation, GW Pharmaceuticals
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 87.6338%; width: 56.4706%; height: 2.0214%;">Dr Stephen Wright, the Chief Medical Officer of GW Pharmaceuticals
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/4c2686c8-fd88-4875-80c3-b3e91b5bb1f2" class="drive-viewer-paginated-page-img" alt="Page 39 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 40 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 29.916%; height: 2.0214%;">Nick Ellis, Chief Executive UKCBD Ltd
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 11.0583%; width: 26.0504%; height: 2.0214%;">Lisa-Marie, Francom UKCBD Ltd
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 13.912%; width: 27.395%; height: 2.0214%;">Jason Reed, Chief Executive LEAP
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 16.6468%; width: 14.1176%; height: 1.9025%;">Neil Woods LEAP
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 19.5006%; width: 11.9328%; height: 1.78359%;">2 March 2016
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.7111%; width: 76.6387%; height: 2.0214%;">Tom Lloyd (former Chief Constable of Cambridgeshire), Chair of the National Cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.9703%; width: 7.56303%; height: 1.30797%;">Coalition
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 27.3484%; width: 35.1261%; height: 2.0214%;">Roland Gyallay-Pap, Chief Executive CLEAR
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 30.0832%; width: 27.395%; height: 2.0214%;">Peter Reynolds, President, CLEAR
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 32.937%; width: 11.9328%; height: 1.78359%;">9 March 2016
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.0285%; width: 18.8235%; height: 2.0214%;">Gerald Heddell, MHRA
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 38.8823%; width: 28.5714%; height: 1.9025%;">Bernadette Sinclair-Jenkins, MHRA
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.4709%; width: 30.084%; height: 1.9025%;">APPG members present at hearings
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.0868%; width: 37.3109%; height: 2.0214%;">APPG members present at hearings included:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.9405%; width: 23.6975%; height: 2.0214%;">Caroline Lucas MP (Co-chair)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 52.6754%; width: 23.8655%; height: 2.0214%;">Baroness Meacher (Co-chair)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 55.5291%; width: 16.1345%; height: 2.0214%;">Baroness Walmsley
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 58.264%; width: 15.2941%; height: 1.78359%;">Baroness Hamwee
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 61.1177%; width: 7.39496%; height: 1.78359%;">Lord Rea
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 63.8526%; width: 10.2521%; height: 1.78359%;">Lord Walton
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.7063%; width: 11.5966%; height: 1.78359%;">Jeff Smith MP
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 69.4411%; width: 8.23529%; height: 1.78359%;">Lord Dear
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 72.2949%; width: 11.4286%; height: 1.78359%;">Lord Howarth
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 75.0297%; width: 15.1261%; height: 1.78359%;">Lord Ramsbotham
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 77.8835%; width: 10.084%; height: 1.78359%;">Lord Norton
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 80.6183%; width: 13.7815%; height: 1.78359%;">Lord MacLennan
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 83.4721%; width: 14.6218%; height: 2.0214%;">Mary Glindon MP
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 86.2069%; width: 16.3025%; height: 2.0214%;">Paul Monaghan MP
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 89.0606%; width: 13.4454%; height: 1.78359%;">Baroness Afshar
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/2a8d85d6-7185-4e56-8439-c9e0a0f78dc2" class="drive-viewer-paginated-page-img" alt="Page 40 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 41 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 75.9664%; height: 3.09156%;">Appendix 2: Survey of those who use medicinal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 45.042%; height: 2.0214%;">All-Party Parliamentary Group for Drug Policy Reform
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.6956%; width: 26.5546%; height: 2.0214%;">Inquiry into medicinal cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.4304%; width: 76.6387%; height: 2.0214%;">This questionnaire is intended to look at the extent and range of use of cannabis for medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 76.8067%; height: 2.0214%;">purposes in the UK. This questionnaire was administered by the United Patients Alliance.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 22.1165%; width: 40.6723%; height: 2.0214%;">Responses were taken in the strictest confidence.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.9703%; width: 43.1933%; height: 2.0214%;">Questionnaire for those using cannabis medicinally
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 27.7051%; width: 17.9832%; height: 2.0214%;">1. What is your age?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.5589%; width: 32.2689%; height: 2.0214%;">2. What is your gender? Male/Female
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.4126%; width: 52.7731%; height: 2.0214%;">3. What is your ethnicity? White/Asian/African/Afro-Caribbean
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.2663%; width: 29.7479%; height: 2.0214%;">4. What is your medical condition?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.1201%; width: 35.1261%; height: 2.0214%;">5. How long have you had this condition?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.8549%; width: 76.6387%; height: 2.0214%;">6. What medicines have you been prescribed for this condition by your doctor or a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 44.2331%; width: 9.91597%; height: 1.30797%;">consultant?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.4923%; width: 53.2773%; height: 2.0214%;">7. How effective has this medication been? (Please give details)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.346%; width: 56.6387%; height: 2.0214%;">8. What are the side effects of this medication? (Please give details)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.1998%; width: 76.8067%; height: 2.0214%;">9. How long after you had been prescribed other medicines did you decide that cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 53.9834%; width: 34.4538%; height: 2.0214%;">was a viable medicine for your condition?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 56.8371%; width: 32.2689%; height: 2.0214%;">10. How did you come to this decision?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 59.6908%; width: 49.0756%; height: 2.0214%;">11. What was the view of your GP or Consultant about this?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 62.5446%; width: 37.479%; height: 2.0214%;">12. How long have you been taking cannabis?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 65.3983%; width: 32.437%; height: 2.0214%;">13. In what form do you take cannabis?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 68.1332%; width: 65.3782%; height: 2.14031%;">14. Can you describe the effect that taking cannabis has had on your condition?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 70.9869%; width: 45.8824%; height: 2.0214%;">15. What have been the side effects of taking cannabis?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 73.8407%; width: 74.1176%; height: 2.0214%;">16. How do you obtain your cannabis? (Please do not feel obliged to answer this question)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 76.6944%; width: 19.8319%; height: 1.78359%;">17. How difficult is this?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 79.5482%; width: 45.2101%; height: 2.0214%;">18. How risky is it in terms of compliance with the law?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 82.283%; width: 69.7479%; height: 2.14031%;">19. If there are risks involved in obtaining your cannabis what do you feel about this?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 85.1367%; width: 76.6387%; height: 2.0214%;">20. What do you think should happen in terms of the law to make it easier/less risky to obtain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 87.0392%; width: 23.6975%; height: 2.0214%;">cannabis for your condition?
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/1d94c043-99f9-4dda-934b-312b71d7b638" class="drive-viewer-paginated-page-img" alt="Page 41 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 42 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 76.8067%; height: 2.0214%;">21. Have you had any advice about using cannabis for your condition from a person or
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 10.2259%; width: 35.7983%; height: 2.0214%;">organisation other than your GP or doctor?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.9608%; width: 22.0168%; height: 1.9025%;">22. What was that advice?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.8145%; width: 23.6975%; height: 2.0214%;">23. How helpful has it been?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.6683%; width: 55.2941%; height: 2.0214%;">24. Do you have any other comments that you would like to make?
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/9f9cac15-ad8a-46b7-ac17-8cb18f002a7b" class="drive-viewer-paginated-page-img" alt="Page 42 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 43 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 74.958%; height: 3.09156%;">Appendix 3: Brief Survey for health professionals on the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 11.415%; width: 35.1261%; height: 2.73484%;">medicinal use of cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 16.0523%; width: 45.3782%; height: 2.0214%;">1. Can you briefly describe in general terms your role?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.8359%; width: 76.6387%; height: 2.14031%;">2. Have you experience of patients who are using cannabis for their condition either
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 19.7384%; width: 73.6134%; height: 2.0214%;">prescribed in the form of Sativex or Dronabinol or imported as Bedrocan from the
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 15.1261%; top: 21.6409%; width: 40.8403%; height: 2.0214%;">Netherlands or obtained by other means? Yes/No
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.5434%; width: 54.1176%; height: 2.0214%;">3. If yes can you estimate the number of such patients in a year?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.4459%; width: 48.0672%; height: 2.0214%;">4. What conditions is cannabis being used for? Please list
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.2295%; width: 76.6387%; height: 2.14031%;">5. What in your judgement has been the impact of cannabis use on the condition/s described
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 29.6076%; width: 6.21849%; height: 1.30797%;">above?
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.9857%; width: 76.8067%; height: 2.0214%;">Would you be willing to be contacted further on this issue? (If so please enter email and/or
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.8882%; width: 21.6807%; height: 2.0214%;">phone number and name)
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/4add3376-e319-4c54-990f-38607abc48a3" class="drive-viewer-paginated-page-img" alt="Page 43 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 44 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 65.2101%; height: 3.09156%;">Appendix 4: Marks medications prior to starting
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 11.415%; width: 33.7815%; height: 2.73484%;">treatment with cannabis
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 16.0523%; width: 76.6387%; height: 2.0214%;"> Phenytoin (to reduce fits): tripled dose when ineffective, then stopped due to side effects
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 18.3115%; width: 8.23529%; height: 1.66468%;">(judders);
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.8086%; width: 76.6387%; height: 2.0214%;"> Carbamazepine (to reduce fits): tripled dose then changed medication. Ineffective and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 22.5922%; width: 14.958%; height: 2.0214%;">reduced memory;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.5648%; width: 76.6387%; height: 2.0214%;"> Gabapentin (for headache): stopped. It was ineffective and caused side effect of night
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 27.9429%; width: 6.38655%; height: 1.42687%;">terrors;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.2021%; width: 25.5462%; height: 2.0214%;"> Omeprazole (for vomiting);
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.0559%; width: 61.0084%; height: 2.0214%;"> Lamotrigine (to reduce fits). Helped but did not stop them completely;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.0285%; width: 53.7815%; height: 2.0214%;"> Clopidogrel (to thin the blood) post-heart attack for one year;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 38.8823%; width: 53.1092%; height: 2.0214%;"> Bisoprolol (to improve heart function post first heart attack);
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.736%; width: 76.6387%; height: 2.0214%;"> Ramipril (to reduce blood pressure after first heart attack). Stopped after two weeks due
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 14.958%; top: 43.5196%; width: 47.563%; height: 2.0214%;">to very low blood pressure. Caused postural hypotension;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.2545%; width: 59.6639%; height: 2.14031%;"> Aspirin (to thin the blood). Still on this following second heart attack;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.2271%; width: 55.2941%; height: 2.0214%;"> Simvastatin (to lower cholesterol). In fact cholesterol is normal;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.0809%; width: 60.5042%; height: 2.0214%;"> Amitriptyline (to control headaches and assist with sleep). Ineffective.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/800da5d1-340d-4d09-8ef3-5fda7d29f019" class="drive-viewer-paginated-page-img" alt="Page 44 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"><a href="http://www.evidence.nhs.uk/formulary/bnf/current/4-centralnervous-system/46-drugs-used-in-nausea-and-vertigo/cannabinoid/nabilone" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.evidence.nhs.uk/formulary/bnf/current/4-centralnervous-system/46-drugs-used-in-nausea-and-vertigo/cannabinoid/nabilone" style="left: 11.9328%; top: 14.8633%; width: 75.7983%; height: 2.85375%;"></a><a href="https://www.theguardian.com/world/2016/mar/24/uruguay-legal-marijuana-next-phase-regulation" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.theguardian.com/world/2016/mar/24/uruguay-legal-marijuana-next-phase-regulation" style="left: 11.9328%; top: 19.1439%; width: 63.3613%; height: 1.42687%;"></a><a href="http://www.governing.com/topics/public-justice-safety/gov-medical-marijuana-becoming-mainstream.html" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.governing.com/topics/public-justice-safety/gov-medical-marijuana-becoming-mainstream.html" style="left: 11.9328%; top: 23.5434%; width: 69.5798%; height: 1.42687%;"></a><a href="http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx" style="left: 11.9328%; top: 27.9429%; width: 45.7143%; height: 1.30797%;"></a><a href="http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881#Massachusetts" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881#Massachusetts" style="left: 22.6891%; top: 30.7967%; width: 63.5294%; height: 1.42687%;"></a><a href="http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881#Massachusetts" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881#Massachusetts" style="left: 22.6891%; top: 35.1962%; width: 63.5294%; height: 1.42687%;"></a><a href="http://csdp.org/research/2005TeenUseReport.pdf" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://csdp.org/research/2005TeenUseReport.pdf" style="left: 40.1681%; top: 68.371%; width: 34.7899%; height: 1.42687%;"></a><a href="http://ftp.iza.org/dp6592.pdf" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://ftp.iza.org/dp6592.pdf" style="left: 34.4538%; top: 77.17%; width: 20.5042%; height: 1.42687%;"></a></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 45 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 12.1008%; top: 8.32342%; width: 13.4454%; height: 2.73484%;">Endnotes
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.5065%; width: 75.1261%; height: 3.21046%;">1British National Formulary. Nabilone. Available from: www.evidence.nhs.uk/formulary/bnf/current/4-central-
nervous-system/46-drugs-used-in-nausea-and-vertigo/cannabinoid/nabilone (accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.3603%; width: 69.7479%; height: 1.78359%;">2Uruguays legal marijuana policy en route to next phase of regulation. The Guardian. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.9061%; width: 75.4622%; height: 1.66468%;">www.theguardian.com/world/2016/mar/24/uruguay-legal-marijuana-next-phase-regulation (6/16) (accessed
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.3329%; width: 13.7815%; height: 1.66468%;">2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.7598%; width: 74.2857%; height: 1.78359%;">3Governing the states and localities. Medical Marijuana: Do States Know How to Regulate It? Available from
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 23.5434%; width: 69.5798%; height: 1.42687%;">www.governing.com/topics/public-justice-safety/gov-medical-marijuana-becoming-mainstream.html
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.6136%; width: 20.6723%; height: 1.78359%;">(accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 26.1593%; width: 61.5126%; height: 1.66468%;">4National Conference of State Legislatures. State medical marijuana laws. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.5862%; width: 66.3866%; height: 1.66468%;">www.ncsl.org/research/health/state-medical-marijuana-laws.aspx (accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 29.0131%; width: 73.4454%; height: 1.78359%;">5ProCon.org. 24 Legal Medical Marijuana States and DC, Laws, Fees, and Possession Limits: State of Maine.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.44%; width: 74.2857%; height: 1.78359%;">Available from: http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881#Massachusetts
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.8668%; width: 20.6723%; height: 1.78359%;">(accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.4126%; width: 73.4454%; height: 1.66468%;">6ProCon.org. 24 Legal Medical Marijuana States and DC, Laws, Fees, and Possession Limits: Massachusetts.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.8395%; width: 74.2857%; height: 1.78359%;">Available from: http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881#Massachusetts
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.2663%; width: 20.6723%; height: 1.78359%;">(accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.6932%; width: 70.9244%; height: 1.78359%;">7Ethan Nadelmann, Executive Director, Drug Policy Alliance (1 July 2015): Overview of Marijuana Policy
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.1201%; width: 27.0588%; height: 1.78359%;">Reforms in the U.S. and Internationally.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.6659%; width: 74.2857%; height: 1.66468%;">8Morris RG et al. The effect of medical marijuana laws on crime: evidence from state panel data, 19902006.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 42.0927%; width: 75.9664%; height: 1.78359%;">PLoS One. 2014;9(3):e92816; The central finding gleaned from the present study was that [medical marijuana
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.5196%; width: 74.958%; height: 1.78359%;">legalization] is not predictive of higher crime rates and may be related to reductions in rates of homicide and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.9465%; width: 74.4538%; height: 3.09156%;">assault.; see also Anderson DM &amp; Rees DI. The legalization of recreational marijuana: how likely is the worst-
case scenario? J Policy Anal Manage. 2014;33(1):221232(anticipating a decrease in violent and property
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.8002%; width: 43.1933%; height: 1.66468%;">crime because of the likely decreased consumption of alcohol).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 49.4649%; width: 0.840336%; height: 0.832342%;">9
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 12.437%; top: 49.2271%; width: 69.4118%; height: 1.78359%;">Id; see also Kepple NJ &amp; Freisthler B. Exploring the ecological association between crime and medical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.654%; width: 75.6303%; height: 1.78359%;">marijuana dispensaries. J Stud Alcohol Drugs. 2012;73(4):523-30 (showing no association between the density
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 52.0809%; width: 74.4538%; height: 1.78359%;">of medical marijuana dispensaries and violent or property crime rates); Freisthler B et al. Evaluating medical
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.6266%; width: 73.2773%; height: 1.66468%;">marijuana dispensary policies: spatial methods for the study of environmentally-based interventions. Am J
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 55.0535%; width: 72.2689%; height: 1.66468%;">Community Psychol. 2013;51(12):278288 (finding that security measures like surveillance cameras and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.4804%; width: 58.3193%; height: 1.78359%;">doormen may reduce crime within the immediate vicinity of marijuana dispensaries).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.9073%; width: 59.3277%; height: 1.78359%;">10Evidence as in 11 cited by Professor Val Curran in oral evidence on 10 February 2016.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 59.3341%; width: 72.7731%; height: 1.78359%;">11See Hasin DS et al. Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.8799%; width: 72.437%; height: 1.66468%;">results from annual, repeated cross-sectional surveys. Lancet Psychiatry. 2015;2:601608; Gorman DM &amp;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.3068%; width: 74.958%; height: 1.66468%;">Charles Huber J Jr. Do medical cannabis laws encourage cannabis use? Int J Drug Policy. 2007;18(3):160167;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.7337%; width: 75.9664%; height: 1.78359%;">Harper S, Strumpf EC &amp; Kaufman JS. Do medical marijuana laws increase marijuana use? Replication study and
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 65.1605%; width: 32.605%; height: 1.78359%;">extension. Ann Epidemiol. 2012;22(3):207212.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.5874%; width: 72.1008%; height: 1.78359%;">12OKeefe K &amp; Earleywine M. Marijuana use by young people: the impact of state medical marijuana laws.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 68.1332%; width: 71.5966%; height: 1.66468%;">Marijuana Policy Project. Available from: http://csdp.org/research/2005TeenUseReport.pdf (accessed 2
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.56%; width: 12.1008%; height: 1.78359%;">September 2016.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.9869%; width: 74.7899%; height: 1.78359%;">13Lynne-Landsman SD, Livingston MD &amp; Wagenaar AC. Effects of state medical marijuana laws on adolescent
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.4138%; width: 71.5966%; height: 1.78359%;">marijuana use. Am J Public Health. 2013;103(8):15001506; Anderson DM &amp; Rees DI. The legalization of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.8407%; width: 72.7731%; height: 1.78359%;">recreational marijuana: how likely is the worst-case scenario? J Policy Anal Manage. 2014;33(1):221232;
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.3864%; width: 75.4622%; height: 1.66468%;">Anderson DM, Hansen B &amp; Rees DI. Medical marijuana laws and teen marijuana use. IZA Discussion Paper No.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 76.8133%; width: 73.4454%; height: 1.78359%;">6592, May 2012. Available from: http://ftp.iza.org/dp6592.pdf (accessed 2 September 2016) (showing that
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.2402%; width: 72.9412%; height: 1.78359%;">teen use rates do not change when states legalized medical marijuana); Choo EK et al. The impact of state
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.6671%; width: 74.6218%; height: 1.78359%;">medical marijuana legislation on adolescent marijuana use. J Adolesc Health. 2014;55(2):160166 (showing a
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.2128%; width: 72.9412%; height: 1.66468%;">statistically significant difference in youth marijuana use before and the legalisation of medical marijuana).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.6397%; width: 72.437%; height: 1.66468%;">14Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.0666%; width: 51.0924%; height: 1.78359%;">evidence from epidemiological studies. Accid Anal Prev. 2013;60:254267.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 85.4935%; width: 73.4454%; height: 1.78359%;">15Bachhuber MA et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.9203%; width: 39.1597%; height: 1.78359%;">19992010. JAMA Intern Med. 2014;174(10):16681673.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 0.840336%; height: 1.66468%;">
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/8fafc70f-c137-45fb-a833-bc72e9c6c7b8" class="drive-viewer-paginated-page-img" alt="Page 45 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"><a href="http://www.drugpolicy.org/drug-overdose" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.drugpolicy.org/drug-overdose" style="left: 55.6303%; top: 13.1986%; width: 25.3782%; height: 1.42687%;"></a><a href="http://ftp.iza.org/dp6280.pdf" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://ftp.iza.org/dp6280.pdf" style="left: 36.8067%; top: 33.5315%; width: 20.5042%; height: 1.42687%;"></a><a href="http://sundhedsstyrelsen.dk/en/news/2014/~/media/57439DD97F054C60AE9B6A7FFC68F3BC.ashx" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://sundhedsstyrelsen.dk/en/news/2014/~/media/57439DD97F054C60AE9B6A7FFC68F3BC.ashx" style="left: 11.9328%; top: 42.2117%; width: 68.7395%; height: 1.42687%;"></a><a href="http://www.cannabisbureau.nl/en/doc/pdf/5089-A5-BMC-Pat-ENG-web_35842.pdf" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.cannabisbureau.nl/en/doc/pdf/5089-A5-BMC-Pat-ENG-web_35842.pdf" style="left: 11.9328%; top: 52.1998%; width: 53.1092%; height: 1.42687%;"></a><a href="http://www.cannabisbureau.nl/Media/Default/PDF/5089-A5-BMC-Pat-ENG-web_35842.pdf" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.cannabisbureau.nl/Media/Default/PDF/5089-A5-BMC-Pat-ENG-web_35842.pdf" style="left: 11.9328%; top: 55.1724%; width: 58.6555%; height: 1.42687%;"></a><a href="https://www.rt.com/news/341745-medical-marijuana-germany-legalization/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="https://www.rt.com/news/341745-medical-marijuana-germany-legalization/" style="left: 11.9328%; top: 63.8526%; width: 54.1176%; height: 1.42687%;"></a><a href="https://sensiseeds.com/en/blog/legal-status-of-cannabis-in-italy-an-overview/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="https://sensiseeds.com/en/blog/legal-status-of-cannabis-in-italy-an-overview/" style="left: 11.9328%; top: 66.7063%; width: 54.1176%; height: 1.42687%;"></a><a href="https://sensiseeds.com/en/blog/legal-status-of-cannabis-in-italy-an-overview/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="https://sensiseeds.com/en/blog/legal-status-of-cannabis-in-italy-an-overview/" style="left: 11.9328%; top: 69.679%; width: 54.1176%; height: 1.42687%;"></a><a href="http://drugpolicyreform.net/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://drugpolicyreform.net" style="left: 56.4706%; top: 72.6516%; width: 19.6639%; height: 1.42687%;"></a><a href="http://www.pharmaceutical-journal.com/opinion/comment/medicinal-cannabis-time-for-acomeback/20067185.article" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.pharmaceutical-journal.com/opinion/comment/medicinal-cannabis-time-for-acomeback/20067185.article" style="left: 11.9328%; top: 75.6243%; width: 62.6891%; height: 2.85375%;"></a><a href="https://www.usatoday.com/story/news/nation/2015/03/11/hemp-oil-warnings/70161114/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.usatoday.com/story/news/nation/2015/03/11/hemp-oil-warnings/70161114/" style="left: 11.9328%; top: 90.1308%; width: 57.8151%; height: 1.42687%;"></a></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 46 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 0.840336%; height: 1.66468%;">
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 9.98811%; width: 73.2773%; height: 1.66468%;">16The Drug Policy Alliance (DPA) has played a leading role in overdose prevention efforts across the United
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 11.415%; width: 69.916%; height: 1.78359%;">States, advocating especially for the passage of Good Samaritan limited immunity protections and for
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 76.1345%; height: 1.78359%;">increased access to the opioid overdose reversal drug naloxone (www.drugpolicy.org/drug-overdose). The DPA
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.2687%; width: 43.8655%; height: 1.78359%;">would be pleased to provide a memo expanding on this subject.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.6956%; width: 76.1345%; height: 1.78359%;">17Bradford AC &amp; Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.2414%; width: 31.5966%; height: 1.66468%;">Health Aff (Millwood). 2016;35:7123071236.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.6683%; width: 74.958%; height: 1.66468%;">18Anderson DM &amp; Rees DI. The legalization of recreational marijuana: how likely is the worst-case scenario? J
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.0951%; width: 28.9076%; height: 1.78359%;">Policy Anal Manage. 2014;33(1):221232.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.522%; width: 74.2857%; height: 1.78359%;">19Smith PH et al. Couples marijuana use is inversely related to their intimate partner violence over the first 9
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.9489%; width: 43.0252%; height: 1.78359%;">years of marriage. Psychol Addict Behav. 2014;28(3):734742 .
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.4946%; width: 74.958%; height: 1.66468%;">20Anderson DM &amp; Rees DI. The legalization of recreational marijuana: how likely is the worst-case scenario? J
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.9215%; width: 28.9076%; height: 1.78359%;">Policy Anal Manage. 2014;33(1):221232.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.3484%; width: 74.6218%; height: 1.78359%;">21See Rylander M, Valdez C &amp; Nussbaum AM. Does the legalization of medical marijuana increase completed
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.7753%; width: 74.7899%; height: 1.78359%;">suicide? Am J Drug Alcohol Abuse. 2014;40(4):269273; Anderson DM, Rees DI &amp; Sabia JJ. Medical marijuana
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.2021%; width: 56.9748%; height: 1.78359%;">laws and suicides by gender and age. Am J Public Health. 2014;104(12):23692376.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.7479%; width: 75.4622%; height: 1.66468%;">22Anderson DM, Rees DI &amp; Sabia JJ. High on life? Medical marijuana laws and suicide. Iza Discussion Paper No.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.1748%; width: 72.9412%; height: 1.78359%;">6280, January 2012. Available from: http://ftp.iza.org/dp6280.pdf (accessed 2 September 2016); Anderson
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 34.6017%; width: 68.7395%; height: 1.78359%;">DM, Rees DI &amp; Sabia JJ. Medical marijuana laws and suicides by gender and age. Am J Public Health.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 36.0285%; width: 73.7815%; height: 1.78359%;">2014;104(12):23692376; see also Anderson DM &amp; Rees DI.The legalization of recreational marijuana: how
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 37.5743%; width: 75.2941%; height: 1.66468%;">likely is the worst-case scenario? J Policy Anal Manage. 2014;33(1):221232 (anticipating decreases in suicide
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 39.3579%; width: 4.70588%; height: 1.30797%;">rates).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 40.4281%; width: 64.7059%; height: 1.78359%;">23Danish Health and Medicines Authority. Medicinal use of cannabis. 2nd edn. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 41.8549%; width: 76.1345%; height: 1.78359%;">http://sundhedsstyrelsen.dk/en/news/2014/~/media/57439DD97F054C60AE9B6A7FFC68F3BC.ashx (accessed
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 43.2818%; width: 13.7815%; height: 1.78359%;">2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 44.8276%; width: 76.4706%; height: 1.54578%;">24Bifulco M &amp; Pisanti S. Medicinal use of cannabis in Europe: the fact that more countries legalize the medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 46.1356%; width: 67.563%; height: 1.66468%;">use of cannabis should not become an argument for unfettered and uncontrolled use. EMBO Rep.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 47.9191%; width: 14.6218%; height: 1.42687%;">2015;16(2):130132.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 48.9893%; width: 74.7899%; height: 1.78359%;">25Institute of Responsible Medicine Use and the Office of Medicinal Cannabis of the CIBG, Ministry of Health,
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 50.4162%; width: 66.8908%; height: 1.78359%;">Welfare and Sport, the Netherlands. Wat is het Bureau voor Medicinale Cannabis. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 51.962%; width: 73.7815%; height: 1.66468%;">www.cannabisbureau.nl/en/doc/pdf/5089-A5-BMC-Pat-ENG-web_35842.pdf (accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 53.3888%; width: 73.9496%; height: 1.78359%;">26CIBG, Ministry of Health, Welfare and Sport. Medicinal cannabis: information for patients. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 54.8157%; width: 75.1261%; height: 1.78359%;">www.cannabisbureau.nl/Media/Default/PDF/5089-A5-BMC-Pat-ENG-web_35842.pdf (accessed 2 September
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 56.5993%; width: 4.53782%; height: 1.42687%;">2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 57.6694%; width: 46.0504%; height: 1.78359%;">27Oral evidence from Professor Val Curran dated 10 February 2016.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 59.2152%; width: 76.4706%; height: 1.66468%;">28Bifulco M &amp; Pisanti S. Medicinal use of cannabis in Europe: the fact that more countries legalize the medicinal
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 60.6421%; width: 67.563%; height: 1.78359%;">use of cannabis should not become an argument for unfettered and uncontrolled use. EMBO Rep.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 62.4257%; width: 14.6218%; height: 1.42687%;">2015;16(2):130132.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 63.4958%; width: 75.2941%; height: 1.78359%;">29https://www.rt.com/news/341745-medical-marijuana-germany-legalization/ (accessed 3rd September 2016)
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 64.9227%; width: 52.1008%; height: 1.78359%;">30Sensi Seeds. Legal status of cannabis in Italy: an overview. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 66.4685%; width: 74.7899%; height: 1.66468%;">https://sensiseeds.com/en/blog/legal-status-of-cannabis-in-italy-an-overview/ (accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 67.8954%; width: 52.1008%; height: 1.78359%;">31Sensi Seeds. Legal status of cannabis in Italy: an overview. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 69.3222%; width: 74.7899%; height: 1.78359%;">https://sensiseeds.com/en/blog/legal-status-of-cannabis-in-italy-an-overview/ (accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 70.868%; width: 71.0924%; height: 1.78359%;">32Professor Barnes MD FRCP is Honorary Professor of Neurological Rehabilitation, Newcastle University.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 72.4138%; width: 64.5378%; height: 1.66468%;">33The full evidence review can be accessed on the APPG website: http://drugpolicyreform.net.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 73.8407%; width: 75.1261%; height: 1.78359%;">34Nutt D. Medical cannabis, time for a comeback? The Pharmaceutical Journal, 19 November 2014. Available
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 75.2675%; width: 62.0168%; height: 3.21046%;">from: www.pharmaceutical-journal.com/opinion/comment/medicinal-cannabis-time-for-a-
comeback/20067185.article (accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 78.2402%; width: 59.1597%; height: 1.66468%;">35Calculation based on American sources where medicinal cannabis is available legally.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 79.6671%; width: 71.5966%; height: 1.78359%;">36Swift W, Gates P &amp; Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 81.5696%; width: 7.56303%; height: 1.18906%;">2005;2:18.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 82.5208%; width: 71.5966%; height: 1.78359%;">37Swift W, Gates P &amp; Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 84.4233%; width: 7.56303%; height: 1.30797%;">2005;2:18.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 85.4935%; width: 74.2857%; height: 1.66468%;">38Measham F, Aldridge J &amp; Parker H. Dancing On Drugs: Risk, Health and Hedonism in the British Club Scene.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 86.9203%; width: 26.5546%; height: 1.66468%;">London: Free Association Books; 2001.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 88.3472%; width: 53.7815%; height: 1.78359%;">39USA Today. Federal drug regulators caution hemp oil sellers. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 89.7741%; width: 70.9244%; height: 1.78359%;">www.usatoday.com/story/news/nation/2015/03/11/hemp-oil-warnings/70161114/ (6/16) (accessed 2
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 91.201%; width: 12.605%; height: 1.78359%;">September 2016).
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/ed95250b-8c3b-48d9-950f-4fbd4317ac71" class="drive-viewer-paginated-page-img" alt="Page 46 of 47" aria-hidden="true"></div><div class="drive-viewer-paginated-page" style="padding-bottom: 141.375%;"><div class="drive-viewer-paginated-page-links drive-viewer-focus-to-default"><a href="https://www.usatoday.com/story/news/nation/2015/03/11/hemp-oil-warnings/70161114/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.usatoday.com/story/news/nation/2015/03/11/hemp-oil-warnings/70161114/" style="left: 11.9328%; top: 11.7717%; width: 57.8151%; height: 1.42687%;"></a><a href="https://www.reddit.com/r/CBD/comments/3gno1d/how_much_does_cbd_oil_cost_in_any_legal_state/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.reddit.com/r/CBD/comments/3gno1d/how_much_does_cbd_oil_cost_in_any_legal_state/" style="left: 11.9328%; top: 16.0523%; width: 66.5546%; height: 1.42687%;"></a><a href="http://www.policyconnect.org.uk/cppc/home" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.policyconnect.org.uk/cppc/home" style="left: 51.4286%; top: 19.025%; width: 27.0588%; height: 1.30797%;"></a><a href="http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=469#1" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=469#1" style="left: 27.0588%; top: 27.7051%; width: 58.4874%; height: 1.42687%;"></a><a href="http://marijuanagames.org/medical-marijuana-in-germany-set-for-regulation/" target="_blank" class="drive-viewer-paginated-page-link" tabindex="0" rel="noreferrer" role="link" aria-label="http://marijuanagames.org/medical-marijuana-in-germany-set-for-regulation/" style="left: 11.9328%; top: 31.9857%; width: 53.9496%; height: 1.42687%;"></a></div><div class="drive-viewer-paginated-page-reader-content-container"><h2 class="drive-viewer-paginated-page-reader-header" tabindex="0">Page 47 of 47</h2><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 8.32342%; width: 0.840336%; height: 1.66468%;">
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 9.98811%; width: 53.7815%; height: 1.66468%;">40USA Today. Federal drug regulators caution hemp oil sellers. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 11.415%; width: 70.9244%; height: 1.78359%;">www.usatoday.com/story/news/nation/2015/03/11/hemp-oil-warnings/70161114/ (6/16) (accessed 2
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 12.8419%; width: 12.605%; height: 1.78359%;">September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 14.2687%; width: 15.9664%; height: 1.54578%;">41CBD. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 15.6956%; width: 75.1261%; height: 1.78359%;">www.reddit.com/r/CBD/comments/3gno1d/how_much_does_cbd_oil_cost_in_any_legal_state/ (accessed 2
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 17.2414%; width: 12.605%; height: 1.66468%;">September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 18.6683%; width: 75.2941%; height: 1.66468%;">42Chronic Pain Coalition. What about me? Available from: www.policyconnect.org.uk/cppc/home (accessed 2
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 20.0951%; width: 12.605%; height: 1.78359%;">September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 21.522%; width: 70.4202%; height: 1.78359%;">43Nutt D. Illegal drug laws: clearing a 50-year-old obstacle to research. PLoS Biol. 2015;13(1):e1002047.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 22.9489%; width: 70.4202%; height: 1.78359%;">44Nutt D. Illegal drug laws: clearing a 50-year-old obstacle to research. PLoS Biol. 2015;13(1):e1002047.
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 24.4946%; width: 71.7647%; height: 1.66468%;">45Germany: The government presents a draft for a law, which would make cannabis flowers available on
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 25.9215%; width: 73.6134%; height: 1.78359%;">prescription by every doctor and force health insurances to reimburse cannabis-based medicines in certain
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 27.3484%; width: 73.6134%; height: 1.78359%;">cases. Available from: www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=469#1
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 28.7753%; width: 26.2185%; height: 1.78359%;">(06/16) (accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 30.2021%; width: 59.1597%; height: 1.78359%;">46Marijuana Games. Medical marijuana in Germany set for regulation. Available from:
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 31.7479%; width: 74.7899%; height: 1.66468%;">http://marijuanagames.org/medical-marijuana-in-germany-set-for-regulation/ (accessed 2 September 2016).
</p><p class="drive-viewer-paginated-page-reader-block" style="left: 11.9328%; top: 33.1748%; width: 46.0504%; height: 1.78359%;">47Oral evidence from Professor Val Curran dated 10 February 2016.
</p></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-selection"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-ui-text-search"></div><div class="drive-viewer-ui-text-highlightset drive-viewer-paginated-anchor-selection"></div><img src="blob:https://drive.google.com/cf012e60-bc17-43cc-8b4a-b9c1504dfad1" class="drive-viewer-paginated-page-img" alt="Page 47 of 47" aria-hidden="true"></div></div><span class="drive-viewer-paginated-tab-sentinel" tabindex="0"></span></div><div class="drive-viewer-gradient-top" style="display: none;"></div><div class="drive-viewer-gradient-rgt" style="display: none;"></div><div class="drive-viewer-gradient-bottom" style="display: none;"></div><div class="drive-viewer-gradient-lft" style="display: none;"></div><div class="drive-viewer-ui-text-searchbar" aria-hidden="true"><div class="drive-viewer-ui-text-searchbar-container"><div class="drive-viewer-ui-text-searchbar-input-container"><input class="drive-viewer-ui-text-searchbar-input label-input-label" placeholder="Find in document" aria-label="Find in document" tabindex="-1"></div><div class="drive-viewer-ui-text-searchbar-count-container"><span class="drive-viewer-ui-text-searchbar-count"></span></div></div><div class="drive-viewer-ui-text-searchbar-prev drive-viewer-icon drive-viewer-ui-text-searchbar-btn goog-inline-block drive-viewer-button" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="Find previous" data-tooltip="Find previous" style="-webkit-user-select: none;"></div><div class="drive-viewer-ui-text-searchbar-next drive-viewer-icon drive-viewer-ui-text-searchbar-btn goog-inline-block drive-viewer-button" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="Find next" data-tooltip="Find next" style="-webkit-user-select: none;"></div><div class="drive-viewer-ui-text-searchbar-close drive-viewer-icon drive-viewer-ui-text-searchbar-btn goog-inline-block drive-viewer-button" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="Close find bar" data-tooltip="Close find bar" style="-webkit-user-select: none;"></div></div></div></div></div><div class="drive-viewer-toolstrip" role="toolbar" style="opacity: 0;"><div class="drive-viewer-toolstrip-inner"><div class="drive-viewer-toolstrip-lft"><div class="drive-viewer-toolstrip-icon" tabindex="-1" role="img" aria-label="PDF icon" style="background-image: url(&quot;//ssl.gstatic.com/docs/doclist/images/mediatype/icon_3_pdf_x16.png&quot;); background-position: left top; background-repeat: no-repeat;"></div><div class="drive-viewer-toolstrip-metadata" tabindex="-1"><div class="drive-viewer-toolstrip-name" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" style="width: 271px;">MC Inquiry report28 08 16_edited_clean.pdf</div><div class="drive-viewer-toolstrip-name drive-viewer-toolstrip-name-sizing">MC Inquiry report28 08 16_edited_clean.pdf</div><div class="drive-viewer-toolstrip-secondary-name" style="display: none;"></div><div class="drive-viewer-toolstrip-secondary-name drive-viewer-toolstrip-secondary-name-sizing"></div></div></div><div class="drive-viewer-toolstrip-mid-panel"><div class="drive-viewer-toolstrip-open-and-openwith"><div class="drive-viewer-toolstrip-open drive-viewer-dark-button goog-inline-block drive-viewer-button drive-viewer-toolstrip-open-has-openwith" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-hidden="false" aria-label="Open with DocHub - View, Edit &amp; Sign PDFs" style="-webkit-user-select: none;" tabindex="0" data-tooltip="Open with DocHub - View, Edit &amp; Sign PDFs"><div class="drive-viewer-open-app-icon" style="background-image: url(&quot;https://lh3.googleusercontent.com/-CW4crbKmZeU/Vgq4WNXuBaI/AAAAAAAAALk/5Nc3ALV_N6Y/s32-c-k/icon_32.png&quot;); background-position: left top; background-repeat: no-repeat;"></div><div class="drive-viewer-open-label">Open with DocHub - View, Edit &amp; Sign PDFs</div></div><div class="drive-viewer-toolstrip-extract drive-viewer-dark-button goog-inline-block drive-viewer-button drive-viewer-toolstrip-open-has-openwith" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-hidden="true" style="-webkit-user-select: none; display: none;"><div class="drive-viewer-toolstrip-extract-content">Extract</div><div class="drive-viewer-toolstrip-extracting-icon"><div class="drive-spinner"><div class="drive-quantum-spinner active"><div class="spinner-layer spinner-blue"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-red"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-yellow"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-green"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div></div></div></div></div><div class="drive-viewer-toolstrip-openwith drive-viewer-dark-button goog-inline-block drive-viewer-button drive-viewer-toolstrip-openwith-mini" role="button" aria-expanded="false" aria-haspopup="true" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="Open with" data-tooltip="Open with" aria-hidden="false" style="-webkit-user-select: none;" tabindex="0"><div class="drive-viewer-toolstrip-open-separator"></div><div class="drive-viewer-toolstrip-openwith-inner"><div class="drive-viewer-toolstrip-openwith-text" tabindex="-1">Open with</div><div class="drive-viewer-toolstrip-menu-button-arrow"><div class="drive-viewer-icon"></div></div></div></div></div><div class="drive-viewer-toolstrip-custom-panel"></div></div><div class="drive-viewer-toolstrip-rgt-panel"><div class="drive-viewer-popout-button drive-viewer-dark-button" aria-label="Pop-out" style="display: none;"><div class="drive-viewer-icon drive-viewer-nav-icon"></div></div><div class="drive-viewer-toolstrip-actions"><div class="drive-viewer-toolstrip-add-to-drive drive-viewer-dark-button goog-inline-block drive-viewer-button" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-hidden="false" style="-webkit-user-select: none;" aria-label="Add to My Drive" data-tooltip="Add to My Drive" tabindex="0"><div class="drive-viewer-toolstrip-add-to-my-drive-icon"><div class="drive-spinner"><div class="drive-quantum-spinner active"><div class="spinner-layer spinner-blue"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-red"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-yellow"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div><div class="spinner-layer spinner-green"><div class="spinner-circle-clipper spinner-left"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-gap-patch"><div class="spinner-circle spinner-fit"></div></div><div class="spinner-circle-clipper spinner-right"><div class="spinner-circle spinner-fit"></div></div></div></div></div></div></div><div class="drive-viewer-toolstrip-custom-panel"><div class="drive-viewer-dark-button drive-viewer-custom-button goog-inline-block drive-viewer-button drive-viewer-custom-button-with-icon" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-disabled="false" aria-hidden="false" aria-label="Print" style="-webkit-user-select: none;" tabindex="0" data-tooltip="Print"><div class="drive-viewer-icon drive-viewer-custom-button-icon drive-viewer-print-icon"></div></div><div class="drive-viewer-dark-button drive-viewer-custom-button goog-inline-block drive-viewer-button drive-viewer-custom-button-with-icon" role="button" tabindex="0" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="Download" data-tooltip="Download" style="-webkit-user-select: none;"><div class="drive-viewer-icon drive-viewer-custom-button-icon drive-viewer-download-icon"></div></div><div class="drive-viewer-more-button drive-viewer-dark-button goog-inline-block drive-viewer-button" role="button" aria-expanded="false" aria-haspopup="true" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="More actions" data-tooltip="More actions" aria-hidden="false" tabindex="0" style="-webkit-user-select: none;"><div class="drive-viewer-icon"></div></div></div></div><div class="drive-viewer-profile-icon" title="Shane Le Brun 
(lebrun_shane@hotmail.com)"><img src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/photo.jpg" class="drive-viewer-profile-img" alt="Shane Le Brun 
(lebrun_shane@hotmail.com)" tabindex="0"></div></div></div></div><div class="drive-viewer-details-panel drive-viewer-details-panel-hidden" aria-hidden="true"><div class="drive-viewer-details-header"><div class="drive-viewer-details-tabbar drive-viewer-details-tabbar-horizontal drive-viewer-details-tabbar-top" role="tablist" aria-label="Details panel tab bar. Press left and right arrow keys to switch between tabs." aria-activedescendant="dvdt_goog_73538433" style="-webkit-user-select: none;"><div class="drive-viewer-details-tab drive-viewer-details-tab-hover drive-viewer-details-tab-selected" role="tab" aria-selected="true" id="dvdt_goog_73538433" tabindex="0" style="-webkit-user-select: none;">Details</div><div class="drive-viewer-details-tab drive-viewer-details-tab-indicator" role="tab" aria-selected="false" id="dvdt_goog_73538434" aria-hidden="true" style="-webkit-user-select: none; display: none;">Comments</div></div><div class="drive-viewer-close-button drive-viewer-dark-button drive-viewer-button" role="button" tabindex="0" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-label="Hide details" data-tooltip="Hide details" style="-webkit-user-select: none;"><div class="drive-viewer-icon drive-viewer-nav-icon"></div></div></div><div class="drive-viewer-details-content drive-viewer-scrollable"><div class="drive-viewer-details-info-view" role="tabpanel" aria-labelledby="dvdt_goog_73538433"><div class="drive-viewer-details-subpane" role="region" aria-label="General Info" tabindex="-1"><div class="drive-viewer-details-subpane-header"><span class="drive-viewer-details-subpane-header-text" role="heading">General Info</span><div class="drive-viewer-details-subpane-separator-container"><div class="drive-viewer-details-subpane-separator"></div></div></div><div class="drive-viewer-dark-button drive-viewer-details-edit-button drive-viewer-button" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-hidden="true" style="-webkit-user-select: none; display: none;"><div class="drive-viewer-icon"></div></div><div class="drive-viewer-details-subpane-content"><div class="drive-viewer-details-info-subpane"><div class="drive-viewer-details-info-row"><div class="drive-viewer-details-subpane-label drive-viewer-details-info-label">Type</div><div class="drive-viewer-details-subpane-item">PDF</div></div><div class="drive-viewer-details-info-row" style="display: none;"><div class="drive-viewer-details-subpane-label drive-viewer-details-info-label">Dimensions</div><div class="drive-viewer-details-subpane-item"></div></div><div class="drive-viewer-details-info-row"><div class="drive-viewer-details-subpane-label drive-viewer-details-info-label">Size</div><div class="drive-viewer-details-subpane-item">843 KB</div></div><div class="drive-viewer-details-info-row" style="display: none;"><div class="drive-viewer-details-subpane-label drive-viewer-details-info-label">Location</div><div class="drive-viewer-details-subpane-item"><div class="drive-viewer-details-location-items"></div></div></div><div class="drive-viewer-details-info-row"><div class="drive-viewer-details-subpane-label drive-viewer-details-info-label">Modified</div><div class="drive-viewer-details-subpane-item">04:43 13 Sep</div></div><div class="drive-viewer-details-info-row"><div class="drive-viewer-details-subpane-label drive-viewer-details-info-label">Created</div><div class="drive-viewer-details-subpane-item">04:41 13 Sep</div></div><div class="drive-viewer-details-info-row" style="display: none;"><div class="drive-viewer-details-subpane-label drive-viewer-details-info-label">Opened by me</div><div class="drive-viewer-details-subpane-item"></div></div></div></div></div><div class="drive-viewer-details-subpane" role="region" aria-label="Sharing" tabindex="-1" style=""><div class="drive-viewer-details-subpane-header"><span class="drive-viewer-details-subpane-header-text" role="heading">Sharing</span><div class="drive-viewer-details-subpane-separator-container"><div class="drive-viewer-details-subpane-separator"></div></div></div><div class="drive-viewer-dark-button drive-viewer-details-edit-button drive-viewer-button" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-hidden="true" style="-webkit-user-select: none; display: none;"><div class="drive-viewer-icon"></div></div><div class="drive-viewer-details-subpane-content"><div class="drive-viewer-details-info-subpane"><div class="drive-viewer-details-info-row"><div class="drive-viewer-details-subpane-label drive-viewer-details-permission-label"><div class="drive-viewer-details-permission-avatar"><div class="drive-viewer-details-default-avatar-thumbnail" data-tooltip="ed@anekocreative.com" aria-label="ed@anekocreative.com" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6"><div class="drive-viewer-details-letter-overlay" role="img">E</div></div></div><div class="drive-viewer-details-permission-name" data-tooltip="Ed Hill" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" data-tooltip-only-on-overflow="true">Ed Hill</div></div><div class="drive-viewer-details-permission-role">Owner</div></div><div class="drive-viewer-details-info-row"><div class="drive-viewer-details-subpane-label drive-viewer-details-permission-label"><div class="drive-viewer-details-permission-avatar"><div class="drive-viewer-details-default-avatar-thumbnail" data-tooltip="Anyone" aria-label="Anyone" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6"><div class="drive-viewer-icon drive-viewer-details-avatar-icon drive-viewer-details-anyone-avatar" role="img"></div></div></div><div class="drive-viewer-details-permission-name" data-tooltip="Anyone" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" data-tooltip-only-on-overflow="true">Anyone</div></div><div class="drive-viewer-details-permission-role">Can View</div></div></div></div></div><div class="drive-viewer-details-subpane" role="region" aria-label="Description" tabindex="-1" style=""><div class="drive-viewer-details-subpane-header"><span class="drive-viewer-details-subpane-header-text" role="heading">Description</span><div class="drive-viewer-details-subpane-separator-container"><div class="drive-viewer-details-subpane-separator"></div></div></div><div class="drive-viewer-dark-button drive-viewer-details-edit-button drive-viewer-button" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-hidden="true" aria-label="Edit Description" data-tooltip="Edit Description" style="-webkit-user-select: none; display: none;"><div class="drive-viewer-icon"></div></div><div class="drive-viewer-details-subpane-content"><div><div class="drive-viewer-details-description">No description</div><textarea class="drive-viewer-details-description-edit drive-viewer-scrollable" role="textbox" aria-multiline="true" style="display: none;"></textarea></div></div></div><div class="drive-viewer-details-subpane" role="region" aria-label="Download Permission" tabindex="-1" style=""><div class="drive-viewer-details-subpane-header"><span class="drive-viewer-details-subpane-header-text" role="heading">Download Permission</span><div class="drive-viewer-details-subpane-separator-container"><div class="drive-viewer-details-subpane-separator"></div></div></div><div class="drive-viewer-dark-button drive-viewer-details-edit-button drive-viewer-button" role="button" data-tooltip-unhoverable="true" data-tooltip-delay="500" data-tooltip-class="drive-viewer-jfk-tooltip" data-tooltip-align="b,c" data-tooltip-offset="-6" aria-hidden="true" style="-webkit-user-select: none; display: none;"><div class="drive-viewer-icon"></div></div><div class="drive-viewer-details-subpane-content"><div class="drive-viewer-details-info-row"><div class="drive-viewer-details-download-permission-message" id="dvddp_goog_73538432">Viewers can download</div></div></div></div><div></div></div><div class="drive-viewer-details-comments-view" role="tabpanel" aria-labelledby="dvdt_goog_73538434" style="display: none;"></div></div></div></div><span class="drive-viewer-tab-sentinel" tabindex="0" aria-hidden="true"></span><script aria-hidden="true" type="2fb05f019e6e60363ddfa077-text/javascript">var b=Date.now||function(){return+new Date};var c=function(){function g(){800>a.naturalWidth?e():(a._preloadEndTime=b(),h.getElementsByClassName("drive-viewer-msg-loading")[0].style.display="none")}function e(){a.style.display="none"}var h=document.body.getElementsByClassName("drive-viewer-carousel-slide")[0],a=h.getElementsByClassName("drive-viewer-paginated-page-img")[0];a._preloadStartTime=b();a.complete||a._preloadFailed?0<a.naturalWidth?g():e():(a.addEventListener("load",g,!1),a.addEventListener("error",e,!1))},d=["_initStaticViewer"],
f=this;d[0]in f||!f.execScript||f.execScript("var "+d[0]);for(var k;d.length&&(k=d.shift());)d.length||void 0===c?f=f[k]?f[k]:f[k]={}:f[k]=c;
</script><script aria-hidden="true" type="2fb05f019e6e60363ddfa077-text/javascript">_initStaticViewer()</script><script type="2fb05f019e6e60363ddfa077-text/javascript" src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/3835721713-projector_viewer__en_gb.js.download" aria-hidden="true"></script>
<script aria-hidden="true" type="2fb05f019e6e60363ddfa077-text/javascript">_initProjector({'id': '0B6pbCLVGabYiTXFWaURCWmZZZjQ', 'title': 'MC Inquiry report28 08 16_edited_clean.pdf','enableStandaloneSharing': true,'enableEmbedDialog': true,'projectorFeedbackId': '99950', 'projectorFeedbackBucket': 'viewer-web',},["0",1,"",1,1,1,1,"",,1,1,[1,"",0,"AIzaSyDVQw45DwoYh632gvsP5vPDqEKvb-Ywnb8",0,0,1,0,,"",0,"/drive/v2internal",1,1,1,[0,0,0,"",""]
,0,1]
,1,5,1,"",0,1,"https://docs.google.com",0,1,1,1,1,,1,"20",1,0,1,1,1,[["","0"]
,6,1,1,"ND",""]
,1,1,1,,[0,"Shane Le Brun","lebrun_shane@hotmail.com","//lh4.googleusercontent.com/-CnasPhGHo70/AAAAAAAAAAI/AAAAAAAAABA/WLxZdVMF2Ls/s50-c-k-no/photo.jpg","","","","",1]
,0,1,1,"600000",,"https://docs.google.com",0,1,[0,0,0,1]
,["https://youtube.googleapis.com",1,2]
,1,1,"",0,1,1,1,1,[1,"","",0,"lmjegmlicamnimmfhcmpkclmigmmcbeh",1,1,3000,"lebrun_shane@hotmail.com","",0,0,0]
,,"000770F20345E2F2DD6F872F23399BAE510831AEA77D68D9D2",,[1,1,1,1]
,[1.0E-4,"//www.google.com/insights/consumersurveys/async_survey?site\u003dyb55d3kmxakozfojltljrrdkau"]
,1,0,3,0,1,[1,"https://maps.googleapis.com/maps/api/js?key\u003dAIzaSyBCjpnguVjzi6vS67NdBtyYuvCYz3yBxCY\u0026sensor\u003dfalse"]
,1,0,,1,1,1,0,0]
,[,"MC Inquiry report28 08 16_edited_clean.pdf","https://lh3.googleusercontent.com/7uDoAHPJVVIvLttOh9hTsWwBY9y0BuJvVmBR5OG6ZB0UHO85YVndFkBWNPBNSAJm7-b0CgHjwcN0CCk\u003dw1600-rw","","","","0B6pbCLVGabYiTXFWaURCWmZZZjQ","","","https://drive.google.com/viewerng/upload?ds\u003dAPznzaYm3QZwuvNN5kfbD3Y7a3x8xB90vesVChtXk4I-ElGt4TbMT3ybtBbjYmnMW2flMtLeDNizrnge0JvowNfSCmsVIKmq8p9UHbiV1hEf_vCeiyCR_02DXAcHraw75nXSxv1hn4bujkbHa9qFXdb6qgPeSyLxCQ-uEKe6R2hTFisb9TofT7M%3D\u0026ck\u003ddrive\u0026p\u003dproj","","application/pdf","","",6,"","https://drive.google.com/file/d/0B6pbCLVGabYiTXFWaURCWmZZZjQ/view",1,"https://docs.google.com/uc?authuser\u003d0\u0026id\u003d0B6pbCLVGabYiTXFWaURCWmZZZjQ\u0026export\u003ddownload",,5,0,0,"","",[,0,"863431"]
,"","",,0,"",0,"pdf","",[["0B6pbCLVGabYiTmxmcWNlOUhaM1ltY3JDWUk5YWxXZ1VVWFlrPQ"]
]
,""]
);</script><div ng-non-bindable=""><div class="gb_ud"></div><div class="gb_Zb">Main menu</div></div><script type="2fb05f019e6e60363ddfa077-text/javascript">this.gbar_=this.gbar_||{};(function(_){var window=this;
try{
if(_.X){var Uh;if(Uh=_.C(_.X.C,3))for(var Vh=_.Wg(Uh),Wh=0;Wh<Vh.length;Wh++){var Xh=Vh[Wh];_.Fg&&Xh.dataset?Xh.dataset.ogpc="":Xh.setAttribute("data-"+_.Lg("ogpc"),"")}_.Jh(_.X,!!_.X.b&&_.xh(_.X.b),!1)};
}catch(e){_._DumpException(e)}
try{
var Yh=function(a){_.B(this,a,0,-1,null)};_.u(Yh,_.A);var Zh=function(a){_.B(this,a,0,-1,null)};_.u(Zh,_.A);var $h=function(a){_.Tc("From proto message. b/12014412");a=_.C(a,4)||"";return _.dd(a)};var ai=_.E(_.ic,Yh,17)||new Yh,bi;bi=_.E(ai,Zh,1);var ci=$h(bi),di;di=_.E(ai,Zh,2);var ei=$h(di),fi=function(a,c,d){_.rc.log(46,{att:a,max:c,url:d})},hi=function(a,c,d){_.rc.log(47,{att:a,max:c,url:d});a<c?gi(a+1,c):_.J.log(Error("B`"+a+"`"+c),{url:d})},gi=function(a,c){var d=_.ld(window.document,"SCRIPT");d.async=!0;d.type="text/javascript";d.charset="UTF-8";d.src=_.cd(ci);d.onload=_.Ic(fi,a,c,d.src);d.onerror=_.Ic(hi,a,c,d.src);_.rc.log(45,{att:a,max:c,url:d.src});_.kd("HEAD")[0].appendChild(d)};
gi(1,2);var ii=_.ld(window.document,"LINK");ii.setAttribute("type","text/css");ii.rel="stylesheet";ii.href=_.cd(ei);_.kd("HEAD")[0].appendChild(ii);
}catch(e){_._DumpException(e)}
})(this.gbar_);
// Google Inc.
</script><iframe name="oauth2relay599666313" id="oauth2relay599666313" src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/postmessageRelay.html" tabindex="-1" style="width: 1px; height: 1px; position: absolute; top: -100px;"></iframe><iframe id="apiproxy8f59043c9c0ba3789ac5ff68215ecf13ae58b3110.38869574926561823" name="apiproxy8f59043c9c0ba3789ac5ff68215ecf13ae58b3110.38869574926561823" src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/proxy.html" tabindex="-1" style="width: 1px; height: 1px; position: absolute; top: -100px;"></iframe><div class="gb_qd"><div class="gb_pd"><div>Google account</div><div>Shane Le Brun</div><div><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a3cfc6c1d1d6cdfcd0cbc2cdc6e3cbccd7cec2cacf8dc0ccce">[email&#160;protected]</a></div></div></div><iframe id="apiproxya27d55e8cb1307e9192580774a606ff52530adb70.4432007486827563" name="apiproxya27d55e8cb1307e9192580774a606ff52530adb70.4432007486827563" src="./MC Inquiry report28 08 16_edited_clean.pdf - Google Drive_files/proxy(1).html" tabindex="-1" style="width: 1px; height: 1px; position: absolute; top: -100px;"></iframe><div aria-live="polite" aria-atomic="true" style="position: absolute; top: -1000px; height: 1px; overflow: hidden;">Page 1 of 47</div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="/cdn-cgi/scripts/7d0fa10a/cloudflare-static/rocket-loader.min.js" data-cf-settings="2fb05f019e6e60363ddfa077-|49" defer=""></script></body></html>